<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">103484</article-id><article-id pub-id-type="doi">10.7554/eLife.103484</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.103484.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Suryawanshi</surname><given-names>Rahul K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8374-669X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jaishankar</surname><given-names>Priyadarshini</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0005-2013-8941</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Correy</surname><given-names>Galen J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Rachman</surname><given-names>Moira M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>O'Leary</surname><given-names>Patrick C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2919-5943</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Taha</surname><given-names>Taha Y</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7344-7490</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Matsui</surname><given-names>Yusuke</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6016-2867</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Zapatero-Belinchón</surname><given-names>Francisco J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2751-8411</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>McCavitt-Malvido</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Doruk</surname><given-names>Yagmur U</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Stevens</surname><given-names>Maisie GV</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Diolaiti</surname><given-names>Morgan E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5900-3060</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Jogalekar</surname><given-names>Manasi P</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Huadong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4681-0853</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Richards</surname><given-names>Alicia L</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Kongpracha</surname><given-names>Pornparn</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1759-213X</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Bali</surname><given-names>Sofia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4046-7081</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Montano</surname><given-names>Mauricio</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0353-0037</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Rosecrans</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Matthay</surname><given-names>Michael</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3039-8155</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Togo</surname><given-names>Takaya</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0243-0760</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gonciarz</surname><given-names>Ryan L</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gopalkrishnan</surname><given-names>Saumya</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0003-6713-4492</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Neitz</surname><given-names>R Jeffrey</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2247-9345</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Krogan</surname><given-names>Nevan J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4902-337X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con25"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author"><name><surname>Swaney</surname><given-names>Danielle L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6119-6084</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con26"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Shoichet</surname><given-names>Brian K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6098-7367</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con27"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ott</surname><given-names>Melanie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5697-1274</contrib-id><email>melanie.ott@gladstone.ucsf.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con28"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Renslo</surname><given-names>Adam R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1240-2846</contrib-id><email>adam.renslo@ucsf.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con29"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ashworth</surname><given-names>Alan</given-names></name><email>alan.ashworth@ucsf.edu</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con30"/><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Fraser</surname><given-names>James S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5080-2859</contrib-id><email>jfraser@fraserlab.com</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con31"/><xref ref-type="fn" rid="conf8"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/038321296</institution-id><institution>Gladstone Institute of Virology, Gladstone Institutes</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Pharmaceutical Chemistry, University of California San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Bioengineering and Therapeutic Sciences, University of California San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Quantitative Biosciences Institute (QBI), University of California San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Cellular and Molecular Pharmacology, University of California San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/038321296</institution-id><institution>Data Science and Biotechnology Institute, Gladstone Institutes</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Small Molecule Discovery Center, University of California San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Medicine, University of California San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00knt4f32</institution-id><institution>Chan Zuckerberg Biohub- San Francisco, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Schoggins</surname><given-names>John W</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>The University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Schoggins</surname><given-names>John W</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>The University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Laboratory of Neurological Infections and Immunity, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, United States, Hamilton, United States</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>19</day><month>11</month><year>2025</year></pub-date><volume>14</volume><elocation-id>RP103484</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-11-05"><day>05</day><month>11</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-08-29"><day>29</day><month>08</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.08.08.606661"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-01-06"><day>06</day><month>01</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.103484.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-10-02"><day>02</day><month>10</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.103484.2"/></event></pub-history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-103484-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-103484-figures-v1.pdf"/><abstract><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to pose a threat to public health. Current therapeutics remain limited to direct-acting antivirals that lack distinct mechanisms of action and are already showing signs of viral resistance. The virus encodes an ADP-ribosylhydrolase macrodomain (Mac1) that plays an important role in the coronaviral life cycle by suppressing host innate immune responses. Genetic inactivation of Mac1 abrogates viral replication in vivo by potentiating host innate immune responses. However, it is unknown whether this can be achieved by pharmacologic inhibition and can therefore be exploited therapeutically. Here, we report a potent and selective lead small molecule, AVI-4206, that is effective in an in vivo model of SARS-CoV-2 infection. Standard cellular models indicate that AVI-4206 has high target engagement and can weakly inhibit viral replication in a gamma interferon- and Mac1 catalytic activity-dependent manner. However, a stronger antiviral effect for AVI-4206 is observed in human airway organoids and peripheral blood monocyte-derived macrophages. In an animal model of severe SARS-CoV-2 infection, AVI-4206 reduces viral replication, potentiates innate immune responses, and leads to a survival benefit. Our results provide pharmacological proof of concept that Mac1 is a valid therapeutic target via a novel immune-restoring mechanism that could potentially synergize with existing therapies targeting distinct, essential aspects of the coronaviral life cycle. This approach could be more widely used to target other viral macrodomains to develop antiviral therapeutics beyond COVID-19.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>macrodomain</kwd><kwd>structure-based drug design</kwd><kwd>X-ray crystallography</kwd><kwd>coronavirus</kwd><kwd>COVID</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>U19AI171110</award-id><principal-award-recipient><name><surname>Krogan</surname><given-names>Nevan J</given-names></name><name><surname>Ott</surname><given-names>Melanie</given-names></name><name><surname>Renslo</surname><given-names>Adam R</given-names></name><name><surname>Ashworth</surname><given-names>Alan</given-names></name><name><surname>Fraser</surname><given-names>James S</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The development of new small molecules demonstrates how pharmacologic inhibition of the coronavirus macrodomain restores innate immunity, leading to reduced viral replication and improved outcomes in severe infection.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a major threat to public health. Despite the approval of several biologic and small molecule therapeutics, there is an urgent need for new small molecule antivirals with distinct mechanisms of action to overcome potential resistance to existing agents (<xref ref-type="bibr" rid="bib55">von Delft et al., 2023</xref>). While most antivirals target an essential aspect of viral entry or replication, a potential avenue for new antivirals with alternative mechanisms is to target viral proteins that act to blunt the host immune response (<xref ref-type="bibr" rid="bib32">Minkoff and tenOever, 2023</xref>). For example, SARS-CoV-2 has evolved multiple mechanisms to evade and counter interferon signaling (<xref ref-type="bibr" rid="bib20">Kim and Shin, 2021</xref>). The viral proteins involved in such evasion would be valuable drug targets if their inhibition renders the host immune response sufficient to control virus replication and reduce disease severity.</p><p>The macrodomain (Mac1) of <underline>n</underline>on-<underline>s</underline>tructural <underline>p</underline>rotein 3 (NSP3) in SARS-CoV-2 is one such target that plays an antagonistic role to the host interferon response (<xref ref-type="bibr" rid="bib46">Schuller et al., 2023</xref>). Macrodomains are found across the tree of life and catalyze the hydrolysis of ADP-ribose covalent modifications on protein side chains (<xref ref-type="bibr" rid="bib8">Dasovich and Leung, 2023</xref>). Viral macrodomains are found in alphaviruses, hepatitis E virus, and many betacoronaviruses (<xref ref-type="bibr" rid="bib22">Leung et al., 2022</xref>) and in some systems, like murine hepatitis virus, their activity can be essential for viral replication (<xref ref-type="bibr" rid="bib57">Voth et al., 2021</xref>). While SARS-CoV-2 bearing either catalytically inactivating point mutations (<xref ref-type="bibr" rid="bib52">Taha et al., 2023a</xref>) or deletion of the Mac1 domain (<xref ref-type="bibr" rid="bib1">Alhammad et al., 2023</xref>) have minor phenotypes in cell culture, their replication is profoundly attenuated in animal models. This discordance likely reflects the inability of cellular models to recapitulate the complex intercellular and systemic signaling required for proper viral–host immune interactions. The underlying mechanism of action results from the enzymatic activity of Mac1, which counters the wave of ADP-ribosylation that is catalyzed by poly-adenosine diphosphate-ribose polymerase (PARP) proteins during the interferon response (<xref ref-type="bibr" rid="bib14">Kar et al., 2024</xref>; <xref ref-type="bibr" rid="bib37">Parthasarathy et al., 2024</xref>; <xref ref-type="bibr" rid="bib17">Kerr et al., 2023</xref>). While the critical proteins and sites modified by interferon-induced PARPs are not fully characterized, the inhibition of Mac1 should allow ADP-ribosylation and the resulting downstream signaling to persist (<xref ref-type="bibr" rid="bib14">Kar et al., 2024</xref>). Indeed, multiple interferon genes are down-regulated upon infection with wild-type SARS-CoV-2 relative to a Mac1-deficient mutant, consistent with the hypothesis that antiviral interferon signaling could be productively enhanced by Mac1 inhibition (<xref ref-type="bibr" rid="bib53">Taha et al., 2023b</xref>; <xref ref-type="bibr" rid="bib1">Alhammad et al., 2023</xref>).</p><p>We (<xref ref-type="bibr" rid="bib10">Gahbauer et al., 2023</xref>; <xref ref-type="bibr" rid="bib45">Schuller et al., 2021</xref>), and others (<xref ref-type="bibr" rid="bib34">O’Connor et al., 2023</xref>; <xref ref-type="bibr" rid="bib46">Schuller et al., 2023</xref>; <xref ref-type="bibr" rid="bib58">Wazir et al., 2024</xref>), have previously developed inhibitors of Mac1 with activity in vitro. However, the therapeutic hypothesis that pharmacological Mac1 inhibition would restore host immune responses and lead to a survival benefit after SARS-CoV-2 infection has not yet been tested. Here, we build on our experimental fragment (<xref ref-type="bibr" rid="bib45">Schuller et al., 2021</xref>) and virtual screening approach (<xref ref-type="bibr" rid="bib10">Gahbauer et al., 2023</xref>) with medicinal chemistry, to develop a potent lead compound, AVI-4206, that engages Mac1 in cellular models and has suitable pharmacological properties to test antiviral efficacy in vivo. In an animal model of SARS-CoV-2 infection, AVI-4206 reduces viral replication, restores an interferon response, and leads to a survival benefit. Therefore, our results validate Mac1 as a therapeutic target via a novel immune-restoring mechanism that could synergize with existing therapies targeting essential aspects of viral replication. The approach could be more widely used to target other macrodomains in viruses beyond SARS-CoV-2.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Optimization of in vitro potency against the SARS-CoV-2 macrodomain</title><p>Previously, we described two novel Mac1 inhibitors, AVI-92 and AVI-219 (<xref ref-type="bibr" rid="bib10">Gahbauer et al., 2023</xref>), which evolved from fragment screening and virtual screening hits, respectively. Their potency was determined using an ADPr-conjugated peptide displacement-based homogeneous time-resolved fluorescence (HTRF) assay (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The superposition of the Mac1 crystal structures in complex with both leads inspired a parallel approach to optimization, which was supported by additional high-resolution X-ray structures of the complexes (<xref ref-type="fig" rid="fig1">Figure 1A, E</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). First, we generated a merged compound that used the urea function of AVI-92 in the more lead-like AVI-219 scaffold, thus avoiding the phenolic and carboxylate functionalities present in AVI-92. Indeed, the X-ray structure of the resulting complex between Mac1 and AVI-4051 shows that it preserves and favorably orients the two hydrogen bonding contacts with the carboxylate of Asp22 and exhibits a ~fivefold lower IC<sub>50</sub> value as compared to AVI-219 in the HTRF assay (<xref ref-type="fig" rid="fig1">Figure 1B, E</xref>). Further structure–activity relationship (SAR) studies revealed a strong preference for urea (e.g., AVI-1500, IC<sub>50</sub> of ~120 nM) over acetamide (AVI-1501) or carbamate (AVI-3367) in productively engaging Asp22 (<xref ref-type="fig" rid="fig1">Figure 1B, E</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Iterative structure-based design and optimization of AVI-4206 activity against Mac1.</title><p>(<bold>A</bold>) Evolution of the early lead AVI-219 to AVI-4206 by introducing and optimizing urea functionality as found in AVI-92 to contact Asp22 and introducing geminal dimethyl substitution of the pyrrolidinone ring. Homogeneous time-resolved fluorescence (HTRF)-based IC<sub>50</sub> values from (<bold>B</bold>) and (<bold>C</bold>), and PDB codes from (<bold>E</bold>) are indicated. HTRF-based dose–response curves showing peptide displacement of an ADPr-conjugated peptide from Mac1 by compounds from the urea (<bold>B</bold>) and the pyrrolidinone ring (<bold>C</bold>) optimization paths. Data is plotted as % competition mean ± SD of three technical replicates. Data were fitted with a sigmoidal dose–response equation using non-linear regression and the IC<sub>50</sub> values are quoted with 95% confidence intervals. (<bold>D</bold>) Mac1 catalytic activity dose–response curve for indicated compounds. Data is plotted as % inhibition mean ± SD of four technical replicates. IC<sub>50</sub> values are quoted with 95% confidence intervals. (<bold>E</bold>) X-ray structures indicating conserved interactions during the optimization path from AVI-92 and AVI-219 (left) to AVI-4206 (right). Structures of compounds from the urea and the pyrrolidinone ring optimization paths are presented in the top and bottom middle panels, respectively. Multiple ligand conformations were observed for AVI-3367, AVI-3762, and AVI-4636 (labeled A and B). The <italic>F</italic><sub>O</sub> − <italic>F</italic><sub>C</sub> difference electron density map calculated prior to ligand modeling is shown for AVI-4206 (purple mesh contoured at 5 σ). Electron density maps used to model ligand other ligands are shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>X-ray density for ligand modeling.</title><p>Ligands were modeled using either traditional <italic>F</italic><sub>O</sub> − <italic>F</italic><sub>C</sub> electron density maps (AVI-1500, AVI-1501, and AVI-4206) or PanDDA event maps (AVI-4051, AVI-3367, AVI-3763, AVI-3762, AVI-3765, AVI-3764, and AVI-4636). The diffraction resolution and refined occupancy are indicated for each ligand. The occupancy is indicated for each confirmation when multiple ligand poses were modeled.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>AVI-4206 and AVI-219 inhibition of Mac1 determined using auto-mono-ADP-ribosylated PARP10 as a substrate.</title><p>(<bold>A</bold>) Standard curve of ADP-ribose detected using 100 nM NUDT5 and the AMP-Glo assay kit. Data are presented as mean ± SD for four technical replicates. Data were fitted with a power function in the form <italic>y = kx<sup>a</sup></italic> using non-linear regression (gray line). (<bold>B</bold>) Titration of Mac1 with auto-mono-ADP-ribosylated PARP10. The concentration of PARP10 was 10 μM based on absorbance at 280 nm, but the titration indicated that the concentration of ADP-ribose released by Mac1 was fivefold lower (~2 μM). Data are presented as mean ± SD for four technical replicates. (<bold>C</bold>) Counterscreen of compounds against 100 nM NudT5 with 2 μM ADP-ribose as a substrate. No inhibition was detected up to 1 mM compound. Data are presented as mean ± SD for four technical replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig1-figsupp2-v1.tif"/></fig></fig-group><p>At the other end of the adenosine site, we explored a subsite that is engaged by the pyrrolidinone ring of AVI-219 with the carbonyl function involved in hydrogen bonding with the backbone amides of Phe156/Asp157 (<xref ref-type="fig" rid="fig1">Figure 1C, E</xref>). In a parallel SAR effort, we had explored this same subsite using a shape-based virtual screening approach called FrankenROCS and noted a hydrophobic patch opposite and below the more polar backbone amides (<xref ref-type="bibr" rid="bib6">Correy et al., 2025</xref>). Leveraging this information, and seeking to enhance hydrophobic contact with these residues, we explored substitutions of the pyrrolidinone ring at C-5. While substituents as large as phenyl were tolerated (AVI-3762 and AVI-3763), these analogs showed reduced ligand efficiency compared to AVI-219. By contrast, a methyl group at C-5 in either stereochemical configuration (AVI-3764 and AVI-3765) improved potency and ligand efficiency. Introducing two methyl groups at C-5 afforded the achiral, gem-dimethyl pyrrolidinone AVI-4636 with an impressive fivefold improvement in potency (IC<sub>50</sub> of ~200 nM) and enhanced ligand efficiency compared to AVI-219 (<xref ref-type="fig" rid="fig1">Figure 1C, E</xref>).</p><p>Ultimately, combining the ethyl urea side chain of AVI-1500 with the gem-dimethyl pyrrolidinone of AVI-4636 produced AVI-4206, the most potent Mac1 inhibitor identified from this series, with an IC<sub>50</sub> value of ~20 nM (<xref ref-type="fig" rid="fig1">Figure 1A, E</xref>). This potency approaches the floor of our HTRF assay, which uses 12 nM of enzyme, and indicates that AVI-4206 is at least ~25- and 60-fold more potent than the AVI-92 and AVI-219 starting points, respectively. The high-resolution co-crystal structure of AVI-4206 confirmed that the desired interaction elements and conformations were maintained from the separate optimization paths (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). To confirm that the high-affinity binding of AVI-4206 was reflected in inhibition of Mac1 catalytic activity, we used auto ADP-ribosylated PARP10 and a coupled NudT5/AMP-Glo assay to measure ADP-ribose released by the enzymatic reaction (<xref ref-type="bibr" rid="bib15">Kasson et al., 2021</xref>; <xref ref-type="bibr" rid="bib56">Voorneveld et al., 2018</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). This assay demonstrated AVI-4206 potently inhibits Mac1 with an IC<sub>50</sub> of 64 nM (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p></sec><sec id="s2-2"><title>AVI-4206 engages Mac1 in cells with high specificity</title><p>Having discovered AVI-4206 as a potent inhibitor of Mac1, we next determined whether this compound could enter cells and bind to Mac1 in this context. Therefore, to assess cellular target engagement, we developed a nanoluciferase-based CEllular Thermal Shift Assay (CETSA-nLuc) assay (<xref ref-type="bibr" rid="bib27">Martinez et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">Sanchez et al., 2022</xref>) to measure thermal stabilization of Mac1 upon compound binding. A549 cells transiently expressing a HiBiT- and FLAG-tagged Mac1 protein were treated with compounds for 1 hr and then incubated across a gradient of temperatures. After heat exposure, cells were lysed and incubated with LgBiT protein which binds to soluble HiBiT-Mac1 protein reconstituting nanoluciferase and producing a luminescent signal. We observed that the <italic>T</italic><sub>agg</sub> (the temperature at which 50% of protein is soluble) shift for compounds at 10 µM mirrored the affinities measured by the HTRF assay, suggesting a dominant role for Mac1 affinity, rather than bioavailability, or another factor, in determining target engagement in cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Furthermore, we observed a dose-dependent shift in <italic>T</italic><sub>agg</sub> by AVI-4206, with a marked ~10°C shift in cells treated with 10 µM of compound compared to DMSO-treated control cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). The observations were also validated by Western blotting with a FLAG-specific antibody (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Encouragingly, we were also able to adapt our CETSA assay for SARS-1 and MERS macrodomain proteins and find that AVI-4206 can shift the melting temperature of both proteins, albeit to a lesser degree than that seen for Mac1 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>AVI-4206 engages Mac1 with high potency and selectivity in cells.</title><p>(<bold>A</bold>) CETSA-nLuc shows differential Mac1 stabilization after treatment of A549 cells with 10 μM of indicated compounds. Data are presented as mean ± SD of two technical replicates. Data were fitted with a sigmoidal dose–response equation using non-linear regression (gray line) and the <italic>T</italic><sub>agg</sub> values are quoted with 95% confidence intervals. (<bold>B</bold>) CETSA-nLuc shows a dose-dependent thermal stabilization of Mac1 after treatment of A549 cells with increasing concentrations of AVI-4206. Data are presented as mean ± SD of two technical replicates. Homogeneous time-resolved fluorescence (HTRF)-based dose–response curves showing displacement of an ADPr-conjugated peptide from indicated proteins by ADP-ribose (<bold>C</bold>) or AVI-4206 (<bold>D</bold>). ADP-ribose was used as a positive control. Data are presented as mean ± SD of three technical replicates. IC<sub>50</sub> values are quoted with 95% confidence intervals. (<bold>E</bold>) Structural modeling of MacroD2 (top, PDB code 4IQY) and Targ1 (bottom, PDB code 4J5S) showing design elements that prevent AVI-4206 cross-reactivity. The atoms of clashing residues (Cys140 in MacroD2, Arg122 in Targ1) are shown with a dot representation. The ADP-ribose present in both human macrodomain structures has been omitted for clarity.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>AVI-4206 increases thermal stability of Mac1 in cells.</title><p>(<bold>A</bold>) CETSA-WB shows thermal stabilization of FLAG-tagged Mac1 protein after treatment of A549 cells with 10 μM of AVI-4206. (<bold>B</bold>) Densitometry values were normalized to the lowest temperature for each treatment. Data are presented as a single densitometry measurement. (<bold>C</bold>) CETSA-nLuc shows differential stabilization of SARS-CoV2, SARS-CoV, and MERS macrodomain proteins in A549 cells treated with 10 μM of AVI-4206. Data are presented as mean ± SD of two technical replicates. Data were fitted with a sigmoidal dose–response equation using non-linear regression (gray line), and the <italic>T</italic><sub>agg</sub> values are quoted with 95% confidence intervals.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Labeled full gel of CETSA-WB shows thermal stabilization of FLAG-tagged Mac1 protein after treatment of A549 cells with 10 μM of AVI-4206.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-103484-fig2-figsupp1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Unlabeled full gels of CETSA-WB show thermal stabilization of FLAG-tagged Mac1 protein after treatment of A549 cells with 10 μM of AVI-4206.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-103484-fig2-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Alignment of AVI-4206-bound SARS-CoV-2 Mac1 with diverse macrodomains suggests the origin of AVI-4206 selectivity.</title><p>(<bold>A</bold>) For human and (<bold>B</bold>) viral macrodomains, AVI-4206 is shown with teal spheres/sticks, SARS-CoV-2 Mac1 is shown with white sticks and the macrodomains being compared are shown with purple sticks. Selected Mac1 residues are labeled with black text, and the most important clashing human/viral residue is labeled and shown with red dots. For the clashing asparagine residue in the viral macrodomains (position equivalent to Phe156 in SARS-CoV-2 Mac1), rotation of the residue around the χ1 dihedral angle (shown with a red arrow) could relieve the clash and allow AVI-4206 binding. The human/viral macrodomain structures compared are bound to ADP-ribose, except for PARP9 MOD1, where no experimental structure is available and the Alphafold 2 model is shown. (<bold>C</bold>) The SARS-CoV-2 Mac1 sequence was aligned to human/viral macrodomains shown in (<bold>A</bold>) and (<bold>B</bold>) for SARS-CoV-2 Mac1 residues within 5 Å of AVI-4206. The SARS-CoV-2 residue numbering and the % identity for each sequence compared to SARS-CoV-2 Mac1 is indicated. (<bold>D</bold>) Surface view of Mac1 (PDB 9CY0) sliced through a plane containing AVI-4206 (teal sticks) and the site of the Val34Leu mutation (purple spheres).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>PARP14 macrodomain 1 activity is not inhibited by AVI-4206.</title><p>(<bold>A</bold>) Titration of AVI-4206 shows full inhibition of WT Mac1, but no effect against catalytically active PARP14:MD1-MD2. Negative controls of Mac1 N40D and PARP14: MD2 are included. We note that the IC<sub>50</sub> for WT Mac1 here is higher than in our other experiments, which we attribute to differences in the substrate preparation, the higher enzyme concentrations used (50 vs. 10 nM), and the exact timing of the end point measurements. (<bold>B</bold>) Enzyme activity measurements to verify that WT Mac1 and PARP14:MD1-MD2 are active and that PARP14:MD2 and Mac1 N40D are inactive.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Thermal proteome profiling in A549 cellular lysates.</title><p>(<bold>A</bold>) Melting curve for Mac1 in A549 lysates treated in duplicate with either DMSO or 100 μM of AVI-4206. Data were normalized to the mean intensity at 37°C. Data were fitted with a sigmoidal dose–response equation using non-linear regression (gray line). (<bold>B</bold>) Volcano plot of the statistical significance and degree of melting temperature shift for all proteins with high-quality melting curves (<italic>n</italic> = 3446 proteins). Teal circles indicate proteins with a statistically significant shift in melting temperature (adjusted p value &lt;0.05). The highest non-significant proteins are labeled and do not have obvious functional overlap with macrodomains.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig2-figsupp4-v1.tif"/></fig></fig-group><p>After confirming Mac1 target engagement in cells, we next tested the selectivity of AVI-4206 for Mac1 over two human macrodomains, Targ1 and MacroD2. In an adapted HTRF assay, both human proteins bind to ADP-ribose in the same low-μM range as Mac1 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), AVI-4206 does not bind appreciably to either protein in this assay (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). The selectivity of AVI-4206 for the active site of Mac1 can be rationalized by the presence of larger residues at key positions in the binding pocket in the human orthologs. In Targ1, Cys104 occupies the analogous position to Ala52 of Mac1, leading to a putative clash with the urea moiety (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Similarly, in MacroD2, Arg122 occupies the analogous position to Leu 126; both the larger arginine side chain and accompanying backbone shift are predicted to clash with the gem-dimethyl of AVI-4206 (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Modeling of other diverse macrodomains, including those within human PARP9 and PARP14, further suggests that AVI-4206 is selective for Mac1 (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Indeed, a catalytically active macrodomain-containing construct of PARP14 (MD1–MD2) is not inhibited by AVI-4206 (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Due to the shared adenosine motif in the substrates for macrodomains and kinases, and the therapeutic importance of protein kinases, we assessed AVI-4206 at 10 μM against a panel of diverse kinases and found no inhibition &gt;35% (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2a</xref>). Lastly, we used mass spectrometry-based thermal proteome profiling (TPP) (<xref ref-type="bibr" rid="bib44">Savitski et al., 2014</xref>) to evaluate the selectivity of AVI-4206 against a complex proteome. We added 50 nM recombinant Mac1 protein into cellular lysates from A549 cells that were treated either with DMSO or with 100 µM of AVI-4206. We find that Mac1, but no native protein from the A459 lysate, displays a statistically significant shift in melting temperature (3.02°C, adjusted p value = 0.045) (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>). While this assay may not be sensitive to detection of proteins with low abundance or low thermal shift upon ligand binding, collectively, these results indicate that AVI-4206 can cross cellular membranes and engage with high specificity for Mac1.</p></sec><sec id="s2-3"><title>AVI-4206 displays limited efficacy in simple cellular models</title><p>To determine whether AVI-4206 can inhibit viral replication in cellular models of SARS-CoV-2 infection, we treated IFN-deficient Vero cells stably expressing TMPRSS2 (Vero-TMPRSS2) and IFN-competent A549 cells stably expressing high levels of ACE2 (A549-ACE2<sup>h</sup>) with AVI-4206 and infected them with an mNeon reporter SARS-CoV-2 WA1 strain (<xref ref-type="bibr" rid="bib59">Xie et al., 2020</xref>). We observed that treatment with AVI-4206 did not reduce viral replication in Vero-TMPRSS2 or A549-ACE2<sup>h</sup> cells (<xref ref-type="fig" rid="fig3">Figure 3A, B</xref>), consistent with previous studies showing that Mac1-deficient SARS-CoV-2 can replicate efficiently in several cell lines (<xref ref-type="bibr" rid="bib53">Taha et al., 2023b</xref>; <xref ref-type="bibr" rid="bib1">Alhammad et al., 2023</xref>). This result stands in contrast to a SARS-CoV-2 protease inhibitor, nirmaltrevir, which potently inhibited replication in both cell lines (EC<sub>50</sub> 275 and 9.4 nM, respectively) (<xref ref-type="fig" rid="fig3">Figure 3A, B</xref>). Nonetheless, this experiment, together with a viability assay, indicated no direct cytotoxicity of AVI-4206 at concentrations as high as 100 μM (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A, B</xref>). Next, we explored whether interferon pretreatment could potentiate the response of AVI-4206 using SARS-CoV-2 replicons (<xref ref-type="bibr" rid="bib52">Taha et al., 2023a</xref>) as we previously demonstrated for a Mac1-deficient SARS-CoV-2 replicon (WA1 N40D mutant, often referred to as N1062D in full length Nsp3) (<xref ref-type="bibr" rid="bib53">Taha et al., 2023b</xref>; <xref ref-type="bibr" rid="bib1">Alhammad et al., 2023</xref>; <xref ref-type="fig" rid="fig3">Figure 3C</xref>). We did not observe a reduction in viral RNA replication of the Mac1-deficient replicon compared with the wild-type replicon in Vero cells stably expressing ACE2 and TMPRSS2 (VAT) or A549-ACE2<sup>h</sup> cells treated with or without AVI-4206 and 1000 IU/ml of IFN-gamma (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C, D</xref>). However, there was a modest dose-dependent decrease in replication of the wild-type, but not Mac1-deficient, replicon in A549-ACE2<sup>h</sup> cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). When the IFN-gamma dose was increased to 10,000 IU/ml, we observed a small (~1.6-fold) effect for the Mac1-deficient replicon relative to the wild-type replicon (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Treatment with the highest dose (100 μM) of AVI-4206 led to a statistically significant, but small (~1.7-fold), reduction in replication for the wild-type, but not Mac1-deficient, replicon (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). From these experiments, we conclude that cellular models of SARS-CoV-2 infection give, at best, only a narrow window for assessing the efficacy of Mac1 inhibition and that high concentrations of AVI-4206 can achieve a limited anti-viral response without cytotoxicity in an IFN- and Mac1 catalytic activity-dependent manner.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Vero-TMPRSS2 (<bold>A</bold>) or A549-ACE2<sup>h</sup> (<bold>B</bold>) cells were pretreated with compounds and infected with mNeonGreen reporter SARS-CoV-2.</title><p>mNeonGreen expression was measured by the Incucyte system. Graphs represent mean ± SD of % replication normalized to the DMSO control 24 post-infection of three independent experiments performed in triplicate. Data were fitted with a sigmoidal dose–response equation using non-linear regression (gray line) and the EC<sub>50</sub> values are quoted with 95% confidence intervals. (<bold>C</bold>) Schematic of the replicon assay to test the efficacy of AVI-4206 in A549 ACE2<sup>h</sup> cells. (<bold>D</bold>) Luciferase readout of A549 ACE2<sup>h</sup> cells infected with WA1 or WA1 Mac1 N40D replicons and treated with or without AVI-4206 and IFN-ɣ at indicated concentrations; *p &lt; 0.05 by two-tailed Student’s <italic>t</italic>-test relative to the no AVI-4206 and no IFN-ɣ control. Results are plotted as normalized mean ± standard deviation luciferase values of a representative biological experiment containing two technical replicates. (<bold>E</bold>) Representative images of A549 cells stably expressing Mac1 and Mac1-N40D treated with IFN-γ and/or RBN012759 or AVI-4206. DMSO-treated cells are shown as vehicle control. Poly/mono ADPr signal comes from Poly/Mono-ADP Ribose (D9P7Z) Rabbit mAb (CST, 89190S) staining. (<bold>F</bold>) Relative mean cytoplasmic poly/mono ADPr intensity of cells from (<bold>F</bold>). Data shown as mean values ± SD. At least 8000 cells were analyzed in each group, from triplicate wells. Two-tailed Student’s <italic>t</italic>-test was used to compare ADPr intensity levels of each treatment. *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>AVI-4206 has limited antiviral efficacy and no cytotoxicity in cellular models of infection.</title><p>Drug cytotoxicity of AVI-4206 in Vero-TMPRSS2 (<bold>A</bold>) and A549 ACE2<sup>h</sup> (<bold>B</bold>) was measured using the CellTiter-Glo viability assay. Graphs represent the mean ± SD of three biological replicates each conducted in triplicate. Luciferase readout of VAT (<bold>C</bold>) and A549 ACE2<sup>h</sup> (<bold>D</bold>) cells infected with WA1 or WA1 Mac1 N40D replicons and treated with or without AVI-4206 and IFN-ɣ at indicated concentrations. Results are plotted as normalized mean ± SD luciferase values of a representative biological experiment containing three technical replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Relative mean cytoplasmic poly/mono ADPr intensity of A549 cells stably expressing Mac1 and Mac1-N40D treated with IFN-γ and/or AVI-4206.</title><p>DMSO-treated cells are shown as vehicle control. Poly/mono ADPr signal comes from Poly/Mono-ADP Ribose (E6F6A) Rabbit mAb (CST, 83732S) staining. Data shown as mean values ± SD. At least 10,000 cells were analyzed each group, from triplicate wells. Two-tailed Student’s <italic>t</italic>-test was used to compare ADPr intensity levels of each treatment. *p &lt; 0.05; **p &lt; 0.01.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>ADP-ribosylation profiling during infection by Western Blot.</title><p>(<bold>A</bold>) Immunoblot showing pan-ADP-ribose (panADPr) levels in Calu-3 cells under indicated infection conditions. UI = uninfected cells, WT = cells infected with WA1, N40D = cells infected with WA1 NSP3 Mac1 N40D, with or without 100 μM AVI-4206 treatment. HeLa cells treated with H₂O₂ were included as a positive control for the ADPr signal. Actin serves as a loading control. (<bold>B</bold>) Densitometric analysis of panADPr levels normalized to actin. Data are presented as mean ± SD (n = 3), with p- values indicated. (<bold>C</bold>) Immunoblot showing mono-ADP-ribose (monoADPr) levels under the same conditions as (<bold>A</bold>). (<bold>D</bold>) Densitometric analysis of monoADPr levels normalized to actin. No statistically significant differences (ns) were observed between conditions. Data are shown as mean ± SD (n = 3).</p><p><supplementary-material id="fig3s3sdata1"><label>Figure 3—figure supplement 3—source data 1.</label><caption><title>Annotated Iimmunoblot showing pan-ADP-ribose (panADPr) and mono-ADP-ribose (monoADPr) levels in Calu-3 cells under indicated infection conditions.</title><p>UI = uninfected cells, WT = cells infected with WA1, N40D = cells infected with WA1 NSP3 Mac1 N40D, with or without 100 μM AVI-4206 treatment. HeLa cells treated with H₂O₂ were included as a positive control for the ADPr signal. Actin serves as a loading control.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-103484-fig3-figsupp3-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig3s3sdata2"><label>Figure 3—figure supplement 3—source data 2.</label><caption><title>Full gels of immunoblot showing pan-ADP-ribose (panADPr) and mono-ADP-ribose (monoADPr) levels in Calu-3 cells under indicated infection conditions.</title><p>UI = uninfected cells, WT = cells infected with WA1, N40D = cells infected with WA1 NSP3 Mac1 N40D, with or without 100 μM AVI-4206 treatment. HeLa cells treated with H₂O₂ were included as a positive control for the ADPr signal. Actin serves as a loading control.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-103484-fig3-figsupp3-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig3-figsupp3-v1.tif"/></fig></fig-group><p>Although the IFN response was not sufficient to control viral replication, it is possible that the changes in ADP-ribosylation, in particular marks catalyzed by PARP14, downstream of IFN treatment could serve as a marker for Mac1 efficacy (<xref ref-type="bibr" rid="bib40">Ribeiro et al., 2025</xref>). To investigate whether downstream signals from PARP14 were specifically erased by Mac1, we used an immunofluorescence assay that showed that Mac1 could remove IFN-γ-induced ADP-ribosylation that is mediated by PARP14 (<xref ref-type="bibr" rid="bib14">Kar et al., 2024</xref>). We stably expressed either wild-type Mac1 or the N40D mutant Mac1 in A549 cells. The data showed that Mac1 expression decreased IFN-γ-induced ADP-ribosylation, whereas the Mac1-N40D mutant did not (<xref ref-type="fig" rid="fig3">Figure 3E, F</xref>), indicating that Mac1 mediates the hydrolysis of IFN-γ-induced ADP-ribosylation. The PARP14 inhibitor RBN012759 completely blocked IFN-γ-induced ADP-ribosylation (<xref ref-type="fig" rid="fig3">Figure 3E, F</xref>), further confirming that IFN-γ-induced ADP-ribosylation is mediated by PARP14. AVI-4206 reversed the Mac1-induced hydrolysis of ADP-ribosylation and enhanced the ADP-ribosylation signal in Mac1-overexpressing cells (<xref ref-type="fig" rid="fig3">Figure 3E, F</xref>), further demonstrating its ability to inhibit the hydrolase activity of Mac1. We further validated this result using different ADP-ribosylation antibodies for immunofluorescence (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). However, we observed no strong consistent signals of global pan-ADP-ribose (panADPr) or mono-ADP-ribose (monoADPr) accumulation in infected cells treated with AVI-4206 in immunoblot analyses . Collectively, these results provide further evidence that simple cellular models are insufficient to explore the effects of Mac1 inhibition and that monitoring specific PARP14-mediated ADP-ribosylation patterns can provide an accessible biomarker for the efficacy of Mac1 inhibition.</p></sec><sec id="s2-4"><title>AVI-4206 displays efficacy in organoids and primary cell models</title><p>Next, we tested AVI-4206 in a system that more closely replicates both the structural and functional characteristics of the human airway epithelium. We used human airway organoids (HAOs), which are derived from primary stem cells generated from human lungs and grow as complex three-dimensional structures (<xref ref-type="bibr" rid="bib42">Sachs et al., 2019</xref>). These cells can be differentiated into the various cell types found in the airway epithelium, including ciliated, goblet, and basal cells (<xref ref-type="bibr" rid="bib23">Li et al., 2023a</xref>; <xref ref-type="bibr" rid="bib49">Simoneau et al., 2024</xref>). We (<xref ref-type="bibr" rid="bib49">Simoneau et al., 2024</xref>) and others (<xref ref-type="bibr" rid="bib24">Li et al., 2023b</xref>) have utilized differentiated HAOs as a more relevant infection model that encompasses more robust innate immune functions. We therefore sought to test the efficacy of AVI-4206 in HAOs infected with SARS-CoV-2 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The Mac1-deficient virus (WA1 N40D mutant) showed no reduction, 10-fold reduction, and 1000-fold reduction in viral particle production at 24, 48, and 72 hr post-infection compared to the wild-type virus (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). AVI-4206 treatment reduced viral particle production 10- and 100-fold at 48 and 72 hr post-infection, respectively, and 20 μM AVI-4206 reduced viral particle production by 10-fold at 72 hr post-infection (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). As we have observed previously (<xref ref-type="bibr" rid="bib53">Taha et al., 2023b</xref>; <xref ref-type="bibr" rid="bib1">Alhammad et al., 2023</xref>), the faster clearance of infection in AVI-4206 treated HAOs, similar to that seen with the Mac1-deficient virus, is likely due to a potent innate immune response rather than a direct effect of Mac1 on viral replication.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>AVI-4206 displays efficacy in organoids and primary cell models.</title><p>(<bold>A</bold>) Schematic of the human airway organoid (HAO) experiment. (<bold>B</bold>) Viral particle production was measured by plaque assay at indicated time points and AVI-4206 concentrations. Error bars indicate SEM. **p &lt; 0.01; *p &lt; 0.05 by two-tailed Student’s <italic>t</italic>-test relative to the vehicle control. (<bold>C</bold>) Monocyte-derived macrophages (MDMs) were exposed to SARS-CoV-2, and virus particle production was assessed 24 hr later using a plaque assay. **p &lt; 0.01 by two-tailed Student’s t-test relative to WA1. (<bold>D</bold>) Plaque assay of MDMs infected with WA1 or WA1 Mac1 N40D viruses and treated with AVI-4206 at indicated concentrations and IFN-γ at 50 ng/ml. *p &lt; 0.05 by two-tailed Student’s <italic>t</italic>-test compared to the untreated control. (<bold>E</bold>) MDMs were incubated with AVI-4206 for 24 hr, after which cytotoxicity was assessed using an ATP-based cytotoxicity assay.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig4-v1.tif"/></fig><p>The signs of efficacy in organoids suggested that a more native cellular model might serve as a better surrogate for pharmacological interventions in vivo. We turned to peripheral blood monocyte-derived macrophages (MDMs), key effector cells of the innate immune system with a high capacity to produce and respond to type I interferons via pattern recognition receptors (<xref ref-type="bibr" rid="bib12">Ivashkiv, 2013</xref>; <xref ref-type="bibr" rid="bib16">Kawai and Akira, 2010</xref>). Additionally, due to their interferon-competent nature, primary macrophages have previously been used to understand the role of host PARPs and virally encoded macrodomains in a pathogenic murine coronavirus (<xref ref-type="bibr" rid="bib11">Grunewald et al., 2019</xref>). To validate the potential for MDMs to assess the antiviral activity of AVI-4206, MDMs were first exposed to SARS-CoV-2 variants at a multiplicity of infection (MOI) of 1, and viral particle production was confirmed by plaque assay 24 hr post-infection (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). To evaluate the efficacy of AVI-4206, MDMs were pretreated with the compound in the presence of IFN-γ, followed by infection with the SARS-CoV-2 WA1 strain. AVI-4206 suppressed viral particle production in a concentration-dependent manner, reducing viral particle production by approximately threefold at 4 μM and fivefold at 100 μM after 24 hr (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). No statistically significant difference was observed between the antiviral effect of the WA1 N40D mutant and treatment with 100 μM AVI-4206. Importantly, no apparent cytotoxicity was detected at any of the tested concentrations (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). These findings demonstrate that MDMs provide a physiologically relevant platform for evaluating the antiviral efficacy of macrodomain pharmacological inhibition. While these cellular and organoid experiments gave some indication of an effect of AVI-4206, testing in animal models was required to establish whether this compound had significant activity in reducing viral pathogenesis.</p></sec><sec id="s2-5"><title>AVI-4206 has favorable pharmacological properties</title><p>Prior to testing the efficacy of AVI-4206 in animal models, we assessed the pharmacological properties of the compound to predict a dosing regime that would provide sufficient target coverage to test efficacy. In parallel with optimizing compounds for potent inhibition of Mac1, as described above, we employed data from standard in vitro assays of metabolism, permeability, and physicochemical properties to drive our medicinal chemistry campaign. Thus, the series leading to AVI-4206 was optimized for stability in mouse liver microsomes and human hepatocytes, low plasma protein binding (good free fraction), and high aqueous solubility (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). However, the introduction of the urea functionality in this series negatively impacted permeability in Caco-2 monolayers when compared to the parent AVI-219, predicting low oral bioavailability. Indeed, in mouse pharmacokinetic (PK) studies, AVI-4206 showed poor oral bioavailability (&lt;4%), while intrinsic clearance was moderate, about 60% of hepatic blood flow (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2b</xref>). Bioavailability via the intraperitoneal (IP) route, however, was excellent and free drug concentrations ~100-fold above the biochemical IC<sub>50</sub> were achieved for 8 hr following a single IP dose at 100 mg/kg (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2b</xref>). In a separate PK experiment employing a 10 mg/kg IP dose, total exposure of AVI-4206 in lung was higher than in plasma at later time points (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), suggesting its suitability for an in vivo infection model to validate Mac1 as an antiviral target. Moreover, AVI-4206 showed minimal inhibition of common cytochrome P450 (CYP) isoforms (<xref ref-type="fig" rid="fig5">Figure 5D</xref>) and screening across a broader panel of potential off targets (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2c</xref>) identified no significant liabilities among major channels, receptors, or enzymes. Overall, the biochemical potency and PK profile of AVI-4206 suggested the likelihood of sustained target engagement in mice with twice-daily doses (BID) of 100 mg/kg by the IP route allowing us to test proof of concept.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>AVI-4206 has a favorable pharmacological profile.</title><p>(<bold>A</bold>) Pharmacokinetic properties of AVI-4206. (<bold>B</bold>) Unbound plasma exposure time course of AVI-4206, corrected for plasma protein binding, following administration by IV, PO, or IP routes in male CD-1 mice at the indicated doses. (<bold>C</bold>) Free plasma exposure of AVI-4206 and total exposure in lung homogenate following an IP dose of 10 mg/kg in female C57BL/6 mice. (<bold>D</bold>) Inhibition of CYP isoforms by AVI-4206 at a fixed concentration of 10 μM. Two experiments were performed with CYP3A4 using different positive controls. (<bold>E</bold>) Heatmap of AVI-4206 activity in an off-target safety panel including receptors, ion channels, and proteases, showing no antagonist response &gt;15% at 10 μM.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig5-v1.tif"/></fig></sec><sec id="s2-6"><title>AVI-4206 is effective in a mouse model of SARS-CoV-2 infection</title><p>To assess the efficacy of AVI-4206 in vivo, we used the K18-hACE2 mouse model, which mimics severe SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib60">Zheng et al., 2021</xref>). The K18-hACE2 mouse is a stringent model to test efficacy, as previous studies using potent protease inhibitors did not lead to full survival, unless combined with molnupiravir (<xref ref-type="bibr" rid="bib36">Papini et al., 2024</xref>). In our experiment, animals were divided into three groups (wild-type WA1 virus with compound or vehicle treatment, and a Mac1-deficient mutant-infected positive control) with treatment (AVI-4206 at 100 mg/kg intraperitoneally, nirmatrelvir at 300 mg/kg orally, or vehicle control for each drug) initiated 1 day prior to infection (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). AVI-4206 or nirmatrelvir was administered twice daily until 5 days post-infection, during which the mice were closely monitored for disease parameters such as weight loss and hunched posture. Both vehicle-treated groups experienced weight loss starting at 3–4 days post-infection and continued losing weight until the end of the study at 7 days post-infection (<xref ref-type="fig" rid="fig6">Figure 6B, C</xref>). The AVI-4206 and nirmatrelvir treated groups experienced weight loss starting at 4 days post-infection, but the extent of weight loss was about 5–10% lower on average at days 5–7 post-infection compared with their respective vehicle-treated groups (<xref ref-type="fig" rid="fig6">Figure 6B, C</xref>). Consequently, ~70% of the AVI-4206 treated group and 40% of the nirmatrelvir treated group survived, whereas all mice in the vehicle treated groups died by the end of the study based on the humane endpoints of hunched posture or &gt;20% decrease in body weight (<xref ref-type="fig" rid="fig6">Figure 6D, E</xref>). Consistent with previous studies (<xref ref-type="bibr" rid="bib53">Taha et al., 2023b</xref>), none of the mice in the mutant-infected positive control group experienced weight loss, and all survived the infection (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). These results indicate that AVI-4206 can significantly reduce disease severity and prevent death in the K18-hACE2 model and is comparable to the FDA-approved main protease inhibitor nirmatrelvir.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>AVI-4206 reduces viral replication and increases survival and cytokine abundance in vivo.</title><p>(<bold>A</bold>) K18-hACE2 mice were intranasally infected and dosed as indicated with either AVI-4206 (<italic>n</italic> = 15, intraperitoneally), nirmatrelvir (<italic>n</italic> = 5, per os), or vehicle (<italic>n</italic> = 10 for the AVI-4206 group or <italic>n</italic> = 5 for the nirmatrelvir group). Mice infected with the WA1 N40D mutant, which lacks Mac1 catalytic activity, served as a positive control (<italic>n</italic> = 10). Lungs were harvested at indicated time points for virus titration by plaque assay. (<bold>B</bold>) The percent body weight loss for all animals treated with AVI-4206 (100 mg/kg IP) (<bold>C</bold>) or nirmatrelvir (300 mg/kg PO). The data are presented as mean ± SD. *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001 by two-tailed Student’s <italic>t</italic>-test relative to the vehicle control at each time point. (<bold>D</bold>) Survival curve plotted based on the percent weight loss humane endpoint (20%) for AVI-4206 and (<bold>E</bold>) nirmatrelvir. (<bold>F</bold>) Viral load in the lungs and brain of infected mice at the indicated time points. The data are shown as mean ± SEM. *p &lt; 0.05; **p &lt; 0.01 by Mann–Whitney’s test relative to the vehicle control. (<bold>G</bold>) Schematics and graphs demonstrating the abundance of indicated cytokines at 4 and 7 days post-infection in the lungs of infected mice. The data are presented as mean ± SEM. *p &lt; 0.05; **p &lt; 0.01 by two-tailed Student’s <italic>t</italic>-test relative to the vehicle control at each time point. None of the mice reached the humane endpoint at day 4 post-infection. For mice that reached the humane endpoint before day 7 post-infection, the tissues were collected and analyzed with mice at the 7-day time point.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Lung histology.</title><p>We examined determinants of tissue damage by either (<bold>A</bold>) caspase 3 staining for apoptosis (**&quot;, signifies a p value of 0.0013 in a two tailed unpaired T-test analysis) or (<bold>B</bold>) Masson’s Trichrome stain for collagen deposition and pulmonary fibrosis. In the lungs of AVI-4206 treated animals, apoptosis is significantly reduced compared to the lungs of the vehicle cohort. While collagen deposition in the lungs of AVI-4206 treated animals is trending lower, the result is not significant. There is no difference in pathology between the N40D cohort and vehicle-treated cohort with these markers. This could suggest that AVI-4206 provides an additional mechanism that results in protection.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Lower dose AVI-4206 reduces viral replication and increases survival in vivo.</title><p>(<bold>A</bold>) K18-hACE2 mice were intranasally infected with SARS-CoV-2 WA1 or SARS-CoV-2 WA1 Mac1 N40D mutant. Mice were treated as indicated with AVI-4206 (BID, 30 mg/kg) or vehicle. Each group was composed of n = 10 mice (5 mice per time point). (<bold>B</bold>) The percent body weight loss is presented as mean ± SD. **, p &lt; 0.01; ***, p &lt; 0.001 by two-tailed Student’s t-test relative to the vehicle control at each time point. (<bold>C</bold>) Survival curve based on the percent body weight loss humane endpoint. (<bold>D</bold>) Viral load in the lung at indicated time points is presented as mean ± SEM **, p &lt; 0.01 by Mann –Whitney’s test relative to the vehicle control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig6-figsupp2-v1.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>AVI-4206 suppresses replication of mouse-adapted SARS-CoV-2 in wild-type mice.</title><p>(<bold>A</bold>) Wild-type mice were intranasally infected with SARS-CoV-2 and treated with AVI-4206, AVI-6451, or vehicle (n = 10 per group). Mice infected with the WA1 N40D mutant served as a positive control (n = 10). Lung tissues were collected at designated time points for viral titer analysis using a plaque assay. Viral load in the lungs of wild-type mice treated with AVI-4206 (<bold>B</bold>, day 2; <bold>C</bold>, day 5). **, p &lt; 0.01 by Mann –Whitney’s test relative to the vehicle control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-fig6-figsupp3-v1.tif"/></fig></fig-group><p>To understand the mechanism of AVI-4206 action during the course of infection, mice from each group were euthanized at either day 4 or 7. We observed that AVI-4206 treatment reduced viral load in the lungs by ~10- and ~100-fold at 4 and 7 days post-infection, respectively, and reduced transmission to the brain (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). Although it is possible that AVI-4206 crosses the blood–brain barrier, it is more likely that the reduction of viral load in the brain is as a consequence of a reduction in overall systemic viral load. The prevention of virus localization to the brain is especially important in this model because human ACE2 overexpression allows virus replication and spread to brain tissue, which ultimately leads to encephalitis and the death of infected mice (<xref ref-type="bibr" rid="bib2">Bao et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Oladunni et al., 2020</xref>). The faster clearance of viral load in the lungs for AVI-4206 treated and Mac1-deficient virus infected mice compared with the vehicle-treated mice, rather than an early antiviral effect post-infection, is consistent with an immune response mediated mechanism rather than a direct antiviral mechanism.</p><p>To further investigate the antiviral mechanism of AVI-4206, we measured the abundance of the antiviral cytokines IP-10, IL-2, IL-6, and TNF-α in lung tissue at 4 and 7 days post-infection (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). We found that levels of all of these cytokines were elevated at 4 days post-infection. At 7 days post-infection, the AVI-4206 treated and Mac1-deficient virus infected mice maintained significantly higher levels of IP-10, IL-2, and IL-6 (p &lt; 0.05) compared to the vehicle treated group; TNF-α showed a similar trend but did not reach statistical significance (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). The lower levels of cytokines in the vehicle-treated group at 7 days post-infection are likely mediated by the immune-suppressive capability of SARS-CoV-2 macrodomain. However, when the macrodomain is inactivated, either through AVI-4206 treatment or infection with Mac-1 defective variant, the antiviral response is enhanced, which blocks viral replication. The cumulative cytokine abundance (IP-10, IL-2, and IL-6) indicates an antiviral immune response, likely mediated through the activation of the NF-κB pathway (<xref ref-type="bibr" rid="bib41">Robertson et al., 2023</xref>; <xref ref-type="bibr" rid="bib33">Neufeldt et al., 2022</xref>). Caspase 3 staining shows that AVI-4206 treatment reduces apoptosis in the lungs compared to vehicle controls. Additionally, histology reveals a reduction in Caspase 3 staining and Masson’s Trichrome staining for collagen deposition, which are surrogates for lung pathology, in the lungs of AVI-4206 treated animals (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). We additionally tested the efficacy of AVI-4206 at a lower dosage of 30 mg/kg using the same experimental setup. Even at this lower dose, AVI-4206 enhanced survival and produced lower viral load at 7 days post-infection relative to vehicle (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>), but to a more modest degree than at the higher dose (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Finally, we assessed the antiviral efficacy of AVI-4206 using a wild-type mouse model infected with a mouse-adapted SARS-CoV-2 strain, which exhibits reduced neuroinvasiveness compared to ACE2 transgenic models. Treatment with AVI-4206 resulted in a measurable reduction in pulmonary viral load as early as 2 days post-infection (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3</xref>). Collectively, our observations of enhanced survival of mice in a lethal model, reduced viral load in multiple mouse models, and the observed increase in antiviral cytokines suggest that AVI-4206 is capable of potentiating the host immune response, thereby reducing disease severity.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we provide strong pharmacological evidence validating Mac1 and de-ADP-ribosylation as a therapeutic target for SARS-CoV-2. AVI-4206 is a competitive inhibitor that blocks the ADP-ribosylhydrolase activity of Mac1. This activity antagonizes the PARP-mediated ADP-ribosylation that is part of the antiviral interferon response. Although mechanistic links are still emerging between specific post-translational modifications and an effective antiviral response, our pharmacologic studies add to the genetic and biochemical evidence of the importance of this signaling axis for viral replication in vivo (<xref ref-type="bibr" rid="bib53">Taha et al., 2023b</xref>; <xref ref-type="bibr" rid="bib1">Alhammad et al., 2023</xref>). Our work also adds to the growing role of modulating ADP-ribosylation signaling in therapeutic development (<xref ref-type="bibr" rid="bib8">Dasovich and Leung, 2023</xref>). For example, inhibitors of PARP1, which catalyzes the addition of poly- ADP-ribose marks, have been developed for treating tumors with mutations in either <italic>BRCA1</italic> or <italic>BRCA2</italic> (<xref ref-type="bibr" rid="bib26">Lord and Ashworth, 2017</xref>) and inhibitors of PARG, which catalyzes the removal of α(1′′–2′) O-glycosidic linkages in PAR chains, are under investigation for a variety of cancers (<xref ref-type="bibr" rid="bib50">Slade, 2020</xref>). The presence of macrodomains and experimental evidence for them as interferon signaling antagonists in other diverse viruses, such as Chikungunya (<xref ref-type="bibr" rid="bib30">McPherson et al., 2017</xref>), suggests that inhibiting this target class may be effective for treatment of other virally induced diseases beyond COVID.</p><p>While AVI-4206 is protective in an animal model of infection, it was initially developed without many of the normal intermediate markers of improvement in cellular models. This discordance was expected based on the mechanism of action, as interferon-based antiviral activity likely requires intra- and inter-cellular and systemic communication between different cell types (<xref ref-type="bibr" rid="bib39">Platanias, 2005</xref>). The limited replication defect difference between wild-type and Mac1-deficient viruses in cellular models renders them largely ineffective as a model to test the effects of macrodomain inhibition, which has led others to question the validity of Mac1 as a target (<xref ref-type="bibr" rid="bib21">Lee et al., 2024</xref>). AVI-4206 did in fact demonstrate modest antiviral activity only in the presence of exogenous IFN in cells, which is consistent with most other studies that have examined Mac1 activity (<xref ref-type="bibr" rid="bib53">Taha et al., 2023b</xref>; <xref ref-type="bibr" rid="bib1">Alhammad et al., 2023</xref>; <xref ref-type="bibr" rid="bib18">Kerr et al., 2024</xref>). While a larger replication defect is observed in HAOs likely due to their more relevant antiviral innate immune responses (<xref ref-type="bibr" rid="bib49">Simoneau et al., 2024</xref>), the highest dose of AVI-4206 does not achieve the magnitude of the replication defect of the Mac1-deficient virus. This may reflect an unoptimized prophylactic dosing schedule or the need to better tune the pharmacological properties of the inhibitor. Taken together, the concordance of in vitro (HTRF) and cellular target engagement assays (CETSA) stands out as particularly important in the development path of macrodomain inhibitors. Nonetheless, developing a cellular model for assessing macrodomain function and inhibition is important. We have now been able to leverage SARS-CoV-2–infected macrophages, where an active immune response is induced, including inflammasome activation (<xref ref-type="bibr" rid="bib47">Sefik et al., 2022</xref>), to assess the antiviral efficacy of AVI-4206 by detecting and quantifying transient viral particle production following infection. This macrophage-based cell model will enable more physiologically relevant evaluation of macrodomain inhibitors. This cell model will also be important for elucidating the molecular details underlying how macrodomain inhibition results in antiviral activity. In addition to dissecting molecular mechanisms of macrodomain function and inhibition, future efforts will focus on improving PK properties, including a cellular efflux liability that results in low oral bioavailability of AVI-4206.</p><p>In conclusion, AVI-4206 blocks the viral enzymatic removal of post-translational modifications important for the immune response, which is an important mechanism for blocking virus replication and reducing disease severity. Notably, Mac1 represents a second pharmacologically validated enzymatic domain within Nsp3: a recently developed inhibitor of the papain-like protease (PLpro) domain also shows efficacy in animal models and acts by removing a distinct set of host post-translational modifications (ubiquitin and interferon-stimulated gene 15 (ISG15)) (<xref ref-type="bibr" rid="bib54">Tan et al., 2024</xref>). In summary, AVI-4206 provides proof of concept for the validation of a novel antiviral target, Mac1. By restoring the antiviral immune response, the novel mechanism of action of AVI-4206 could be synergistic or additive with orthogonally acting direct antivirals, such as protease and polymerase inhibitors, in combination therapies for the treatment of SARS-CoV-2 infection and beyond.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Synthetic chemistry</title><sec id="s4-1-1"><title>General experimental procedures</title><p>Unless otherwise noted, all chemical reagents and solvents used are commercially available. AVI-92 and AVI-219 were synthesized as previously described (<xref ref-type="bibr" rid="bib10">Gahbauer et al., 2023</xref>). Reverse phase chromatography was carried out on one of the following instruments: (1) Waters 2535 Separation module with Waters 2998 Photodiode Array Detector. Separations were carried out on XBridge Preparative C18, 19 × 50 mm column at ambient temperature using a mobile phase gradient of water–acetonitrile–0.1% formic acid. (2) Gilson GX-281 instrument, separations using Xtimate Prep C18, 21.2*250 mm, 150 Å, 10 μm particle size column. (3) Agilent 1260 Infinity systems equipped with DAD and mass detector. Separations carried out on Chromatorex 18 SMB100-5T 100 × 19 mm 5 μm column using mobile phase gradient of water/methanol/0.005% HCl. Chiral separations were carried out on CHIRALPAK IA (250 × 21 mm, 5 mkm)-II column at ambient temperature using a mobile phase of hexane (0.3% DEA): IPA:MeOH, 90:5:5. LC/MS data were acquired by one of the following instruments: (1) Waters Acquity UPLC QDa mass spectrometer equipped with Quaternary Solvent Manager, Photodiode Array Detector, and Evaporative Light Scattering Detector. Separations were carried out with Acquity UPLC BEH C18 1.7 mm, 2.1 × 50 mm column at 25°C, using a mobile phase gradient of water–acetonitrile containing a constant 0.1% formic acid. Detection: UV (254 nm), ELS, and MS (ESI, positive mode), (2) Agilent 1100 Series LC/MSD system with DAD/ELSD Alltech 2000ES and Agilent LC/MSD VL (G1956B), SL (G1956B) mass-spectrometer, (3) Agilent 1200 Series LC/MSD system with DAD/ELSD Alltech 3300 and Agilent LC/MSD G6130A, G6120B mass-spectrometer, (4) Agilent Technologies 1260 Infinity LC/MSD system with DAD/ELSD Alltech 3300 and Agilent LC/MSD G6120B mass-spectrometer, or (5) Agilent Technologies 1260 Infinity II LC/MSD system with DAD/ELSD G7102A 1290 Infinity II and Agilent LC/MSD G6120B mass-spectrometer. Separations were carried out with InfinityLab Poroshell 120 SB-C18 4.6 × 30 mm 2.7 μm column at 25°C, using a mobile phase gradient of water–acetonitrile containing a constant 0.1% formic acid. Detection using DAD1A 215 nm, DAD1B 254 nm MSD – single quadrupole, AP-ESI (positive/negative mode switching). (6) Agilent 1200 Infinity LC with an Agilent 1956 single quadrupole MS using electrospray ionization. Separations were carried out on a SunFire C18 (4.6 × 50 mm, 3.5 μm) column at 50°C using a mobile phase gradient of water (10 mmol NH<sub>4</sub>HCO<sub>3</sub>)/acetonitrile. Detection: UV (214, 254 nm) and MS (ESI, POS mode, 103–100 atomic mass units). Chemical shifts are reported in units of ppm. NMR spectra were referenced relative to residual NMR solvent peaks. Coupling constants (<italic>J</italic>) are reported in hertz (Hz). NMR spectra were recorded on one of the following instruments: (1) Bruker AVANCE DRX 500 (500 MHz magnet with 5 mm QNP <sup>31</sup>P/<sup>13</sup>C/<sup>15</sup>N and 5 mm TXI probe), (2) Agilent ProPulse 600 (600 MHz magnet with 5 mm OneNMR probe), and (3) Bruker Avance III HD 400 MHz spectrometer.</p></sec><sec id="s4-1-2"><title>1-((8-Amino-9<italic>H</italic>-pyrimido[4,5-b]indol-4-yl)amino)pyrrolidin-2-one</title><fig id="C1" position="anchor"><label>Chemical structure 1.</label><caption><title>1-((8-Amino-9<italic>H</italic>-pyrimido[4,5-b]indol-4-yl)amino)pyrrolidin-2-one.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-chem1-v1.tif"/></fig><p>A solution 3-fluoro-2-nitroaniline (11 g, 70.51 mmol) in acetic anhydride (20 ml) was stirred at room temperature for 16 hr. The reaction mixture was filtered and the solids were washed with petroleum ether (100 ml) and dried to obtain 10.7 g (77%) of <italic>N</italic>-(3-fluoro-2-nitrophenyl)acetamide as a brown solid. LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 199.3 (M+H)<sup>+</sup>.</p><p>To a solution of <italic>N</italic>-(3-fluoro-2-nitrophenyl)acetamide (10.7 g, 54.04 mmol) in DMF (100 ml) was added methyl 2-isocyanoacetate (8.02 g, 81.06 mmol) and potassium carbonate (14.92 g, 108.08 mmol). After stirring at 80°C for 2 hr, the reaction mixture was cooled to room temperature, acidified with 2 N HCl (ca. 2000 ml), and extracted with ethyl acetate (300 ml *3). The combined organic layers were washed with brine (100 ml), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (10:1 petroleum ether/ethyl acetate) to obtain 11 g (73%) of methyl 2-(3-acetamido-2-nitrophenyl)-2-isocyanoacetate as a yellow solid. LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 278.2 (M+H)<sup>+</sup>.</p><p>To a solution of methyl 2-(3-acetamido-2-nitrophenyl)-2-isocyanoacetate (11 g, 39.71 mmol) in <italic>glacial</italic> acetic acid (100 ml), was added slowly zinc dust (25.81 g, 397.10 mmol) in two portions. After stirring at 60°C for 2 hr, the reaction mixture was cooled to room temperature, filtered, and washed with THF. The filtrate was concentrated under reduced pressure and purified by silica gel chromatography (10:1 dichloromethane/methanol) to obtain 6.2 g (63%) of methyl 7-acetamido-2-amino-1<italic>H</italic>-indole-3-carboxylate as a yellow solid. LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 248.3 (M+H)<sup>+</sup>.</p><p>A solution of methyl 7-acetamido-2-amino-1<italic>H</italic>-indole-3-carboxylate (6.2 g, 25.10 mmol) in formamide (450 ml) was stirred at 220°C for 2 hr. The reaction mixture was then cooled to room temperature and poured into 100 ml of water. The resulting mixture was allowed to stand for 15 min before the solids were collected by filtration, washed with water, and dried to obtain 4.1 g of a 1:2 mixture of <italic>N</italic>-(4-hydroxy-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)acetamide and <italic>N</italic>-(4-hydroxy-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)formamide. This mixture was taken in methanol (25 ml) and aqueous 12 N NaOH (25 ml). After stirring at 60°C for 16 hr, the reaction mixture was then cooled to room temperature, concentrated under reduced pressure to remove methanol, and the residue was poured into 100 ml of water. The resulting mixture was allowed to stand for 15 min before the solids were collected by filtration, washed with water, and dried to obtain 3.5 g (70%) of 8-amino-9<italic>H</italic>-pyrimido[4,5-b]indol-4-ol as a brown solid. LC–MS (ESI): <italic>m</italic>/z=201.2 (M+H)<sup>+</sup>.</p><p>A solution of 8-amino-9<italic>H</italic>-pyrimido[4,5-b]indol-4-ol (3.5 g, 17.5 mmol) in formamide (30 ml) was stirred at 150°C. After 6 hr, the reaction mixture was cooled to room temperature and poured into water (200 ml). The resulting mixture was allowed to stand for 15 min before the solids were collected by filtration, washed with water, and dried to obtain 3.5 g (88%) of <italic>N</italic>-(4-hydroxy-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)formamide as a brown solid. LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 229.2 (M+H)<sup>+</sup>.</p><p>To a solution of <italic>N</italic>-(4-hydroxy-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)formamide (3.5 g, 15.35 mmol) in phosphorous oxychloride (30 ml) was added <italic>N</italic>,<italic>N</italic>-diiisopropylethylamine (5.94 g, 46.05 mmol). After refluxing for 16 hr, the reaction mixture was cooled to room temperature, concentrated, and poured into water (20 ml). The resulting solid was filtered to obtain 500 mg of a mixture of <italic>N</italic>-(4-chloro-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)formamide and 4-chloro-9<italic>H</italic>-pyrimido[4,5-b]indol-8-amine as a black solid. This mixture was taken in 4 N HCl in dioxane (15 ml). After stirring at room temperature for 4 hr, the reaction mixture was concentrated under reduced pressure, the residue was adjusted to pH 7 with aqueous Na<sub>2</sub>CO<sub>3</sub>, and extracted with ethyl acetate (3 × 30 ml). The organic layers were dried over sodium sulfate, concentrated under reduced pressure, and the residue was purified by reverse phase chromatography (water/acetonitrile/0.1% ammonium bicarbonate) to obtain 320 mg (10%) of 4-chloro-9<italic>H</italic>-pyrimido[4,5-b]indol-8-amine as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO) δ 12.42 (s, 1H), 8.74 (s, 1H), 7.58 (d, <italic>J</italic> = 7.8 Hz, 1H), 7.25–7.08 (m, 1H), 6.93 (d, <italic>J</italic> = 7.7 Hz, 1H), 5.76 (s, 2H). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 219.2 (M+H)<sup>+</sup>.</p><p>A mixture of 4-chloro-9<italic>H</italic>-pyrimido[4,5-b]indol-8-amine (28 mg, 0.13 mmol) and 1-aminopyrrolidin-2-one hydrochloride (35 mg, 0.26 mmol) in isopropanol/water (10: 1, 1.1 ml) was heated to 100°C for 18 hr. The reaction mixture was filtered, the residue was washed with ethyl acetate and dried to obtain 28 mg (77%) of 1-((8-amino-9<italic>H</italic>-pyrimido[4,5-b]indol-4-yl)amino)pyrrolidin-2-one as brown solid. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz) δ 12.99 (br s, 1H), 8.62 (s, 1H), 7.92 (br d, 1H, <italic>J</italic> = 7.5 Hz), 7.27 (t, 1H, <italic>J</italic> = 7.9 Hz), 7.05 (br d, 1H, <italic>J</italic> = 7.5 Hz), 3.70 (br t, 2H, <italic>J =</italic> 6.9 Hz), 2.44–2.53 (m, 2H), 2.20 (br t, 2H, <italic>J =</italic> 7.4 Hz). <sup>13</sup>C NMR (METHANOL-d<sub>4</sub>, 100 MHz) δ 175.9, 155.9, 154.3, 153.2, 132.5, 125.7, 121.9, 119.4, 111.3, 111.1, 97.0, 48.6, 28.5, 15.9. LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 283 (M+H)<sup>+</sup>.</p></sec><sec id="s4-1-3"><title>1-Amino-5,5-dimethylpyrrolidin-2-one hydrochloride</title><fig id="C2" position="anchor"><label>Chemical structure 2.</label><caption><title>1-Amino-5,5-dimethylpyrrolidin-2-one hydrochloride.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-chem2-v1.tif"/></fig><p>To a cooled (0°C) solution of 5,5-dimethylpyrrolidin-2-one (3 g, 26.54 mmol) in THF (60 ml) was added sodium hydride (2.13 g, 53.09 mmol), followed by addition of (aminooxy)diphenylphosphine oxide (12.4 g, 53.09 mmol) after 30 min. After stirring the resultant white suspension at 0°C for 2 hr, the reaction mixture was filtered through a Celite pad, the filtrate was concentrated and purified by silica gel chromatography (10:1 dichloromethane/methanol) to afford 3 g (75%) of 1-amino-5,5-dimethylpyrrolidin-2-one as yellow oil. LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 129.1 (M+18)<sup>+</sup>.</p><p>A solution of 1-amino-5,5-dimethylpyrrolidin-2-one (1.5 g, crude) in 4 N HCl in dioxane (15 ml) was stirred at room temperature for 4 hr. The mixture was concentrated under reduced pressure, residue was triturated with diethyl ether and filtered to afford 1 g (53%) of 1-amino-5,5-dimethylpyrrolidin-2-one hydrochloride salt as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.48 (s, 3 H), 2.39 (t, 2H, <italic>J</italic> = 7.8 Hz), 1.90 (t, 2H, <italic>J</italic> = 7.8 Hz), 1.30 (s, 6H). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 129.1 (M+18)<sup>+</sup>.</p></sec><sec id="s4-1-4"><title>AVI-4051</title><fig id="C3" position="anchor"><label>Chemical structure 3.</label><caption><title>AVI-4051.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-chem3-v1.tif"/></fig><p>To a solution of 1-((8-amino-9<italic>H</italic>-pyrimido[4,5-b]indol-4-yl)amino)pyrrolidin-2-one (20 mg, 0.071 mmol) and triethylamine (0.040 ml, 0.28 mmol) in THF (1 ml), was added cyclopropyl isocyanate (24 mg, 0.28 mmol). After stirring at 65°C for 48 hr, the reaction mixture was purified by reverse phase chromatography (water/acetonitrile/0.1% formic acid) to obtain 12 mg (41%) of 1-cyclopropyl-3-(4-((2-oxopyrrolidin-1-yl)amino)-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)urea formic acid salt (AVI-4051) as a white solid. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz) δ 11.81 (br s, 1H), 9.31 (s, 1H), 8.50 (br s, 1H), 8.41 (s, 1H), 7.99 (d, 1H, <italic>J =</italic> 7.8 Hz), 7.63 (d, 1H, <italic>J =</italic> 7.8 Hz), 7.21 (t, 1H, <italic>J =</italic> 7.9 Hz), 6.74 (br s, 1H), 3.70 (br t, 2H, <italic>J =</italic> 7.1 Hz), 3.12–3.17 (m, 2H), 2.54–2.65 (m, 1H), 2.39–2.43 (m, 2H), 0.98 (t, 2H, <italic>J =</italic> 7.1 Hz), 0.68–0.70 (m, 2H). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 366 (M+H)<sup>+</sup>.</p></sec><sec id="s4-1-5"><title>AVI-1501</title><fig id="C4" position="anchor"><label>Chemical structure 4.</label><caption><title>AVI-1501.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-chem4-v1.tif"/></fig><p>To a solution of 1-((8-amino-9<italic>H</italic>-pyrimido[4,5-b]indol-4-yl)amino)pyrrolidin-2-one (15 mg, 0.053 mmol) and triethylamine (0.015 ml, 0.11 mmol) in THF (1 ml), was added acetyl chloride (0.004 ml, 0.056 mmol). After stirring at 65°C for 3 hr, the reaction mixture was purified by reverse phase chromatography (water/acetonitrile/0.1% formic acid) to obtain 9 mg (50%) of <italic>N</italic>-(4-((2-oxopyrrolidin-1-yl)amino)-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)acetamide formic acid (<bold>AVI-1501</bold>) as a white solid. <sup>1</sup>H NMR (METHANOL-d<sub>4</sub>, 400 MHz) δ 8.39 (s, 1H), 7.90 (d, 1H, <italic>J =</italic> 7.8 Hz), 7.45 (d, 1H, <italic>J =</italic> 7.8 Hz), 7.19–7.21 (m, 1H), 3.81–3.85 (m, 2H), 2.59–2.63 (m, 2H), 2.27–2.31 (m, 5H). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 325 (M+H)<sup>+</sup>.</p></sec><sec id="s4-1-6"><title>AVI-3367</title><fig id="C5" position="anchor"><label>Chemical structure 5.</label><caption><title>AVI-3367.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-chem5-v1.tif"/></fig><p>To a solution of 1-((8-amino-9<italic>H</italic>-pyrimido[4,5-b]indol-4-yl)amino)pyrrolidin-2-one (15 mg, 0.053 mmol) and triethylamine (0.015 ml, 0.11 mmol) in THF (1 ml), was added ethyl chloroformate (0.005 ml, 0.056 mmol). After stirring at 65°C for 18 hr, the reaction mixture was purified by reverse phase chromatography (water/acetonitrile/0.1% formic acid) to obtain 2.7 mg (13%) of ethyl (4-((2-oxopyrrolidin-1-yl)amino)-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)carbamate formic acid salt (<bold>AVI-3367</bold>) as tan solid. <sup>1</sup>H NMR (METHANOL-d4, 400 MHz) δ 8.42 (s, 1H), 7.94 (d, 1H, <italic>J</italic> = 7.8 Hz), 7.59 (br s, 1H), 7.28 (t, 1H, <italic>J</italic> = 7.9 Hz), 4.1–4.26–4.30 (m, 2H), 3.84 (t, 2H, <italic>J</italic> = 7.1 Hz), 2.60 (t, 2H, <italic>J</italic> = 8.0 Hz), 2.30–2.33 (m, 2H), 1.36–1.39 (m, 3H). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 355 (M+H)<sup>+</sup>.</p></sec><sec id="s4-1-7"><title>AVI-1500</title><fig id="C6" position="anchor"><label>Chemical structure 6.</label><caption><title>AVI-1500.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-chem6-v1.tif"/></fig><p>To a solution of 4-chloro-9<italic>H</italic>-pyrimido[4,5-b]indol-8-amine (50 mg, 0.23 mmol) and triethylamine (0.064 ml, 0.46 mmol) in THF (2 ml), was added ethyl isocyanate (0.018 ml, 0.23 mmol). After stirring at 65°C for 18 hr, the reaction mixture was filtered. The residue was washed with ethyl acetate and dried to obtain 50 mg of 1-(4-chloro-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)-3-ethylurea as a white solid that was used without further purification. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz) δ 12.39 (br s, 1H), 8.80 (s, 1H), 8.43 (s, 1H), 7.96 (d, 1H, <italic>J</italic> = 7.6 Hz), 7.72 (d, 1H, <italic>J</italic> = 7.8 Hz), 7.35 (t, 1H, <italic>J</italic> = 7.9 Hz), 6.38 (s, 1H), 3.18–3.21 (m, 2H), 1.12 (t, 3H, <italic>J</italic> = 7.2 Hz). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 290, 292 (M+H)<sup>+</sup>.</p><p>A mixture of 1-(4-chloro-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)-3-ethylurea (26 mg, 0.09 mmol) and 1-aminopyrrolidin-2-one hydrochloride (25 mg, 0.18 mmol) in isopropanol/water (10: 1, 1.1 ml) was heated to 100°C for 18 hr. The reaction mixture was purified by reverse phase chromatography (water/acetonitrile/0.1% formic acid) to obtain 8 mg (20%) of 1-ethyl-3-(4-((2-oxopyrrolidin-1-yl)amino)-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)urea formic acid salt (<bold>AVI-1500</bold>) as a white solid. <sup>1</sup>H NMR (DMSO-d6, 400 MHz) δ 11.75 (br s, 1H), 9.31 (s, 1H), 8.53 (s, 1H), 8.41 (s, 1H), 7.97 (d, 1H, <italic>J</italic> = 7.8 Hz), 7.63 (d, 1H, <italic>J</italic> = 7.8 Hz), 7.20 (t, 1H, <italic>J</italic> = 7.9 Hz), 6.37 (br s, 1H), 3.70 (t, 2H, <italic>J</italic> = 7.1 Hz), 3.17–3.20 (m, 2H), 2.39–2.41 (m, 2H), 2.12–2.16 (m, 2H), 1.09–1.13 (m, 3H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz) δ 173.5, 156.2, 155.9, 155.5, 155.0, 128.5, 125.5, 121.3, 120.3, 117.1, 116.7, 96.4, 48.4, 34.8, 28.9, 16.7, 15.9. LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 354 (M+H)<sup>+</sup>.</p></sec><sec id="s4-1-8"><title>AVI-3762 and AVI-3763</title><fig id="C7" position="anchor"><label>Chemical structure 7.</label><caption><title>AVI-3762 and AVI-3763.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-chem7-v1.tif"/></fig><p>4-Chloro-7-fluoro-9<italic>H</italic>-pyrimido[4,5-b]indole (123 mg, 0.55 mmol) and 1-amino-5-phenyl-pyrrolidin-2-one (117 mg, 0.66 mmol) in a mixture of dioxane*HCl/IPA (1.5 ml/1.5 ml) was stirred at 95°C overnight. Upon completion, the mixture was cooled to rt and concentrated under reduced pressure. The crude material was purified by HPLC (30–80% MeOH/H<sub>2</sub>O) to afford 1-((7-fluoro-9<italic>H</italic>-pyrimido[4,5-b]indol-4-yl)amino)-5-phenylpyrrolidin-2-one (69 mg, HCl salt, 34% yield). It was further separated by chiral chromatography (Hexane-IPA-MeOH, 50-25-25) to obtain <bold>AVI-3762</bold> (27 mg, retention time = 14.04 min, 99% optic ee) and <bold>AVI-3763</bold> (26 mg, retention time = 11.17 min, 100% optic ee).</p><sec id="s4-1-8-1"><title>AVI-3762</title><p><sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz) δ 12.22 (br s, 1H), 9.41 (br s, 1H), 8.44 (s, 1H), 8.26 (dd, 1H, <italic>J</italic> = 5.4, 8.8 Hz), 7.48 (br d, 2H, <italic>J</italic> = 7.3 Hz), 7.22–7.36 (m, 4H), 7.10 (ddd, 1H, <italic>J</italic> = 2.2, 8.8, 9.7 Hz), 5.21 (br s, 1H), 2.55–2.65 (m, 3H), 1.87–1.92 (m, 1H). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 362 (M+H)<sup>+</sup>.</p></sec><sec id="s4-1-8-2"><title>AVI-3763</title><p><sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz) δ 12.22 (s, 1H), 9.41 (br s, 1H), 8.44 (s, 1H), 8.26 (dd, 1H, <italic>J</italic> = 5.4, 8.8 Hz), 7.48 (br d, 2H, <italic>J</italic> = 7.5 Hz), 7.22–7.36 (m, 4H), 7.10 (ddd, 1H, <italic>J</italic> = 2.4, 8.8, 9.7 Hz), 5.21 (br s, 1H), 2.57–2.65 (m, 3H), 1.87–1.92 (m, 1H). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 362 (M+H)<sup>+</sup>.</p></sec></sec></sec><sec id="s4-2"><title>AVI-3764 and AVI-3765</title><fig id="C8" position="anchor"><label>Chemical structure 8.</label><caption><title>AVI-3764 and AVI-3765.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-chem8-v1.tif"/></fig><p>4-Chloro-7-fluoro-9<italic>H</italic>-pyrimido[4,5-b]indole (222 mg, 1.0 mmol) and 1-amino-5-methyl-pyrrolidin-2-one (196 mg, 1.3 mmol) in a mixture of dioxane*HCl/IPA (1.5 ml/1.5 ml) was stirred at 95°C overnight. Upon completion, the mixture was cooled to rt and concentrated under reduced pressure. The crude material was purified by HPLC (40–90% H<sub>2</sub>O/MeOH/0.005% HCl) to afford 1-((7-fluoro-9<italic>H</italic>-pyrimido[4,5-b]indol-4-yl)amino)-5-methylpyrrolidin-2-one (HCl salt, 0.155 g, 46% yield). It was further subjected to chiral chromatography (hexane (0.3% DEA): IPA:MeOH, 90:5:5) to obtain <bold>AVI-3765</bold> (39 mg, retention time = 46.18 min, 99% optic ee) and <bold>AVI-3764</bold> (36 mg, retention time = 51.98 min, 90% optic ee).</p><sec id="s4-2-1"><title>AVI-3765</title><p><sup>1</sup>H NMR (500 MHz, DMSO) δ 12.22 (s, 1H), 9.31 (s, 1H), 8.47–8.3 (m, 2H), 7.25 (dd, <italic>J</italic> = 9.6, 1.9 Hz, 1H), 7.18–7.11 (m, 1H), 4.03 (s, 1H), 2.39–2.26 (m, 3H), 1.7–1.63 (m, 1H), 1.21 (d, <italic>J</italic> = 6 Hz, 3H). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 300 (M+H)<sup>+</sup>.</p></sec><sec id="s4-2-2"><title>AVI-3764</title><p><sup>1</sup>H NMR (500 MHz, DMSO) δ 12.22 (s, 1H), 9.31 (s, 1H), 8.45–8.37 (m, 1H), 8.35 (s, 1H), 7.25 (dd, <italic>J</italic> = 9.4, 2.3 Hz, 1H), 7.2–7.04 (m, 1H), 4.11–3.93 (m, 1H), 2.42–2.19 (m, 3H), 1.75–1.57 (m, 1H), 1.21 (d, <italic>J</italic> = 6.3 Hz, 3H). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 300 (M+H)<sup>+</sup>.</p></sec></sec><sec id="s4-3"><title>AVI-4636</title><fig id="C9" position="anchor"><label>Chemical structure 9.</label><caption><title>AVI-4636.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-chem9-v1.tif"/></fig><p>A mixture of 4-chloro-7-fluoro-9<italic>H</italic>-pyrimido[4,5-b]indole (25 mg, 0.11 mmol) and 1-amino-5,5-dimethylpyrrolidin-2-one hydrochloride salt (28 mg, 0.17 mmol) in isopropanol/aqueous 1 N HCl (2: 1, 0.6 ml) was heated to 100°C for 18 hr. The reaction mixture was purified by reverse phase chromatography (water/acetonitrile/0.1% formic acid) to obtain 10 mg (25%) of 1-((7-fluoro-9<italic>H</italic>-pyrimido[4,5-b]indol-4-yl)amino)-5,5-dimethylpyrrolidin-2-one formic acid salt (<bold>AVI-4636</bold>) as a white solid. <sup>1</sup>H NMR (METHANOL-d<sub>4</sub>, 400 MHz) δ 8.30 (s, 1H), 8.09 (dd, 1H, <italic>J</italic> = 5.1, 8.8 Hz), 7.21 (dd, 1H, <italic>J</italic> = 2.3, 9.4 Hz), 6.97 (t, 1H, <italic>J</italic> = 9.2 Hz), 2.59–2.63 (m, 2H), 2.20 (br s, 2H), 1.38 (s, 6H). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 314 (M+H)<sup>+</sup>.</p></sec><sec id="s4-4"><title>AVI-4206</title><fig id="C10" position="anchor"><label>Chemical structure 10.</label><caption><title>AVI-4206.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103484-chem10-v1.tif"/></fig><p>A solution of 3-fluoro-2-nitroaniline (25.00 g, 160 mmol) in THF (500 ml) was added triethylamine (48 g, 480 mmol) and triphosgene (14.2 g, 48 mmol) at 0°C. After stirring for an hour, ethylamine as 2.0 M solution in THF (200 ml) was added. Upon completion of the reaction, the mixture was poured into 500 ml of water, extracted with ethyl acetate (3 × 500 ml), the combined organic layers were washed with brine (500 ml), dried over sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (0–20% ethyl acetate/hexanes) to afford 1-ethyl-3-(3-fluoro-2-nitrophenyl)urea as yellow solid (22.00 g, yield: 60.57%). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 228.1 (M+H)<sup>+</sup>.</p><p>To a solution of 1-ethyl-3-(3-fluoro-2-nitrophenyl)urea (48 g, 211.45 mmol) in DMF (300 ml) were added methyl 2-isocyanoacetate (41.86 g, 422.90 mmol) and potassium carbonate (87.54 g, 634.36 mmol). The solution was stirred at 80°C for 16 hr. The mixture was adjusted to be weakly acidic by 2 N HCl, extracted with ethyl acetate (500 ml *3), the combined organic layers were washed with brine (300 ml), dried over sodium sulfate, filtered, and concentrated under reduced pressure, the residue was purified via column chromatography on silica gel (0–20% ethyl acetate/hexanes) to afford methyl 2-cyano-2-(3-(3-ethylureido)-2-nitrophenyl)acetate as yellow solid (44.3 g, yield: 68.46%). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 307.2 (M+H)<sup>+</sup>.</p><p>A mixture of methyl 2-cyano-2-(3-(3-ethylureido)-2-nitrophenyl)acetate (42 g, 137.25 mmol) and acetic acid (250 ml) was heated to 40°C. Zinc (89.75 g, 1372.54 mmol) was then added in portions at a rate such that the reaction temperature did not rise above 60°C. After the addition was complete, the reaction mixture was stirred at 60°C for 2 hr. The reaction mixture was cooled to room temperature and filtered through a celite pad. The filtrate was concentrated under vacuum. The crude product was purified via column chromatography on silica gel (DCM: MeOH = 10:1) to give methyl 2-amino-7-(3-ethylureido)-1<italic>H</italic>-indole-3-carboxylate as a white solid (16 g, yield: 42.23%). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 277.2 (M+H)<sup>+</sup>.</p><p>Methyl 2-amino-7-(3-ethylureido)-1<italic>H</italic>-indole-3-carboxylate (2.0 g, 7.25 mmol) and formamidine acetate (4.53 g, 43.48 mmol) were heated to 140°C for 1 hr. The mixture was cooled to room temperature and diluted with approximately 100 ml of water. The resulting mixture was stirred for 15 min before the solid was collected by filtration. The residue was triturated with DMSO and filtered to afford 1-ethyl-3-(4-hydroxy-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)urea as an off-white solid (1.0 g, yield: 50.8%). <sup>1</sup>H NMR (500 MHz, DMSO) δ 12.21 (s, 1H), 11.76 (s, 1H), 8.34 (s, 1H), 8.13 (d, <italic>J</italic> = 3.5 Hz, 1H), 7.64 (d, <italic>J</italic> = 7.7 Hz, 1H), 7.40 (d, <italic>J</italic> = 7.3 Hz, 1H), 7.13 (t, <italic>J</italic> = 7.8 Hz, 1H), 6.28 (t, <italic>J</italic> = 5.5 Hz, 1H), 3.26–3.11 (m, 2H), 1.10 (t, <italic>J</italic> = 7.2 Hz, 3H). LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 272.3 (M+H)<sup>+</sup>.</p><p>To a solution of 1-ethyl-3-(4-hydroxy-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)urea (500 mg, 1.85 mmol) in THF (20 ml) was added di-<italic>tert</italic>-butyl dicarbonate (1.21 g, 5.54 mmol), DIPEA (955 mg, 7.4 mmol), and DMAP (226 mg, 1.85 mmol). The mixture was stirred at room temperature for 16 hr. The mixture was then concentrated under reduced pressure to give crude <italic>tert</italic>-butyl 4-((<italic>tert</italic>-butoxycarbonyl)oxy)-8-(3-ethylureido)-9<italic>H</italic>-pyrimido[4,5-b]indole-9-carboxylate as a yellow oil. It was used in the next step without any purification.</p><p>A solution of <italic>tert</italic>-butyl 4-((<italic>tert</italic>-butoxycarbonyl)oxy)-8-(3-ethylureido)-9<italic>H</italic>-pyrimido[4,5-b]indole-9-carboxylate (crude) in POCl<sub>3</sub> (10 ml) was stirred at 90°C for 30 min. The solution was concentrated under reduced pressure and diluted with acetonitrile, then the pH was adjusted to 7.0 with ammonium hydroxide slowly. The resulting solid was filtered with a vacuum filter and washed with water to give the 1-(4-chloro-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)-3-ethylurea (230 mg, two steps yield: 43.1%) as a light yellow solid. LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 290.2 (M+H)<sup>+</sup>.</p><p>To a solution of 1-(4-chloro-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)-3-ethylurea (290 mg, 1.0 mmol) in dry DMSO (6.0 ml) was added 1-amino-5,5-dimethylpyrrolidin-2-one (192 mg, 1.5 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (92 mg, 0.1 mmol), tri-<italic>tert</italic>-butylphosphine tetrafluoroborate (44 mg, 0.15 mmol) and t-BuONa (240 mg, 2.5 mmol). After stirring at 100°C for 8 hr, the reaction mixture was filtered and the filtrate was purified by reversed phase chromatography (water/acetonitrile/0.1% TFA). After lyophilization, then silica gel column chromatography (DCM/MeOH = 10/1) to obtain 1-(4-((2,2-dimethyl-5-oxopyrrolidin-1-yl)amino)-9<italic>H</italic>-pyrimido[4,5-b]indol-8-yl)-3-ethylurea (<bold>AVI-4206</bold>) (120 mg, yield: 31.5%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.67 (s, 1H), 9.06 (s, 1H), 8.37 (d, <italic>J</italic> = 15.7 Hz, 2H), 8.07 (d, <italic>J</italic> = 7.6 Hz, 1H), 7.59 (d, <italic>J</italic> = 7.8 Hz, 1H), 7.20 (t, <italic>J</italic> = 7.9 Hz, 1H), 6.28 (t, <italic>J</italic> = 5.4 Hz, 1H), 3.27–3.10 (m, 2H), 2.42 (t, <italic>J</italic> = 7.8 Hz, 2H), 2.03 (t, <italic>J</italic> = 7.8 Hz, 2H), 1.26 (d, <italic>J</italic> = 21.1 Hz, 6H), 1.11 (t, <italic>J</italic> = 7.2 Hz, 3H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz) δ 171.8, 157.8, 155.9, 155.8, 154.9, 128.6, 125.4, 125.3, 121.2, 120.4, 117.2, 117.1, 96.6, 61.1, 34.8, 34.7, 32.4, 27.8, 26.6, 15.9. LC–MS (ESI): <italic>m</italic>/<italic>z</italic> = 382 (M+H)<sup>+</sup>.</p></sec><sec id="s4-5"><title>In vitro validation</title><sec id="s4-5-1"><title>X-ray crystallography</title><p>Mac1 crystals (P4<sub>3</sub> construct, residues 3–169) were grown by sitting-drop vapor diffusion in 28% wt/vol polyethylene glycol (PEG) 3000 and 100 mM <italic>N</italic>-cyclohexyl-2-aminoethanesulfonic acid (CHES) pH 9.5 as described previously (<xref ref-type="bibr" rid="bib45">Schuller et al., 2021</xref>; <xref ref-type="bibr" rid="bib10">Gahbauer et al., 2023</xref>). Compounds prepared in DMSO (100 mM) were added to crystal drops using an Echo 650 acoustic dispenser (<xref ref-type="bibr" rid="bib4">Collins et al., 2017</xref>) (final concentration of 10 mM). Crystals were incubated at room temperature for 2–4 hr prior to vitrification in liquid nitrogen without additional cryoprotection. X-ray diffraction data were collected at the Advanced Light Source (ALS beamline 8.3.1) or the Stanford Synchrotron Light Source (SSRL beamline 9–2). Data were indexed, integrated, and scaled with XDS (<xref ref-type="bibr" rid="bib13">Kabsch, 2010</xref>) and merged with Aimless (<xref ref-type="bibr" rid="bib9">Evans and Murshudov, 2013</xref>). The P4<sub>3</sub> Mac1 crystals contain two copies of the protein in the asymmetric unit (chains A and B). The active site of chain A is open; however, chain B is blocked by a crystal contact. We previously observed that potent Mac1 inhibitors dissolve crystals, likely through the displacement of the B chain crystal contact (<xref ref-type="bibr" rid="bib10">Gahbauer et al., 2023</xref>). In addition, crystal packing in the chain A active site restricts movement of the Ala129-Gly134 loop, leading to decreased occupancy for compounds with substituents on the pyrrolidinone. To aid modeling the resulting conformational and compositional disorder, we used the PanDDA method (<xref ref-type="bibr" rid="bib38">Pearce et al., 2017</xref>) to model ligands where the occupancy was low (&lt;25%, AVI-4051, AVI-3367, AVI-3763, AVI-3762, AVI-3765, and AVI-3764) or where there was substantial disorder (AVI-4636). After modeling ligands, structures were refined using phenix.refine (<xref ref-type="bibr" rid="bib25">Liebschner et al., 2019</xref>) as described previously (<xref ref-type="bibr" rid="bib10">Gahbauer et al., 2023</xref>). Data collection settings and statistics are reported in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p>To achieve higher ligand occupancy for AVI-4206, we co-crystallized an alternative Mac1 construct previously reported to crystallize in P1, P2<sub>1</sub>, and C2 (residues 2–170) (<xref ref-type="bibr" rid="bib31">Michalska et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Correy et al., 2022</xref>). Crystals grew by sitting-drop vapor diffusion in 200 mM lithium acetate and 20% wt/vol PEG 3350 with 30 mg/ml Mac1 (1.6 mM) and 3.2 mM AVI-4206 (3.2% DMSO). Crystals were vitrified directly in liquid nitrogen, and diffraction data to 0.8 Å were collected at the ALS (beamline 8.3.1). Data were reduced in P1 using the same pipeline as the P4<sub>3</sub> crystals. Solvent content analysis suggested that there were two chains in the asymmetric unit. Phases were obtained using Phaser (<xref ref-type="bibr" rid="bib28">McCoy et al., 2007</xref>) and apo Mac1 coordinates (PDB code 7KQO, chain A). Structural refinement was performed with phenix.refine following the previously described procedures for ultra-high-resolution data (<xref ref-type="bibr" rid="bib5">Correy et al., 2022</xref>). After several rounds of refinement, positive difference density was clear for a second, relatively low occupancy, conformation of the entire chain A and B, each representing a ~3.1 Å translation relative to the major conformation. Modeling and inspection of the minor conformations suggested that they cannot be occupied simultaneously; therefore, they were modeled with distinct alternative location identifiers (altlocs). The major conformation (protein, AVI-4206, and water) was modeled with altloc A and the minor conformations (protein, AVI-4206, and water) were modeled with altlocs C and D. In addition to the rigid body disorder, there was clear density for a third conformation of the residue 57–75 α-helix. In chain A, this was modeled with altloc B, while the density in chain B was too weak to allow modeling. The <italic>F</italic><sub>O</sub> − <italic>F</italic><sub>C</sub> difference electron density maps or PanDDA event maps used to model ligands are shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</p></sec><sec id="s4-5-2"><title>Inhibition assay</title><p>Inhibition of Mac1 ADP-ribosylhydrolase activity by AVI-219 and AVI-4206 was determined using the NUDT5/AMP-Glo assay (<xref ref-type="bibr" rid="bib7">Dasovich et al., 2022</xref>; <xref ref-type="bibr" rid="bib53">Taha et al., 2023b</xref>; <xref ref-type="bibr" rid="bib56">Voorneveld et al., 2018</xref>). The substrate for the reaction was human PARP10 (catalytic domain, residues 819–1007), purified and auto-mono-ADP-ribosylated using NAD+ as described previously (<xref ref-type="bibr" rid="bib53">Taha et al., 2023b</xref>). Briefly, AVI-219 and AVI-4206 were dispensed into 384-well white assay plates (Corning, 3824) using an Echo 650 acoustic dispenser to achieve a final concentration range from 1 mM to 0.4 nM (8 μl reaction volume, 1% DMSO). Purified Mac1 (P4<sub>3</sub> construct, 2 μl, 10 nM final concentration) and NUDT5 (2 μl, 100 nM final concentration) were added to wells and the plates were incubated for 5 min at room temperature. Mono-ADP-ribosylated PARP10 was added to wells (4 μl, 2 μM final concentration) and the plates were incubated at room temperature for an additional hour. The concentration of AMP was measured with an AMP-Glo assay kit (Promega, V5011) following the manufacturer’s instructions using a BioTek Synergy HTX plate reader. Percentage inhibition was calculated relative to control wells containing no inhibitor (DMSO only, 0% inhibition) or no Mac1 (100% inhibition) and IC<sub>50</sub> values were determined by fitting a four-parameter sigmoidal dose–response equation using GraphPad Prism (version 10.1.1), with the top and bottom constrained to 100 and 0% inhibition, respectively. Data are presented as the mean ± SD of four technical replicates. A control reaction with increasing concentrations of Mac1 indicated that &lt;50% of the mono-ADP-ribosylated PARP10 was hydrolyzed in the 0% inhibition control (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). In addition, a counterscreen to test for NUDT5 inhibition or assay interference was performed with identical reactions, except Mac1 was omitted and ADP-ribose was added to a final concentration of 2 μM (Sigma, A0752).</p><p>Inhibition of PARP14 macrodomains was tested with the same protocol as Mac1 with minor adjustments as follows. PARP14 macrodomain activity was tested from 8 to 800 nM. Purified PARP14 MD1-MD2 (residues 784–1196) and PARP14 MD2 (residues 999–1196, serving as a negative control because only MD1 is catalytically active) were added to each well with NUDT5 (2.5 μl, NUDT5: 100 nM final concentration) and the plates were incubated for 5 min at room temperature. Mono-ADP-ribosylated PARP10 was dispensed using Dragonfly (1.5 μM, 2.5 μl) and the plates were incubated at room temperature for an additional hour. The concentration of AMP was measured with an AMP-Glo assay kit (Promega, V5011). Inhibition by AVI-4206 was tested at 50 nM enzyme concentration for PARP14 MD1-2, PARP14 MD2, MAC1 WT, and MAC1 N40D. Enzymes were added to the plate at 50 nM final concentration with NUTD5 at 100 nM final concentration (2 μl). AVI-4206 was dispensed using Integra electronic repeat dispense pipette from 1 mM to 0.4 nM (8 μl reaction volume, 1% DMSO). Mono-ADP-ribosylated PARP10 was dispensed as previously (1.5 μM, 4 μl per well) incubated for an additional hour at room temperature followed by detection of AMP concentration with an AMP-Glo assay kit (Promega, V5011) following the manufacturer’s instructions using a BioTek Synergy HTX plate reader.</p></sec><sec id="s4-5-3"><title>HTRF</title><p>Binding of the compounds to macrodomain proteins was assessed by the displacement of an ADPr-conjugated biotin peptide from His<sub>6</sub>-tagged protein using an HTRF-technology-based screening assay which was performed as previously described (<xref ref-type="bibr" rid="bib45">Schuller et al., 2021</xref>). The protein sequences used for SARS-CoV-2 Mac1 and the human macrodomains TARG1 and MacroD2 are listed in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>. All proteins were expressed and purified as described previously for SARS-CoV-2 Mac1 (<xref ref-type="bibr" rid="bib45">Schuller et al., 2021</xref>). Compounds were dispensed into ProxiPlate-384 Plus (PerkinElmer) assay plates using an Echo 650 Liquid Handler (Beckman Coulter). Binding assays were conducted in a final volume of 16 μl with 12.5 nM NSP3 Mac1 protein, 200 nM peptide ARTK(Bio)QTARK(Aoa-RADP)S (Cambridge Peptides), 1:20,000 Eu<sup>3+</sup> cryptate conjugated to a His<sub>6</sub>-specific antibody (HTRF donor, PerkinElmer AD0402) and 1:500 Streptavidin-XL665 (HTRF acceptor, PerkinElmer 610SAXLB) in assay buffer (25 mM 4-(2-hydroxyethyl)-1-piperazine-1-ethanesulfonic acid (HEPES) pH 7.0, 20 mM NaCl, 0.05% bovine serum albumin and 0.05% Tween-20). TARG1 and MacroD2 binding were measured at 25 nM and 12.5 nM, respectively. Assay reagents were dispensed manually into plates using an electronic multichannel pipette. Macrodomain protein and peptide were dispensed and preincubated for 30 min at room temperature before HTRF reagents were added. Fluorescence was measured after a 1-hr incubation at room temperature using a PerkinElmer EnVision 2105-0010 Dual Detector Multimode microplate reader with dual emission protocol (A = excitation of 320 nm, emission of 665 nm, and B = excitation of 320 nm, emission of 620 nm). Compounds were tested in triplicate in a 14-point dose response. Raw data were processed to give an HTRF ratio (channel A/B × 10,000), which was used to generate IC<sub>50</sub> curves. The IC<sub>50</sub> values were determined by non-linear regression using GraphPad Prism (version 10.1.1). Data are presented as mean ± SD of three technical replicates.</p></sec><sec id="s4-5-4"><title>CETSA</title><p>Cellular target engagement of compounds was assessed using a CETSA-nLuc or CETSA-WB assay (<xref ref-type="bibr" rid="bib27">Martinez et al., 2018</xref>). The SARS-CoV-2 Mac1 macrodomain was cloned into pcDNA3.1 by Genscript with both an N-terminal 3XFLAG tag and a C-terminal HiBiT tag as listed in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>. A 2A mKate was included to identify successfully transfected cells (e.g., pcDNA-3xFLAG-Mac1<sup>WT</sup>-nLuc-t2A-mKate2). Plasmids were reverse transfected into A549 cells using Lipofectamine 3000 transfection reagent (Thermo). After 48 hr, cells were harvested by trypsinization and resuspended at 1 × 10<sup>6</sup> cells/ml in CETSA buffer (1× DPBS (with CaCl<sub>2</sub> and MgCl<sub>2</sub>), 1 g/l glucose and 1× protease inhibitor cocktail Roche, 5892970001). Cells were treated in microcentrifuge tubes with compound or DMSO and incubated at 37°C for 1 hr.</p><p>For CETSA-nLuc experiments, 30 μl of suspended cells were dispensed into a 96-well PCR plate (Bio-Rad) and heated for 3.5 min using a preheated gradient thermal cycler (Eppendorf). A Nano-Glo HiBiT Lytic Detection System (Promega) was used to quantify HiBiT-tagged proteins in cell lysates. 30 μl of a mixture containing Lytic Buffer, LgBiT protein, HiBiT Lytic Substrate were added to the cell suspension, and luminescence intensity was measured using a Biotek Synergy H1. Luminescence values for each sample were normalized to the lowest temperature on the range and <italic>T</italic><sub>agg</sub> (<italic>T</italic>-aggregate) values were determined by fitting data with a four-parameter sigmoidal dose–response equation using non-linear regression in GraphPad Prism (version 10.1.1). Delta values were calculated by subtracting the <italic>T</italic><sub>agg</sub><sup>DMSO</sup> value from the <italic>T</italic><sub>agg</sub><sup>drug</sup> value. Data are presented as mean ± SD of two technical replicates.</p><p>For CETSA-WB experiments, 45 μl of suspended cells were dispensed into PCR strip tubes and heated for 3.5 min using a pre-heated gradient thermal cycler (Eppendorf). Samples were then placed in an aluminum PCR block on a dry ice/ethanol bath for 3 min, followed by incubating at 37°C for 3  min, and vortexing for 3 s. This freeze–thaw cycle was repeated three more times. Insoluble proteins were transferred to a 1.5-ml microcentrifuge tube, separated by centrifugation (20,000 × <italic>g</italic>, 15 min, 4°C), and 40 μl of supernatant corresponding to soluble proteins was kept for WB. Samples were separated on an SDS–polyacrylamide gel and transferred to a PVDF membrane. The following antibodies were used for immunoblotting: anti-FLAG antibody (Sigma, F1804, 1:1000 overnight), anti-mouse HRP antibody (CST, 7076S, 1:3000 for 1 hr). Images were captured using the Azure c600 Western Blot Imaging System, quantified using ImageJ, and plotted as above.</p></sec></sec><sec id="s4-6"><title>Cellular and organoid studies</title><sec id="s4-6-1"><title>SARS-CoV-2 culture</title><p>As described in our previous report (<xref ref-type="bibr" rid="bib53">Taha et al., 2023b</xref>), the pBAC SARS-CoV-2 WT (WA1) and N40D mutant constructs on WA1 background were made by co-transfecting them with an N expression vector into BHK-21 cells. Following 3 days of transfection, the cell supernatants were used to infect Vero cells stably expressing TMPRSS2, followed by passaging to achieve a high viral titer. All viruses generated or used in this study were verified by NGS using the ARTIC Network’s protocol. A previously reported mNeon SARS-CoV-2 infectious clone (ic-SARS-CoV-2-mNG) (<xref ref-type="bibr" rid="bib59">Xie et al., 2020</xref>) was passaged on Vero-TMPRSS2 and used for Incucyte-based antiviral assays.</p></sec><sec id="s4-6-2"><title>Cells</title><p>BHK-21 obtained from ATCC were grown in DMEM (Corning) with 10% fetal bovine serum (FBS) (GeminiBio), 1× Glutamax (Corning), and 1× penicillin–streptomycin (Corning) at 37°C in a 5% CO<sub>2</sub> atmosphere. A549-ACE2h cells were generated by stably expressing hACE2 (<xref ref-type="bibr" rid="bib19">Khalid et al., 2024</xref>) and further selecting for high ACE2 expression levels via FACS with Alexa Fluor 647 conjugated to a hACE2-specific antibody (FAB9332R, R&amp;D Systems). These cells were cultured in DMEM supplemented with 10% FBS, 10 μg/ml blasticidin (Sigma), 1× NEAA (Gibco), and 1% <sc>l</sc>-glutamine (Corning) at 37°C in a 5% CO<sub>2</sub> atmosphere. Vero cells that stably overexpress human TMPRSS2 (Vero TMPRSS2), a gift from the Whelan lab (<xref ref-type="bibr" rid="bib3">Case et al., 2020</xref>), were cultured under the same conditions. Additionally, Vero cells that stably express human ACE2 and TMPRSS2 (VAT), provided by A. Creanga and B. Graham from the NIH, were maintained in DMEM with 10% FBS, 1× penicillin–streptomycin, and 10 μg/ml puromycin at 37°C in a 5% CO<sub>2</sub> atmosphere. A549 cells obtained from ATCC were grown in DMEM Glutamax (Gibco) with 10% FBS (GeminiBio), and 1× penicillin–streptomycin (Corning) at 37°C in a 5% CO<sub>2</sub> atmosphere.</p></sec><sec id="s4-6-3"><title>ADP-ribose Western Blots</title><p>Calu3 cells were obtained from ATCC and cultured in Advanced DMEM (Gibco) supplemented with 2.5% FBS, 1x GlutaMax, and 1x penicillin–streptomycin at 37°C and 5% CO<sub>2</sub>. 5 × 10<sup>6</sup> cells were plated in 15 cm dishes and media was changed every 2–3 days until the cells were 80% confluent. The cells were treated with INFy 50 ng/ml (R&amp;D Systems) w/without AVI-4206 100 μM. After 6 hr, the cells were infected with WA1 or WA1 NSP3 Mac1 N40D at an MOI of 1 for 36 hr. The cells were washed with phosphate-buffered saline (PBS) × 3 and scraped in Pierce IP Lysis Buffer (Thermo Fisher) containing 1x HALT protease and phosphatase inhibitor mix (Thermo Fisher) on ice. The lysate was stored at –80°C until further processing.</p><p>The cell lysate was incubated for 5 min at room temperature with recombinant benzonase. Following incubation, the lysate was centrifuged at 13,000 rpm at 4°C for 20 min, and the supernatant was collected. The samples were then boiled for 5 min at 95°C in 1x NuPAGE LDS sample buffer (Invitrogen) with a final concentration of 1X NuPAGE sample reducing agent (Invitrogen). For the detection of ADPr levels in whole-cell lysates, the samples were subjected to SDS–PAGE and immunoblotting. All primary and secondary antibodies pan-ADP-ribose antibody (MABE1016, Millipore), Mono-ADP-ribose antibody (AbD33204, Bio-Rad), HRP-conjugated (Cell signaling), used at a 1:1000 dilution were diluted in 5% non-fat dry milk in TBST. Signals were detected by chemiluminescence (Thermo) and visualized using the ChemiDoc XRS+ System (Bio-Rad). Densitometric analysis was performed using Image Lab (Bio-Rad). Quantification was normalized to Actin. The data are expressed as mean ± SD. Statistical differences were determined using an unpaired <italic>t</italic>-test in GraphPad Prism 10.3.1.</p></sec><sec id="s4-6-4"><title>Human airway organoids</title><p>Human lung tissues were used to generate self-organizing 3D HAOs consisting of basal cells, multi-ciliated epithelial cells, mucus-producing secretory cells, and club cells. As described previously (<xref ref-type="bibr" rid="bib51">Suryawanshi et al., 2022</xref>; <xref ref-type="bibr" rid="bib53">Taha et al., 2023b</xref>), the human lung tissues obtained from Matthay lab were dissociated to single cells using enzymatic digestion. The isolated single cells were resuspended in Basement Membrane Extract (BME, R&amp;D Biosystems), to form a BME droplet containing cells which was submerged in HAO medium consisting 1 mM HEPES (Corning), 1× GlutaMAX (Gibco), 1× penicillin–streptomycin (Corning), 10% R-spondin1 conditioned medium, 1% B27 (Gibco), 25 ng/ml noggin (Peprotech), 1.25 mM <italic>N</italic>-acetylcysteine (Sigma-Aldrich), 10 mM nicotinamide (Sigma-Aldrich), 5 nM heregulin-β1 (Peprotech), and 100 μg/ml Primocin (InvivoGen) in DMEM. This HAO medium was also supplemented with 5 μM Y-27632, 500 nM A83-01, 500 nM SB202190, 25 ng/ml FGF7, and 100 ng/ml FGF10 (all obtained from Stem Cell Technologies). After sufficient growth of HAO cells, in order to differentiate the HAO cells, the HAO medium was replaced with equal proportion of HAO medium and PneumaCult-ALI medium (Stem Cell Technologies).</p></sec><sec id="s4-6-5"><title>SARS-CoV-2 replicon assay</title><p>The SARS-CoV-2 replicon assay was conducted as described previously (<xref ref-type="bibr" rid="bib53">Taha et al., 2023b</xref>). Briefly, the pBAC SARS-CoV-2 ΔSpike WT or nsp3 Mac1 N40D modified plasmids (40 μg) were transfected into BHK-21 fibroblast cells along with N and S expression vectors (20 μg each) in a 15 cm<sup>2</sup> tissue culture dish. The culture media was replaced with fresh growth medium 12 hr post-transfection. The media containing single-round infectious particles was collected and 0.45-μm-filtered 72 hr post-transfection and stored at –80°C until use.</p><p>Vero-ACE2-TMPRSS2 (VAT) and A549 ACE2<sup>h</sup> cells were plated 2.5 × 10<sup>4</sup> cells per well in 96-well plate in media containing 0, 1000, or 10,000 IU/ml of IFN-γ. After 16 hr, the media was replaced with 50 μl media containing 5x the final desired concentration of IFN-γ and AVI-4206. After 2 hr, 200 μl of supernatant containing WA1 or WA1 nsp3 Mac1 N40D single-round infectious particles was added. After 8 hr, the cells were washed with 200 μl culture medium and 100 μl of culture medium was added. After 16 hr, 50 μl from each well was transferred to a white 96-well plate to measure nanoluciferase activity by adding 50 μl of Nano-Glo luciferase assay buffer and substrate and analyzed on an Infinite M Plex plate reader (Tecan).</p></sec><sec id="s4-6-6"><title>SARS-CoV-2 in vitro antiviral assay</title><p>Antiviral activity of compounds was assessed using the Incucyte live-cell analysis system. 2 × 10<sup>4</sup> A549-ACE2h cells per well were seeded in Edge 2.0 96-well plates filled with 1.5 ml PBS in the outer moats and 100 µl in-between wells and incubated at 37°C and 5% CO<sub>2</sub>. The next day, cells were pretreated with compounds for 2 hr, followed by the removal of the compounds and infection with 50 µl of icSARS-CoV-2-mNG at an MOI of 0.1 for 2 hr. Subsequently, virus inoculum was removed and fresh compounds diluted in DMEM (10% FBS, 1% <sc>l</sc>-glutamine, 1× P/S, 1× NEAA, Incucyte Cytotox Dye) were added. Infected cells were placed in an Incucyte S3 (Sartorius) and infection and cell death were measured over 48 hr at 1-hr intervals using a 10x objective, capturing 3 images per well at each time point under cell maintenance conditions (37°C, 5% CO<sub>2</sub>). Infection and cell death were quantified as Total Green Object Integrated Intensity (300 ms acquisition time) and Red Object Integrated Intensity (400 ms acquisition time), respectively. After in-built software analysis, raw data was exported and antiviral efficacy was determined as the percentage of viral replication normalized to the vehicle control. Nirmatrelvir (HY-138687, MedChemExpress) and uninfected cells were used as intra-assay positive and negative controls, respectively. Unless otherwise stated, experiments were conducted in triplicate with three technical replicates. EC<sub>50</sub> values were calculated using GraphPad PRISM 10 (La Jolla, CA, USA) employing a dose–response inhibition equation with a non-linear fit regression model.</p></sec><sec id="s4-6-7"><title>Antiviral efficacy in HAOs</title><p>The differentiated HAOs were utilized to analyze the dose-dependent anti-SARS-CoV-2 efficacy of AVI-4206. Briefly, 100,000 cells of differentiated HAOs were seeded in a V-bottom plate (Greiner Bio-One). The cells were pretreated for 2 hr prior to infection with various concentrations of AVI-4206 (0, 0.16, 0.8, 4, 20, and 100 μM). After pretreatment, the HAOs were washed and infected with SARS-CoV-2 WA1 at an MOI of 1. A WA1-N40D mutant strain lacking the macrodomain activity was used as a positive control. Following 2 hr of infection, the HAOs were washed three times. Each washing step involved replacing the media with PBS and centrifuging the cells at 1000 rpm for 3 min. After three washes, the PBS was replaced with 100 μl of HAO differentiation medium, with or without varying concentrations of AVI-4206, and the plate was incubated for 72 hr at 37°C with 5% CO<sub>2</sub>. Supernatants collected at 24-hr intervals were used to analyze mature virus particle formation via plaque assay.</p></sec><sec id="s4-6-8"><title>Drug cytotoxicity assay</title><p>A549-ACE2h cells were seeded and incubated as for the in vitro antiviral assay. Cells were treated with compounds at the respective concentrations and vehicle control for 50 hr at 37°C and 5% CO<sub>2</sub>. Subsequently, Cell Titer-Glo reagent was added in a 1:1 ratio to the cells and incubated at room temperature for 5 min before transferring 100 µl of the mixture to a white 96-well plate. Luciferase activity was measured using an Infinite M Plex plate reader (Tecan). Cell viability was determined as the percentage of viability normalized to the vehicle control. Compound cytotoxicity was assessed in parallel with infection experiments using cells of the same passage.</p></sec><sec id="s4-6-9"><title>Macrophage infection assay</title><p>MDMs were generated from peripheral blood mononuclear cells obtained from healthy donors (Vitalant, CA, USA). CD14<sup>+</sup> monocytes were isolated by negative selection using the EasySep Human Monocyte Isolation Kit (STEMCELL Technologies, Vancouver, Canada), and cultured in ImmunoCult-SF Macrophage Medium (STEMCELL Technologies) supplemented with 50 ng/ml M-CSF for 8 days, following the manufacturer’s protocol. Differentiated MDMs were pretreated with AVI-4206 at the indicated concentrations in the presence of 50 ng/ml IFN-γ for 2 hr. Cells were then infected with SARS-CoV-2 (strain USA-WA1/2020) at an MOI of 2 for 2 hr. Following infection, cells were washed three times with PBS to remove unbound virus and cultured for an additional 18 hr in medium containing the corresponding concentrations of AVI-4206 and 50 ng/ml IFN-γ. Viral particle production in the supernatant was quantified by plaque assay. Data were analyzed using GraphPad Prism version 10.2.0 (GraphPad Software, CA, USA).</p></sec><sec id="s4-6-10"><title>A549 Mac1 expression cell construction</title><p>Mac1 wild-type (Mac1) and N40D mutant (Mac1 N40D) gene fragments were loaded into pLVX-EF1α-IRES-Puro (empty vector, EV) using Gibson cloning kit (NEB E5510). Lentivirus was prepared as previously described (<xref ref-type="bibr" rid="bib48">Shifrut et al., 2018</xref>). Briefly, 15 million HEK293T cells were grown overnight on 15 cm poly-<sc>l</sc>-lysine coated dishes and then transfected with 6 µg pMD2.G (Addgene plasmid # 12259; <ext-link ext-link-type="uri" xlink:href="http://n2t.net/addgene:12259">http://n2t.net/addgene:12259</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_12259">Addgene_12259</ext-link>), 18 µg dR8.91 (since replaced by second generation compatible pCMV-dR8.2, Addgene plasmid #8455) and 24 µg pLVX-EF1α-IRES-Puro (EV, Mac1, Mac1-N40D) plasmids using the lipofectamine 3000 transfection reagent per the manufacturer’s protocol (Thermo Fisher Scientific, Cat #L3000001). pMD2.G and dR8.91 were a gift from Didier Trono. The following day, media was refreshed with the addition of viral boost reagent at 500x as per the manufacturer’s protocol (Alstem, Cat #VB100). Viral supernatant was collected 48 hr post-transfection and spun down at 300 × <italic>g</italic> for 10 min to remove cell debris. To concentrate the lentiviral particles, Alstem precipitation solution (Alstem, Cat #VC100) was added, mixed, and refrigerated at 4°C overnight. The virus was then concentrated by centrifugation at 1500 × <italic>g</italic> for 30 min, at 4°C. Finally, each lentiviral pellet was resuspended at 100x of original volume in cold DMEM + 10% FBS + 1% penicillin-streptomycin and stored until use at –80°C. To generate Mac1 overexpressing cells, 2 million A549 cells were seeded in 10 cm dishes and transduced with lentivirus in the presence of 8 μg/ml polybrene (Sigma, TR-1003-G). The media was changed after 24 hr and, after 48 hr, media containing 2 μg/ml puromycin was added. Cells were selected for 72 hr and then expanded without selection. The expression of Mac1 was confirmed by Western Blot.</p></sec><sec id="s4-6-11"><title>Immunofluorescence assay</title><p>To assess the effect of Mac1 on IFN-induced ADP-ribosylation. A549-pLVX-EV, A549-pLVX-Mac1, and A549-pLVX-Mac1-N40D cells were seeded in 96-well plate (10,000 cells/well). Cells were pretreated with medium or 100 unit/ml IFN-γ (Sigma, SRP3058) for 24 hr to induce the expression of ADP-ribosylation. These three cell lines were then treated the next day with the indicated concentrations of AVI-4206 or RBN012759 (Medchemexpress, HY-136979). After 24 hr of exposure to drugs, treated cells were fixed in pre-cooled methanol at –20°C for 20 min, blocked in 3% bovine serum albumin for 15 min, incubated with Poly/Mono-ADP Ribose (E6F6A) Rabbit mAb (CST, 83732S) or Poly/Mono-ADP Ribose (D9P7Z) Rabbit mAb (CST, 89190S) antibodies for 1 hr, and then incubated with Goat anti-Rabbit IgG Secondary Antibody, Alexa Fluor 488 (Thermo Fisher, A-11008) secondary antibodies for 30 min and stained with DAPI for 10 min. Fluorescent cells were imaged with an IN Cell Analyzer 6500 System (Cytiva) and analyzed using IN Carta software (Cytiva).</p></sec><sec id="s4-6-12"><title>TPP assay</title><p>Pelleted A549 cells were resuspended in extraction buffer 1× PBS + phosphatase and protease inhibitors (phosSTOP (Roche) and cOmplete Mini Protease Inhibitor Cocktail (Roche)) with gentle pipetting followed by rotation at 4°C for 30 min. Lysates were centrifuged at 1000 × <italic>g</italic> for 10 min at 4°C and supernatant was transferred to new tubes. Recombinant Mac1 was spiked into lysate to a final concentration of 0.05 μM. Lysates + Mac1 were incubated with compound at a final concentration of 100 µM AVI-4206 or DMSO for 30 min at 25°C. Lysates (2 replicates per condition) were distributed into 10 aliquots (20 μl each) in PCR tubes. Samples were heated from 37 to 64°C in 3°C increments on a Bio-Rad C1000 Touch Thermal cycler and held for 4 min at the specified temperature. Samples were held at room temperature for 3 min. Samples were then subjected to two cycles of flash freezing and thawing at 35°C. Aggregated proteins were removed by centrifugation at 20,000 g for 60 min. 20 μl of lysis buffer (8 M urea, 100 mM Tris, pH ~7.5) was added to each well and samples were incubated for 30 min at room temperature. Samples were reduced and alkylated by the addition of TCEP (100 mM final) and 2-chloroacetamide (44 mM final) followed by incubation at room temperature for 30 min. Urea concentration was diluted to 1 M by the addition of 100 mM tris (pH ~7.5). Samples were digested overnight with LysC (Wako, 1:100 enzyme:protein ratio) and trypsin (Promega, 1:50 enzyme:protein ratio). Samples were desalted with a 96-well mini 20 MG PROTO 300 C18 plate (HNS S18V, The Nest Group) according to manufacturer’s directions. Peptide concentration was determined by NanoDrop (Thermo).</p><p>Following digestion, peptides were injected onto a timsTOF SCP (Bruker) connected to either an EASY-nLC 1200 system (Thermo) or VanquishNeo (Thermo). Peptides were separated on a PepSep reverse-phase C18 column (1.9 μm particles, 15 cm, 150 mm ID) (Bruker) with a gradient of 5–28% buffer B (0.1% formic acid in acetonitrile) over buffer A (0.1% formic acid in water) over 20 min, an increase to 32% B in 3 min, and held at 95% B for 7 min. DIA-PASEF analyses were acquired from 100 to 1700 <italic>m</italic>/<italic>z</italic> over a 1/Kø of 0.70–1.30 Vs/cm<sup>2</sup>, with a ramp and accumulation time set to 75 ms. Library DDA PASEF runs were collected over the same m/z and 1/Kø range and a cycle time of 1.9 s.</p><p>All data was searched against the Uniprot Human database (downloaded 05/25/23) appended with the SARS-CoV-2 database (downloaded 02/20/2024) using a combined DDA and DIA library in Spectronaut (Biognosys, version 19.0). Default settings, including trypsin digestion, variable modifications of methionine oxidation and N-termini acetylation, and fixed modification of cysteine carbamidomethylation, were used. Missing values were imputed for each run using background intensity. Data was filtered to obtain a false discovery rate of 1% at the peptide spectrum match and protein level. Lysate experiments were normalized to the lowest temperature (37°C), and melting points were determined in R using the Inflect package (<xref ref-type="bibr" rid="bib29">McCracken et al., 2021</xref>).</p></sec></sec><sec id="s4-7"><title>PK and in vivo studies</title><sec id="s4-7-1"><title>ADMET target and kinase studies</title><p>The kinase assessment was performed using contract services by Eurofins using their scanEDGE KINOMEscan Assay Platform (Study Code: US073-0032699). Assessment of ADMET targets (cardiac channel profiling, CYP induction, peptidase selectivity panel, and secondary pharmacology profiling) was performed via NIAID’s suite of preclinical services for in vitro assessment (Contract No. HHSN272201800007I/75N93022F00001).</p></sec><sec id="s4-7-2"><title>PK studies</title><p>The PK study of AVI-4206 with IV (10 mg/kg), PO (50 mg/kg), and IP (100 mg/kg) dosing (<xref ref-type="fig" rid="fig4">Figure 4B</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2b</xref>) was performed in male CD1 mice (<italic>n</italic> = 3 per group) using a formulation of 10% DMSO: 50% PEG 400: 40% of a 20% HP-β-CD in water. Microsampling (40 ml) via facial vein was performed at 0, 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 hr into K<sub>2</sub>EDTA tubes. The blood samples were collected and centrifuged to obtain plasma (8000 rpm, 5 min) within 15 min post sampling. Nine blood samples were collected from each mouse; three samples were collected for each time point. Data was processed by Phoenix WinNonlin (version 8.3); samples below the limit of quantitation were excluded in the PK parameters and mean concentration calculation.</p></sec></sec><sec id="s4-8"><title>Animal experiments</title><p>All the mice experiments were approved (AN169239-01) by the Institutional Animal Care and Use committees at the University of California, San Francisco and Gladstone Institutes and performed in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animal. For screening of lead macrodomain inhibitors, we employed a transgenic mice model capable of expressing human ACE2. Female mice were divided into three groups: test, positive control, and negative control. The positive control groups were infected (5 × 10<sup>2</sup> PFUs) with the N40D mutant of SARS-CoV-2, while the other mice were infected with the WA1 strain. Intraperitoneal treatments were administered twice daily, which began at a day prior to infection and continued until 5 days post-infection, with close monitoring for disease parameters such as weight loss, hypothermia, and hunched posture. At 4 and 7 days post-infection, a subset of mice from each group was euthanized, and their lungs and brain tissues were harvested for virus titration by plaque assay and cytokine expression.</p><p>In experiments using wild-type female mice, animals were randomly assigned to one of three groups: an experimental group, a positive control group, and a negative control group. The positive control group was infected intranasally with 1 × 10⁴ PFU of a mouse-adapted SARS-CoV-2 N40D variant strain, while the experimental and negative control groups were infected with a mouse-adapted SARS-CoV-2 WA1 strain. A mouse-adapted (MA)-SARS-CoV-2 (Spike:Q498Y/P499T) was constructed using pGLUE. Intraperitoneal administration of the test compound began 1 day prior to infection and continued twice daily for 4 days post-infection. On days 2 and 5 post-infection, subsets of mice from each group were euthanized, and lung tissues were harvested for viral load quantification by plaque assay.</p></sec><sec id="s4-9"><title>Plaque assay</title><p>The mature virus particles in the lung homogenates were analyzed using plaque assay. Briefly, VAT cells were seeded in a 12-well plate and incubated overnight. The cells were inoculated with 10–10<sup>6</sup> dilutions of the respective lung homogenates. After 1-hr incubation, the lung homogenates in the wells were overlaid with 2.5% Avicel (RC-591, Dupont). And the plates were incubated at 370°C and 5% CO<sub>2</sub> for 48 hr. After incubation, the overlay media was removed and the cells were fixed in 10% formalin. The plaques were visualized by staining the cells with crystal violet. Data analysis was performed by using GraphPad Prism version 10.</p></sec><sec id="s4-10"><title>Cytokine estimation</title><p>Lung homogenates were clarified by centrifugation at 6000 rpm for 10 min and were used for enzyme-linked immunosorbent assay-based cytokine estimation. The assays were performed as per manufacturer’s protocol for IP-10 (Invitrogen, catalog#BMS56018 and BMS6018TEN), IL-2 (Invitrogen, catalog#BMS601, and BMS601TEN), IL-6 (Invitrogen, catalog#BMS103-2, BMS603-2TWO, and BMS603-2TEN), TNF-a (Invitrogen, catalog#BMS607-3 and BMS607-3TEN), and IL1b (Invitrogen, catalog#BMS6002-2 and BMS6002-2TEN).</p></sec><sec id="s4-11"><title>Histology</title><p>Mouse lung tissues were fixed in 4% PFA (Sigma-Aldrich, Cat #47608) for 24 hr, washed three times with PBS, and stored in 70% ethanol. All the stainings were performed at Histo-Tec Laboratory (Hayward, CA). Samples were processed, embedded in paraffin, and sectioned at 4 μm. The slides were dewaxed using xylene and alcohol-based dewaxing solutions. Epitope retrieval was performed by heat-induced epitope retrieval (HIER) of the formalin-fixed, paraffin-embedded tissue using citrate-based pH 6 solution (Leica Microsystems, AR9961) for 20 min at 95°C. The tissues were stained for H&amp;E, caspase-3 (Biocare #CP229c 1:100), and trichrome, dried, coverslipped (TissueTek-Prisma Coverslipper), and visualized using Axioscan 7 slide scanner (ZEISS) at 40X. Image quantification was performed with ImageJ software and GraphPad Prism.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>listed as an inventor on a patent application (Mac1 Inhibitors and Uses Thereof U.S. Provisional Application No. 63/631,958 filed April 9, 2024) describing small molecule macrodomain inhibitors, which includes compounds described herein</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>The Krogan laboratory has received research support from Vir Biotechnology, F Hoffmann-La Roche and Rezo Therapeutics. NJK has a financially compensated consulting agreement with Maze Therapeutics. He is on the Board of Directors and is President of Rezo Therapeutics and is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics, and GEn1E Lifesciences. He is also listed as an inventor on a patent application (Mac1 Inhibitors and Uses Thereof U.S. Provisional Application No. 63/631,958 filed April 9, 2024) describing small molecule macrodomain inhibitors, which includes compounds described herein</p></fn><fn fn-type="COI-statement" id="conf4"><p>co-founder of BlueDolphin LLC, Epiodyne Inc, and Deep Apple Therapeutics, Inc, and serves on the SRB of Genentech, the SAB of Schrodinger LLC, and the SAB of Vilya Therapeutics. Also listed as an inventor on a patent application (Mac1 Inhibitors and Uses Thereof U.S. Provisional Application No. 63/631,958 filed April 9, 2024) describing small molecule macrodomain inhibitors, which includes compounds described herein</p></fn><fn fn-type="COI-statement" id="conf5"><p>cofounder of Directbio and board member of InVisishield. TYT and MO are listed as inventors on a patent application (Rapid generation of infectious clones US-2024/0209381-A1) filed by the Gladstone Institutes that covers the use of pGLUE to generate SARS-CoV-2 infectious clones and replicons. Also listed as an inventor on a patent application (Mac1 Inhibitors and Uses Thereof U.S. Provisional Application No. 63/631,958 filed April 9, 2024) describing small molecule macrodomain inhibitors, which includes compounds described herein</p></fn><fn fn-type="COI-statement" id="conf6"><p>co-founder of TheRas, Elgia Therapeutics, and Tatara Therapeutics, and receives sponsored research support from Merck, Sharp and Dohme. Listed as an inventor on a patent application (Mac1 Inhibitors and Uses Thereof U.S. Provisional Application No. 63/631,958 filed April 9, 2024) describing small molecule macrodomain inhibitors, which includes compounds described herein</p></fn><fn fn-type="COI-statement" id="conf7"><p>co-founder of Tango Therapeutics, Azkarra Therapeutics and Kytarro; a member of the board of Cytomx, Ovibio Corporation, Cambridge Science Corporation; a member of the scientific advisory board of Genentech, GLAdiator, Circle, Bluestar/Clearnote Health, Earli, Ambagon, Phoenix Molecular Designs, Yingli/280Bio, Trial Library, ORIC and HAP10; a consultant for ProLynx, Next RNA and Novartis; receives research support from SPARC; and holds patents on the use of PARP inhibitors held jointly with AstraZeneca from which he has benefited financially (and may do so in the future); listed as an inventor on a patent application (Mac1 Inhibitors and Uses Thereof U.S. Provisional Application No. 63/631,958 filed April 9, 2024) describing small molecule macrodomain inhibitors, which includes compounds described herein</p></fn><fn fn-type="COI-statement" id="conf8"><p>consultant to, shareholder of, and receives sponsored research support from Relay Therapeutics, and is listed as an inventor on a patent application (Mac1 Inhibitors and Uses Thereof U.S. Provisional Application No. 63/631,958 filed April 9, 2024) describing small molecule macrodomain inhibitors, which includes compounds described herein</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con21"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con22"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con23"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con24"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con25"><p>Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con26"><p>Formal analysis, Supervision, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con27"><p>Conceptualization, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con28"><p>Conceptualization, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con29"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con30"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con31"><p>Conceptualization, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>X-ray data collection and refinement deposition statistics.</title></caption><media xlink:href="elife-103484-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Specificity, PK, and ADMET panels.</title><p>(a) Eurofins scanEDGE kinase assay shows no inhibition greater than &gt;35% at 10 μM across a panel of diverse kinases. (b) Pharmacokinetic parameters for AVI-4206 following IV (10 mg/kg), PO (50 mg/kg), and IP (100 mg/kg) doses in male CD1 mice (<italic>n</italic> = 3 per group). (c) ADMET panel shows no antagonist response greater than &gt;15% at 10 μM.</p></caption><media xlink:href="elife-103484-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Macrodomain protein sequences.</title></caption><media xlink:href="elife-103484-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-103484-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>X-ray structures have been deposited in the Protein Data Bank as: 9CXY (AVI-1500), 9CXZ (AVI-1501), 7HC4 (AVI-3367), 7HC5 (AVI-3765), 7HC6 (AVI-3764), 7HC7 (AVI-4051), 7HC8 (AVI-3763), 7HC9 (AVI-3762), 7HCA (AVI-4636), 9CY0 (AVI-4206). All other data supporting the findings of the present study are available in the article, extended data, and supplementary figures.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>9CXY - Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with AVI-1500</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb9cxy/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>9CXZ - Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with AVI-1501</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb9cxz/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodmain in complex with AVI-3367</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb7hc4/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset4"><person-group person-group-type="author"><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodmain in complex with AVI-3765</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb7hc5/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset5"><person-group person-group-type="author"><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodmain in complex with AVI-3764</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb7hc6/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset6"><person-group person-group-type="author"><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodmain in complex with AVI-4051</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb7hc7/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset7"><person-group person-group-type="author"><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodmain in complex with AVI-3763</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb7hc8/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset8"><person-group person-group-type="author"><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodmain in complex with AVI-3762</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb7hc9/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset9"><person-group person-group-type="author"><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodmain in complex with AVI-4636</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb7hca/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset10"><person-group person-group-type="author"><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>PDB Entry - 9CY0 (pdb_00009cy0)</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb9cy0/pdb</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the National Institutes of Health (NIAID Antiviral Drug Discovery (AViDD)) grant U19AI171110. MO is supported by the James B Pendleton Charitable Trust and the Roddenberry Foundation. The synchrotron X-ray diffraction data used to determine Mac1 structures were collected at beamline 8.3.1 of the Advanced Light Source (ALS) and beamlines 9-2, 12-1, and 12-2 of the Stanford Synchrotron Radiation Lightsource (SSRL). The ALS, a US DOE Office of Science User Facility under Contract No. DE-AC02-05CH11231, is supported in part by the ALS-ENABLE program funded by the NIH, National Institute of General Medical Sciences, grant P30 GM124169. Use of the SSRL, SLAC National Accelerator Laboratory, is supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract No. DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute of General Medical Sciences (P30GM133894). RKS is supported by the NIH Division of Intramural Research.</p><p>This research was supported in part by the intramural research program of the National Institutes of Health (NIH). The contributions of the NIH author were made as a part of their official duties as NIH federal employees, are in compliance with the agency policy requirements, and are considered Works of the United States Government. However, the findings and conclusions presented in this paper are those of the author and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhammad</surname><given-names>YM</given-names></name><name><surname>Parthasarathy</surname><given-names>S</given-names></name><name><surname>Ghimire</surname><given-names>R</given-names></name><name><surname>Kerr</surname><given-names>CM</given-names></name><name><surname>O’Connor</surname><given-names>JJ</given-names></name><name><surname>Pfannenstiel</surname><given-names>JJ</given-names></name><name><surname>Chanda</surname><given-names>D</given-names></name><name><surname>Miller</surname><given-names>CA</given-names></name><name><surname>Baumlin</surname><given-names>N</given-names></name><name><surname>Salathe</surname><given-names>M</given-names></name><name><surname>Unckless</surname><given-names>RL</given-names></name><name><surname>Zuñiga</surname><given-names>S</given-names></name><name><surname>Enjuanes</surname><given-names>L</given-names></name><name><surname>More</surname><given-names>S</given-names></name><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in cell culture and in mice</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2302083120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2302083120</pub-id><pub-id pub-id-type="pmid">37607224</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>F</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Lv</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Zhen</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice</article-title><source>Nature</source><volume>583</volume><fpage>830</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2312-y</pub-id><pub-id pub-id-type="pmid">32380511</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Case</surname><given-names>JB</given-names></name><name><surname>Rothlauf</surname><given-names>PW</given-names></name><name><surname>Chen</surname><given-names>RE</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>AS</given-names></name><name><surname>Bloyet</surname><given-names>LM</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Tahan</surname><given-names>S</given-names></name><name><surname>Droit</surname><given-names>L</given-names></name><name><surname>Ilagan</surname><given-names>M</given-names></name><name><surname>Tartell</surname><given-names>MA</given-names></name><name><surname>Amarasinghe</surname><given-names>G</given-names></name><name><surname>Henderson</surname><given-names>JP</given-names></name><name><surname>Miersch</surname><given-names>S</given-names></name><name><surname>Ustav</surname><given-names>M</given-names></name><name><surname>Sidhu</surname><given-names>S</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Theel</surname><given-names>ES</given-names></name><name><surname>Fremont</surname><given-names>DH</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Whelan</surname><given-names>SPJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neutralizing Antibody and Soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2</article-title><source>Cell Host &amp; Microbe</source><volume>28</volume><fpage>475</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.06.021</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>PM</given-names></name><name><surname>Ng</surname><given-names>JT</given-names></name><name><surname>Talon</surname><given-names>R</given-names></name><name><surname>Nekrosiute</surname><given-names>K</given-names></name><name><surname>Krojer</surname><given-names>T</given-names></name><name><surname>Douangamath</surname><given-names>A</given-names></name><name><surname>Brandao-Neto</surname><given-names>J</given-names></name><name><surname>Wright</surname><given-names>N</given-names></name><name><surname>Pearce</surname><given-names>NM</given-names></name><name><surname>von Delft</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Gentle, fast and effective crystal soaking by acoustic dispensing</article-title><source>Acta Crystallographica. Section D, Structural Biology</source><volume>73</volume><fpage>246</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1107/S205979831700331X</pub-id><pub-id pub-id-type="pmid">28291760</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Kneller</surname><given-names>DW</given-names></name><name><surname>Phillips</surname><given-names>G</given-names></name><name><surname>Pant</surname><given-names>S</given-names></name><name><surname>Russi</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>AE</given-names></name><name><surname>Meigs</surname><given-names>G</given-names></name><name><surname>Holton</surname><given-names>JM</given-names></name><name><surname>Gahbauer</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>MC</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><name><surname>Coates</surname><given-names>L</given-names></name><name><surname>Kovalevsky</surname><given-names>A</given-names></name><name><surname>Meilleur</surname><given-names>F</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and x-ray diffraction at room temperature</article-title><source>Science Advances</source><volume>8</volume><elocation-id>eabo5083</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abo5083</pub-id><pub-id pub-id-type="pmid">35622909</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Rachman</surname><given-names>MM</given-names></name><name><surname>Togo</surname><given-names>T</given-names></name><name><surname>Gahbauer</surname><given-names>S</given-names></name><name><surname>Doruk</surname><given-names>YU</given-names></name><name><surname>Stevens</surname><given-names>MGV</given-names></name><name><surname>Jaishankar</surname><given-names>P</given-names></name><name><surname>Kelley</surname><given-names>B</given-names></name><name><surname>Goldman</surname><given-names>B</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Kramer</surname><given-names>T</given-names></name><name><surname>Radchenko</surname><given-names>DS</given-names></name><name><surname>Moroz</surname><given-names>YS</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><name><surname>Riley</surname><given-names>P</given-names></name><name><surname>Shoichet</surname><given-names>BK</given-names></name><name><surname>Renslo</surname><given-names>AR</given-names></name><name><surname>Walters</surname><given-names>WP</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Exploration of structure-activity relationships for the SARS-CoV-2 macrodomain from shape-based fragment linking and active learning</article-title><source>Science Advances</source><volume>11</volume><elocation-id>eads7187</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.ads7187</pub-id><pub-id pub-id-type="pmid">40435250</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasovich</surname><given-names>M</given-names></name><name><surname>Zhuo</surname><given-names>J</given-names></name><name><surname>Goodman</surname><given-names>JA</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>McPherson</surname><given-names>RL</given-names></name><name><surname>Jayabalan</surname><given-names>AK</given-names></name><name><surname>Busa</surname><given-names>VF</given-names></name><name><surname>Cheng</surname><given-names>SJ</given-names></name><name><surname>Murphy</surname><given-names>BA</given-names></name><name><surname>Redinger</surname><given-names>KR</given-names></name><name><surname>Alhammad</surname><given-names>YMO</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name><name><surname>Tsukamoto</surname><given-names>T</given-names></name><name><surname>Slusher</surname><given-names>BS</given-names></name><name><surname>Bosch</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Leung</surname><given-names>AKL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>High-throughput activity assay for screening inhibitors of the SARS-CoV-2 Mac1 Macrodomain</article-title><source>ACS Chemical Biology</source><volume>17</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1021/acschembio.1c00721</pub-id><pub-id pub-id-type="pmid">34904435</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasovich</surname><given-names>M</given-names></name><name><surname>Leung</surname><given-names>AKL</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>PARPs and ADP-ribosylation: Deciphering the complexity with molecular tools</article-title><source>Molecular Cell</source><volume>83</volume><fpage>1552</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2023.04.009</pub-id><pub-id pub-id-type="pmid">37119811</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>PR</given-names></name><name><surname>Murshudov</surname><given-names>GN</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>How good are my data and what is the resolution?</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>69</volume><fpage>1204</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1107/S0907444913000061</pub-id><pub-id pub-id-type="pmid">23793146</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gahbauer</surname><given-names>S</given-names></name><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Schuller</surname><given-names>M</given-names></name><name><surname>Ferla</surname><given-names>MP</given-names></name><name><surname>Doruk</surname><given-names>YU</given-names></name><name><surname>Rachman</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Diolaiti</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Neitz</surname><given-names>RJ</given-names></name><name><surname>Fearon</surname><given-names>D</given-names></name><name><surname>Radchenko</surname><given-names>DS</given-names></name><name><surname>Moroz</surname><given-names>YS</given-names></name><name><surname>Irwin</surname><given-names>JJ</given-names></name><name><surname>Renslo</surname><given-names>AR</given-names></name><name><surname>Taylor</surname><given-names>JC</given-names></name><name><surname>Gestwicki</surname><given-names>JE</given-names></name><name><surname>von Delft</surname><given-names>F</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><name><surname>Ahel</surname><given-names>I</given-names></name><name><surname>Shoichet</surname><given-names>BK</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2212931120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2212931120</pub-id><pub-id pub-id-type="pmid">36598939</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunewald</surname><given-names>ME</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Kuny</surname><given-names>C</given-names></name><name><surname>Maejima</surname><given-names>T</given-names></name><name><surname>Lease</surname><given-names>R</given-names></name><name><surname>Ferraris</surname><given-names>D</given-names></name><name><surname>Aikawa</surname><given-names>M</given-names></name><name><surname>Sullivan</surname><given-names>CS</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression</article-title><source>PLOS Pathogens</source><volume>15</volume><elocation-id>e1007756</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007756</pub-id><pub-id pub-id-type="pmid">31095648</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivashkiv</surname><given-names>LB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Epigenetic regulation of macrophage polarization and function</article-title><source>Trends in Immunology</source><volume>34</volume><fpage>216</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.it.2012.11.001</pub-id><pub-id pub-id-type="pmid">23218730</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabsch</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>XDS</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1107/S0907444909047337</pub-id><pub-id pub-id-type="pmid">20124692</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kar</surname><given-names>P</given-names></name><name><surname>Chatrin</surname><given-names>C</given-names></name><name><surname>Đukić</surname><given-names>N</given-names></name><name><surname>Suyari</surname><given-names>O</given-names></name><name><surname>Schuller</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Prokhorova</surname><given-names>E</given-names></name><name><surname>Bigot</surname><given-names>N</given-names></name><name><surname>Baretić</surname><given-names>D</given-names></name><name><surname>Ahel</surname><given-names>J</given-names></name><name><surname>Elsborg</surname><given-names>JD</given-names></name><name><surname>Nielsen</surname><given-names>ML</given-names></name><name><surname>Clausen</surname><given-names>T</given-names></name><name><surname>Huet</surname><given-names>S</given-names></name><name><surname>Niepel</surname><given-names>M</given-names></name><name><surname>Sanyal</surname><given-names>S</given-names></name><name><surname>Ahel</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Ahel</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>PARP14 and PARP9/DTX3L regulate interferon-induced ADP-ribosylation</article-title><source>The EMBO Journal</source><volume>43</volume><fpage>2929</fpage><lpage>2953</lpage><pub-id pub-id-type="doi">10.1038/s44318-024-00126-0</pub-id><pub-id pub-id-type="pmid">38834853</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasson</surname><given-names>S</given-names></name><name><surname>Dharmapriya</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>IK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Selective monitoring of the protein-free ADP-ribose released by ADP-ribosylation reversal enzymes</article-title><source>PLOS ONE</source><volume>16</volume><elocation-id>e0254022</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0254022</pub-id><pub-id pub-id-type="pmid">34191856</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors</article-title><source>Nature Immunology</source><volume>11</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/ni.1863</pub-id><pub-id pub-id-type="pmid">20404851</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>CM</given-names></name><name><surname>Parthasarathy</surname><given-names>S</given-names></name><name><surname>Schwarting</surname><given-names>N</given-names></name><name><surname>O’Connor</surname><given-names>JJ</given-names></name><name><surname>Pfannenstiel</surname><given-names>JJ</given-names></name><name><surname>Giri</surname><given-names>E</given-names></name><name><surname>More</surname><given-names>S</given-names></name><name><surname>Orozco</surname><given-names>RC</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>PARP12 is required to repress the replication of a Mac1 mutant coronavirus in a cell- and tissue-specific manner</article-title><source>Journal of Virology</source><volume>97</volume><elocation-id>e0088523</elocation-id><pub-id pub-id-type="doi">10.1128/jvi.00885-23</pub-id><pub-id pub-id-type="pmid">37695054</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>CM</given-names></name><name><surname>Pfannenstiel</surname><given-names>JJ</given-names></name><name><surname>Alhammad</surname><given-names>YM</given-names></name><name><surname>O’Connor</surname><given-names>JJ</given-names></name><name><surname>Ghimire</surname><given-names>R</given-names></name><name><surname>Shrestha</surname><given-names>R</given-names></name><name><surname>Khattabi</surname><given-names>R</given-names></name><name><surname>Saenjamsai</surname><given-names>P</given-names></name><name><surname>Parthasarathy</surname><given-names>S</given-names></name><name><surname>McDonald</surname><given-names>PR</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>DK</given-names></name><name><surname>More</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Mutation of a highly conserved isoleucine residue in loop 2 of several β-Coronavirus macrodomains indicates that enhanced ADP-Ribose binding is detrimental to infection</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.01.03.574082</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Khalid</surname><given-names>MM</given-names></name><name><surname>Chen</surname><given-names>I</given-names></name><name><surname>Soveg</surname><given-names>FS</given-names></name><name><surname>Taha</surname><given-names>TY</given-names></name><name><surname>Tabata</surname><given-names>T</given-names></name><name><surname>Suryawanshi</surname><given-names>R</given-names></name><name><surname>Syed</surname><given-names>AM</given-names></name><name><surname>Ciling</surname><given-names>A</given-names></name><name><surname>McCavitt-Malvido</surname><given-names>M</given-names></name><name><surname>Schulze-Gahmen</surname><given-names>U</given-names></name><name><surname>Hayashi</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>IJ</given-names></name><name><surname>Fong</surname><given-names>SW</given-names></name><name><surname>Batra</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>GR</given-names></name><name><surname>Laurent</surname><given-names>R</given-names></name><name><surname>Ng</surname><given-names>LF</given-names></name><name><surname>Krogan</surname><given-names>NJ</given-names></name><name><surname>Doudna</surname><given-names>JA</given-names></name><name><surname>Verdin</surname><given-names>E</given-names></name><name><surname>Ott</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Regulation of virion production by the ORF8 signal peptide across SARS-CoV-2 variants</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.03.05.583578</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Shin</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Type I and III interferon responses in SARS-CoV-2 infection</article-title><source>Experimental &amp; Molecular Medicine</source><volume>53</volume><fpage>750</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1038/s12276-021-00592-0</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AA</given-names></name><name><surname>Amick</surname><given-names>I</given-names></name><name><surname>Aschenbrenner</surname><given-names>JC</given-names></name><name><surname>Barr</surname><given-names>HM</given-names></name><name><surname>Benjamin</surname><given-names>J</given-names></name><name><surname>Brandis</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>G</given-names></name><name><surname>Diaz-Tapia</surname><given-names>R</given-names></name><name><surname>Duberstein</surname><given-names>S</given-names></name><name><surname>Dixon</surname><given-names>J</given-names></name><name><surname>Cousins</surname><given-names>D</given-names></name><name><surname>Fairhead</surname><given-names>M</given-names></name><name><surname>Fearon</surname><given-names>D</given-names></name><name><surname>Frick</surname><given-names>J</given-names></name><name><surname>Gayvert</surname><given-names>J</given-names></name><name><surname>Godoy</surname><given-names>AS</given-names></name><name><surname>Griffin</surname><given-names>EJ</given-names></name><name><surname>Huber</surname><given-names>K</given-names></name><name><surname>Koekemoer</surname><given-names>L</given-names></name><name><surname>Lahav</surname><given-names>N</given-names></name><name><surname>Marples</surname><given-names>PG</given-names></name><name><surname>McGovern</surname><given-names>BL</given-names></name><name><surname>Mehlman</surname><given-names>T</given-names></name><name><surname>Robinson</surname><given-names>MC</given-names></name><name><surname>Singh</surname><given-names>U</given-names></name><name><surname>Szommer</surname><given-names>T</given-names></name><name><surname>Tomlinson</surname><given-names>CWE</given-names></name><name><surname>Vargo</surname><given-names>T</given-names></name><name><surname>von Delft</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>E</given-names></name><name><surname>Winokan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Discovery of Potent SARS-CoV-2 Nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral response</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.08.19.608619</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>AKL</given-names></name><name><surname>Griffin</surname><given-names>DE</given-names></name><name><surname>Bosch</surname><given-names>J</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The conserved macrodomain is a potential therapeutic target for coronaviruses and alphaviruses</article-title><source>Pathogens</source><volume>11</volume><elocation-id>94</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens11010094</pub-id><pub-id pub-id-type="pmid">35056042</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Hilgenfeld</surname><given-names>R</given-names></name><name><surname>Whitley</surname><given-names>R</given-names></name><name><surname>De Clercq</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>Therapeutic strategies for COVID-19: progress and lessons learned</article-title><source>Nature Reviews. Drug Discovery</source><volume>22</volume><fpage>449</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/s41573-023-00672-y</pub-id><pub-id pub-id-type="pmid">37076602</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Wan</surname><given-names>Z</given-names></name><name><surname>Chiu</surname><given-names>MC</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>JP</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Chan</surname><given-names>JFW</given-names></name><name><surname>To</surname><given-names>KKW</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>Human airway and nasal organoids reveal escalating replicative fitness of SARS-CoV-2 emerging variants</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2300376120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2300376120</pub-id><pub-id pub-id-type="pmid">37068258</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liebschner</surname><given-names>D</given-names></name><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Baker</surname><given-names>ML</given-names></name><name><surname>Bunkóczi</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Croll</surname><given-names>TI</given-names></name><name><surname>Hintze</surname><given-names>B</given-names></name><name><surname>Hung</surname><given-names>LW</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Oeffner</surname><given-names>RD</given-names></name><name><surname>Poon</surname><given-names>BK</given-names></name><name><surname>Prisant</surname><given-names>MG</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Sammito</surname><given-names>MD</given-names></name><name><surname>Sobolev</surname><given-names>OV</given-names></name><name><surname>Stockwell</surname><given-names>DH</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Urzhumtsev</surname><given-names>AG</given-names></name><name><surname>Videau</surname><given-names>LL</given-names></name><name><surname>Williams</surname><given-names>CJ</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix</article-title><source>Acta Crystallographica. Section D, Structural Biology</source><volume>75</volume><fpage>861</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1107/S2059798319011471</pub-id><pub-id pub-id-type="pmid">31588918</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>CJ</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PARP inhibitors: Synthetic lethality in the clinic</article-title><source>Science</source><volume>355</volume><fpage>1152</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1126/science.aam7344</pub-id><pub-id pub-id-type="pmid">28302823</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>NJ</given-names></name><name><surname>Asawa</surname><given-names>RR</given-names></name><name><surname>Cyr</surname><given-names>MG</given-names></name><name><surname>Zakharov</surname><given-names>A</given-names></name><name><surname>Urban</surname><given-names>DJ</given-names></name><name><surname>Roth</surname><given-names>JS</given-names></name><name><surname>Wallgren</surname><given-names>E</given-names></name><name><surname>Klumpp-Thomas</surname><given-names>C</given-names></name><name><surname>Coussens</surname><given-names>NP</given-names></name><name><surname>Rai</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>SM</given-names></name><name><surname>Hall</surname><given-names>MD</given-names></name><name><surname>Marugan</surname><given-names>JJ</given-names></name><name><surname>Simeonov</surname><given-names>A</given-names></name><name><surname>Henderson</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano Luciferase</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>9472</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-27834-y</pub-id><pub-id pub-id-type="pmid">29930256</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Winn</surname><given-names>MD</given-names></name><name><surname>Storoni</surname><given-names>LC</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Phaser crystallographic software</article-title><source>Journal of Applied Crystallography</source><volume>40</volume><fpage>658</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id><pub-id pub-id-type="pmid">19461840</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCracken</surname><given-names>NA</given-names></name><name><surname>Peck Justice</surname><given-names>SA</given-names></name><name><surname>Wijeratne</surname><given-names>AB</given-names></name><name><surname>Mosley</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Inflect: Optimizing computational workflows for thermal proteome profiling data analysis</article-title><source>Journal of Proteome Research</source><volume>20</volume><fpage>1874</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.0c00872</pub-id><pub-id pub-id-type="pmid">33660510</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McPherson</surname><given-names>RL</given-names></name><name><surname>Abraham</surname><given-names>R</given-names></name><name><surname>Sreekumar</surname><given-names>E</given-names></name><name><surname>Ong</surname><given-names>SE</given-names></name><name><surname>Cheng</surname><given-names>SJ</given-names></name><name><surname>Baxter</surname><given-names>VK</given-names></name><name><surname>Kistemaker</surname><given-names>HAV</given-names></name><name><surname>Filippov</surname><given-names>DV</given-names></name><name><surname>Griffin</surname><given-names>DE</given-names></name><name><surname>Leung</surname><given-names>AKL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ADP-ribosylhydrolase activity of Chikungunya virus macrodomain is critical for virus replication and virulence</article-title><source>PNAS</source><volume>114</volume><fpage>1666</fpage><lpage>1671</lpage><pub-id pub-id-type="doi">10.1073/pnas.1621485114</pub-id><pub-id pub-id-type="pmid">28143925</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalska</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Jedrzejczak</surname><given-names>R</given-names></name><name><surname>Maltseva</surname><given-names>NI</given-names></name><name><surname>Stols</surname><given-names>L</given-names></name><name><surname>Endres</surname><given-names>M</given-names></name><name><surname>Joachimiak</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Crystal structures of SARS-CoV-2 ADP-ribose phosphatase: from the apo form to ligand complexes</article-title><source>IUCrJ</source><volume>7</volume><fpage>814</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1107/S2052252520009653</pub-id><pub-id pub-id-type="pmid">32939273</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minkoff</surname><given-names>JM</given-names></name><name><surname>tenOever</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Innate immune evasion strategies of SARS-CoV-2</article-title><source>Nature Reviews. Microbiology</source><volume>21</volume><fpage>178</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00839-1</pub-id><pub-id pub-id-type="pmid">36631691</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neufeldt</surname><given-names>CJ</given-names></name><name><surname>Cerikan</surname><given-names>B</given-names></name><name><surname>Cortese</surname><given-names>M</given-names></name><name><surname>Frankish</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Plociennikowska</surname><given-names>A</given-names></name><name><surname>Heigwer</surname><given-names>F</given-names></name><name><surname>Prasad</surname><given-names>V</given-names></name><name><surname>Joecks</surname><given-names>S</given-names></name><name><surname>Burkart</surname><given-names>SS</given-names></name><name><surname>Zander</surname><given-names>DY</given-names></name><name><surname>Subramanian</surname><given-names>B</given-names></name><name><surname>Gimi</surname><given-names>R</given-names></name><name><surname>Padmanabhan</surname><given-names>S</given-names></name><name><surname>Iyer</surname><given-names>R</given-names></name><name><surname>Gendarme</surname><given-names>M</given-names></name><name><surname>El Debs</surname><given-names>B</given-names></name><name><surname>Halama</surname><given-names>N</given-names></name><name><surname>Merle</surname><given-names>U</given-names></name><name><surname>Boutros</surname><given-names>M</given-names></name><name><surname>Binder</surname><given-names>M</given-names></name><name><surname>Bartenschlager</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB</article-title><source>Communications Biology</source><volume>5</volume><elocation-id>45</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-021-02983-5</pub-id><pub-id pub-id-type="pmid">35022513</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Connor</surname><given-names>JJ</given-names></name><name><surname>Ferraris</surname><given-names>D</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>An update on the current state of SARS-CoV-2 Mac1 inhibitors</article-title><source>Pathogens</source><volume>12</volume><elocation-id>1221</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12101221</pub-id><pub-id pub-id-type="pmid">37887737</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oladunni</surname><given-names>FS</given-names></name><name><surname>Park</surname><given-names>JG</given-names></name><name><surname>Pino</surname><given-names>PA</given-names></name><name><surname>Gonzalez</surname><given-names>O</given-names></name><name><surname>Akhter</surname><given-names>A</given-names></name><name><surname>Allué-Guardia</surname><given-names>A</given-names></name><name><surname>Olmo-Fontánez</surname><given-names>A</given-names></name><name><surname>Gautam</surname><given-names>S</given-names></name><name><surname>Garcia-Vilanova</surname><given-names>A</given-names></name><name><surname>Ye</surname><given-names>C</given-names></name><name><surname>Chiem</surname><given-names>K</given-names></name><name><surname>Headley</surname><given-names>C</given-names></name><name><surname>Dwivedi</surname><given-names>V</given-names></name><name><surname>Parodi</surname><given-names>LM</given-names></name><name><surname>Alfson</surname><given-names>KJ</given-names></name><name><surname>Staples</surname><given-names>HM</given-names></name><name><surname>Schami</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>JI</given-names></name><name><surname>Whigham</surname><given-names>A</given-names></name><name><surname>Platt</surname><given-names>RN</given-names></name><name><surname>Gazi</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>J</given-names></name><name><surname>Chuba</surname><given-names>C</given-names></name><name><surname>Earley</surname><given-names>S</given-names></name><name><surname>Rodriguez</surname><given-names>OH</given-names></name><name><surname>Mdaki</surname><given-names>SD</given-names></name><name><surname>Kavelish</surname><given-names>KN</given-names></name><name><surname>Escalona</surname><given-names>R</given-names></name><name><surname>Hallam</surname><given-names>CRA</given-names></name><name><surname>Christie</surname><given-names>C</given-names></name><name><surname>Patterson</surname><given-names>JL</given-names></name><name><surname>Anderson</surname><given-names>TJC</given-names></name><name><surname>Carrion</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Dick</surname><given-names>EJ</given-names></name><name><surname>Hall-Ursone</surname><given-names>S</given-names></name><name><surname>Schlesinger</surname><given-names>LS</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Kaushal</surname><given-names>D</given-names></name><name><surname>Giavedoni</surname><given-names>LD</given-names></name><name><surname>Turner</surname><given-names>J</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L</given-names></name><name><surname>Torrelles</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>6122</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19891-7</pub-id><pub-id pub-id-type="pmid">33257679</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papini</surname><given-names>C</given-names></name><name><surname>Ullah</surname><given-names>I</given-names></name><name><surname>Ranjan</surname><given-names>AP</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Spasov</surname><given-names>KA</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Mothes</surname><given-names>W</given-names></name><name><surname>Crawford</surname><given-names>JM</given-names></name><name><surname>Lindenbach</surname><given-names>BD</given-names></name><name><surname>Uchil</surname><given-names>PD</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Jorgensen</surname><given-names>WL</given-names></name><name><surname>Anderson</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Proof-of-concept studies with a computationally designed M<sup>pro</sup> inhibitor as a synergistic combination regimen alternative to Paxlovid</article-title><source>PNAS</source><volume>121</volume><elocation-id>e2320713121</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2320713121</pub-id><pub-id pub-id-type="pmid">38621119</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Parthasarathy</surname><given-names>S</given-names></name><name><surname>Saenjamsai</surname><given-names>P</given-names></name><name><surname>Hao</surname><given-names>H</given-names></name><name><surname>Ferkul</surname><given-names>A</given-names></name><name><surname>Pfannenstiel</surname><given-names>JJ</given-names></name><name><surname>Bejan</surname><given-names>DS</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Suder</surname><given-names>EL</given-names></name><name><surname>Schwarting</surname><given-names>N</given-names></name><name><surname>Aikawa</surname><given-names>M</given-names></name><name><surname>Muhlberger</surname><given-names>E</given-names></name><name><surname>Hume</surname><given-names>AJ</given-names></name><name><surname>Orozco</surname><given-names>RC</given-names></name><name><surname>Sullivan</surname><given-names>CS</given-names></name><name><surname>Cohen</surname><given-names>MS</given-names></name><name><surname>Davido</surname><given-names>DJ</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>PARP14 is an interferon (IFN)-induced host factor that promotes IFN production and affects the replication of multiple viruses</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.04.26.591186</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>NM</given-names></name><name><surname>Krojer</surname><given-names>T</given-names></name><name><surname>Bradley</surname><given-names>AR</given-names></name><name><surname>Collins</surname><given-names>P</given-names></name><name><surname>Nowak</surname><given-names>RP</given-names></name><name><surname>Talon</surname><given-names>R</given-names></name><name><surname>Marsden</surname><given-names>BD</given-names></name><name><surname>Kelm</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Deane</surname><given-names>CM</given-names></name><name><surname>von Delft</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A multi-crystal method for extracting obscured crystallographic states from conventionally uninterpretable electron density</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>15123</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15123</pub-id><pub-id pub-id-type="pmid">28436492</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platanias</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mechanisms of type-I- and type-II-interferon-mediated signalling</article-title><source>Nature Reviews. Immunology</source><volume>5</volume><fpage>375</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1038/nri1604</pub-id><pub-id pub-id-type="pmid">15864272</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>VC</given-names></name><name><surname>Russo</surname><given-names>LC</given-names></name><name><surname>González Duré</surname><given-names>DM</given-names></name><name><surname>Hoch</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Interferon-induced ADP-ribosylation: technical developments driving ICAB discovery</article-title><source>Bioscience Reports</source><volume>45</volume><elocation-id>BSR20240986</elocation-id><pub-id pub-id-type="doi">10.1042/BSR20240986</pub-id><pub-id pub-id-type="pmid">40014063</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>SJ</given-names></name><name><surname>Bedard</surname><given-names>O</given-names></name><name><surname>McNally</surname><given-names>KL</given-names></name><name><surname>Shaia</surname><given-names>C</given-names></name><name><surname>Clancy</surname><given-names>CS</given-names></name><name><surname>Lewis</surname><given-names>M</given-names></name><name><surname>Broeckel</surname><given-names>RM</given-names></name><name><surname>Chiramel</surname><given-names>AI</given-names></name><name><surname>Shannon</surname><given-names>JG</given-names></name><name><surname>Sturdevant</surname><given-names>GL</given-names></name><name><surname>Rosenke</surname><given-names>R</given-names></name><name><surname>Anzick</surname><given-names>SL</given-names></name><name><surname>Forte</surname><given-names>E</given-names></name><name><surname>Preuss</surname><given-names>C</given-names></name><name><surname>Baker</surname><given-names>CN</given-names></name><name><surname>Harder</surname><given-names>JM</given-names></name><name><surname>Brunton</surname><given-names>C</given-names></name><name><surname>Munger</surname><given-names>S</given-names></name><name><surname>Bruno</surname><given-names>DP</given-names></name><name><surname>Lack</surname><given-names>JB</given-names></name><name><surname>Leung</surname><given-names>JM</given-names></name><name><surname>Shamsaddini</surname><given-names>A</given-names></name><name><surname>Gardina</surname><given-names>P</given-names></name><name><surname>Sturdevant</surname><given-names>DE</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Martens</surname><given-names>C</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Rosenthal</surname><given-names>NA</given-names></name><name><surname>Best</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Genetically diverse mouse models of SARS-CoV-2 infection reproduce clinical variation in type I interferon and cytokine responses in COVID-19</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>4481</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-40076-5</pub-id><pub-id pub-id-type="pmid">37491352</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachs</surname><given-names>N</given-names></name><name><surname>Papaspyropoulos</surname><given-names>A</given-names></name><name><surname>Zomer-van Ommen</surname><given-names>DD</given-names></name><name><surname>Heo</surname><given-names>I</given-names></name><name><surname>Böttinger</surname><given-names>L</given-names></name><name><surname>Klay</surname><given-names>D</given-names></name><name><surname>Weeber</surname><given-names>F</given-names></name><name><surname>Huelsz-Prince</surname><given-names>G</given-names></name><name><surname>Iakobachvili</surname><given-names>N</given-names></name><name><surname>Amatngalim</surname><given-names>GD</given-names></name><name><surname>de Ligt</surname><given-names>J</given-names></name><name><surname>van Hoeck</surname><given-names>A</given-names></name><name><surname>Proost</surname><given-names>N</given-names></name><name><surname>Viveen</surname><given-names>MC</given-names></name><name><surname>Lyubimova</surname><given-names>A</given-names></name><name><surname>Teeven</surname><given-names>L</given-names></name><name><surname>Derakhshan</surname><given-names>S</given-names></name><name><surname>Korving</surname><given-names>J</given-names></name><name><surname>Begthel</surname><given-names>H</given-names></name><name><surname>Dekkers</surname><given-names>JF</given-names></name><name><surname>Kumawat</surname><given-names>K</given-names></name><name><surname>Ramos</surname><given-names>E</given-names></name><name><surname>van Oosterhout</surname><given-names>MF</given-names></name><name><surname>Offerhaus</surname><given-names>GJ</given-names></name><name><surname>Wiener</surname><given-names>DJ</given-names></name><name><surname>Olimpio</surname><given-names>EP</given-names></name><name><surname>Dijkstra</surname><given-names>KK</given-names></name><name><surname>Smit</surname><given-names>EF</given-names></name><name><surname>van der Linden</surname><given-names>M</given-names></name><name><surname>Jaksani</surname><given-names>S</given-names></name><name><surname>van de Ven</surname><given-names>M</given-names></name><name><surname>Jonkers</surname><given-names>J</given-names></name><name><surname>Rios</surname><given-names>AC</given-names></name><name><surname>Voest</surname><given-names>EE</given-names></name><name><surname>van Moorsel</surname><given-names>CH</given-names></name><name><surname>van der Ent</surname><given-names>CK</given-names></name><name><surname>Cuppen</surname><given-names>E</given-names></name><name><surname>van Oudenaarden</surname><given-names>A</given-names></name><name><surname>Coenjaerts</surname><given-names>FE</given-names></name><name><surname>Meyaard</surname><given-names>L</given-names></name><name><surname>Bont</surname><given-names>LJ</given-names></name><name><surname>Peters</surname><given-names>PJ</given-names></name><name><surname>Tans</surname><given-names>SJ</given-names></name><name><surname>van Zon</surname><given-names>JS</given-names></name><name><surname>Boj</surname><given-names>SF</given-names></name><name><surname>Vries</surname><given-names>RG</given-names></name><name><surname>Beekman</surname><given-names>JM</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Long-term expanding human airway organoids for disease modeling</article-title><source>The EMBO Journal</source><volume>38</volume><elocation-id>e100300</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2018100300</pub-id><pub-id pub-id-type="pmid">30643021</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>TW</given-names></name><name><surname>Ronzetti</surname><given-names>MH</given-names></name><name><surname>Owens</surname><given-names>AE</given-names></name><name><surname>Antony</surname><given-names>M</given-names></name><name><surname>Voss</surname><given-names>T</given-names></name><name><surname>Wallgren</surname><given-names>E</given-names></name><name><surname>Talley</surname><given-names>D</given-names></name><name><surname>Balakrishnan</surname><given-names>K</given-names></name><name><surname>Leyes Porello</surname><given-names>SE</given-names></name><name><surname>Rai</surname><given-names>G</given-names></name><name><surname>Marugan</surname><given-names>JJ</given-names></name><name><surname>Michael</surname><given-names>SG</given-names></name><name><surname>Baljinnyam</surname><given-names>B</given-names></name><name><surname>Southall</surname><given-names>N</given-names></name><name><surname>Simeonov</surname><given-names>A</given-names></name><name><surname>Henderson</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Real-time cellular thermal shift assay to monitor target engagement</article-title><source>ACS Chemical Biology</source><volume>17</volume><fpage>2471</fpage><lpage>2482</lpage><pub-id pub-id-type="doi">10.1021/acschembio.2c00334</pub-id><pub-id pub-id-type="pmid">36049119</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savitski</surname><given-names>MM</given-names></name><name><surname>Reinhard</surname><given-names>FBM</given-names></name><name><surname>Franken</surname><given-names>H</given-names></name><name><surname>Werner</surname><given-names>T</given-names></name><name><surname>Savitski</surname><given-names>MF</given-names></name><name><surname>Eberhard</surname><given-names>D</given-names></name><name><surname>Martinez Molina</surname><given-names>D</given-names></name><name><surname>Jafari</surname><given-names>R</given-names></name><name><surname>Dovega</surname><given-names>RB</given-names></name><name><surname>Klaeger</surname><given-names>S</given-names></name><name><surname>Kuster</surname><given-names>B</given-names></name><name><surname>Nordlund</surname><given-names>P</given-names></name><name><surname>Bantscheff</surname><given-names>M</given-names></name><name><surname>Drewes</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tracking cancer drugs in living cells by thermal profiling of the proteome</article-title><source>Science</source><volume>346</volume><elocation-id>1255784</elocation-id><pub-id pub-id-type="doi">10.1126/science.1255784</pub-id><pub-id pub-id-type="pmid">25278616</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuller</surname><given-names>M</given-names></name><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>Gahbauer</surname><given-names>S</given-names></name><name><surname>Fearon</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Díaz</surname><given-names>RE</given-names></name><name><surname>Young</surname><given-names>ID</given-names></name><name><surname>Carvalho Martins</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>DH</given-names></name><name><surname>Schulze-Gahmen</surname><given-names>U</given-names></name><name><surname>Owens</surname><given-names>TW</given-names></name><name><surname>Deshpande</surname><given-names>I</given-names></name><name><surname>Merz</surname><given-names>GE</given-names></name><name><surname>Thwin</surname><given-names>AC</given-names></name><name><surname>Biel</surname><given-names>JT</given-names></name><name><surname>Peters</surname><given-names>JK</given-names></name><name><surname>Moritz</surname><given-names>M</given-names></name><name><surname>Herrera</surname><given-names>N</given-names></name><name><surname>Kratochvil</surname><given-names>HT</given-names></name><name><surname>Aimon</surname><given-names>A</given-names></name><name><surname>Bennett</surname><given-names>JM</given-names></name><name><surname>Brandao Neto</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>AE</given-names></name><name><surname>Dias</surname><given-names>A</given-names></name><name><surname>Douangamath</surname><given-names>A</given-names></name><name><surname>Dunnett</surname><given-names>L</given-names></name><name><surname>Fedorov</surname><given-names>O</given-names></name><name><surname>Ferla</surname><given-names>MP</given-names></name><name><surname>Fuchs</surname><given-names>MR</given-names></name><name><surname>Gorrie-Stone</surname><given-names>TJ</given-names></name><name><surname>Holton</surname><given-names>JM</given-names></name><name><surname>Johnson</surname><given-names>MG</given-names></name><name><surname>Krojer</surname><given-names>T</given-names></name><name><surname>Meigs</surname><given-names>G</given-names></name><name><surname>Powell</surname><given-names>AJ</given-names></name><name><surname>Rack</surname><given-names>JGM</given-names></name><name><surname>Rangel</surname><given-names>VL</given-names></name><name><surname>Russi</surname><given-names>S</given-names></name><name><surname>Skyner</surname><given-names>RE</given-names></name><name><surname>Smith</surname><given-names>CA</given-names></name><name><surname>Soares</surname><given-names>AS</given-names></name><name><surname>Wierman</surname><given-names>JL</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>O’Brien</surname><given-names>P</given-names></name><name><surname>Jura</surname><given-names>N</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><name><surname>Irwin</surname><given-names>JJ</given-names></name><name><surname>Thompson</surname><given-names>MC</given-names></name><name><surname>Gestwicki</surname><given-names>JE</given-names></name><name><surname>von Delft</surname><given-names>F</given-names></name><name><surname>Shoichet</surname><given-names>BK</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name><name><surname>Ahel</surname><given-names>I</given-names></name><collab>QCRG Structural Biology Consortium</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking</article-title><source>Science Advances</source><volume>7</volume><elocation-id>eabf8711</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abf8711</pub-id><pub-id pub-id-type="pmid">33853786</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuller</surname><given-names>M</given-names></name><name><surname>Zarganes-Tzitzikas</surname><given-names>T</given-names></name><name><surname>Bennett</surname><given-names>J</given-names></name><name><surname>De Cesco</surname><given-names>S</given-names></name><name><surname>Fearon</surname><given-names>D</given-names></name><name><surname>von Delft</surname><given-names>F</given-names></name><name><surname>Fedorov</surname><given-names>O</given-names></name><name><surname>Brennan</surname><given-names>PE</given-names></name><name><surname>Ahel</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Discovery and development strategies for SARS-CoV-2 NSP3 macrodomain inhibitors</article-title><source>Pathogens</source><volume>12</volume><elocation-id>324</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12020324</pub-id><pub-id pub-id-type="pmid">36839595</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sefik</surname><given-names>E</given-names></name><name><surname>Qu</surname><given-names>R</given-names></name><name><surname>Junqueira</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Inflammasome activation in infected macrophages drives COVID-19 pathology</article-title><source>Nature</source><volume>606</volume><fpage>585</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04802-1</pub-id><pub-id pub-id-type="pmid">35483404</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shifrut</surname><given-names>E</given-names></name><name><surname>Carnevale</surname><given-names>J</given-names></name><name><surname>Tobin</surname><given-names>V</given-names></name><name><surname>Roth</surname><given-names>TL</given-names></name><name><surname>Woo</surname><given-names>JM</given-names></name><name><surname>Bui</surname><given-names>CT</given-names></name><name><surname>Li</surname><given-names>PJ</given-names></name><name><surname>Diolaiti</surname><given-names>ME</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><name><surname>Marson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function</article-title><source>Cell</source><volume>175</volume><fpage>1958</fpage><lpage>1971</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.10.024</pub-id><pub-id pub-id-type="pmid">30449619</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simoneau</surname><given-names>CR</given-names></name><name><surname>Chen</surname><given-names>PY</given-names></name><name><surname>Xing</surname><given-names>GK</given-names></name><name><surname>Hayashi</surname><given-names>JM</given-names></name><name><surname>Chen</surname><given-names>IP</given-names></name><name><surname>Khalid</surname><given-names>MM</given-names></name><name><surname>Meyers</surname><given-names>NL</given-names></name><name><surname>Taha</surname><given-names>TY</given-names></name><name><surname>Leon</surname><given-names>KE</given-names></name><name><surname>Suryawanshi</surname><given-names>RK</given-names></name><name><surname>McCavitt-Malvido</surname><given-names>M</given-names></name><name><surname>Ashuach</surname><given-names>T</given-names></name><name><surname>Fontaine</surname><given-names>KA</given-names></name><name><surname>Rodriguez</surname><given-names>L</given-names></name><name><surname>Joehnk</surname><given-names>B</given-names></name><name><surname>Walcott</surname><given-names>K</given-names></name><name><surname>Vasudevan</surname><given-names>S</given-names></name><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Maishan</surname><given-names>M</given-names></name><name><surname>Schultz</surname><given-names>S</given-names></name><name><surname>Roose</surname><given-names>JP</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Sil</surname><given-names>A</given-names></name><name><surname>Arjomandi</surname><given-names>M</given-names></name><name><surname>Yosef</surname><given-names>N</given-names></name><name><surname>Ott</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>NF-κB inhibitor alpha controls SARS-CoV-2 infection in ACE2-overexpressing human airway organoids</article-title><source>Scientific Reports</source><volume>14</volume><elocation-id>15351</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-66003-2</pub-id><pub-id pub-id-type="pmid">38961189</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slade</surname><given-names>Dea</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>PARP and PARG inhibitors in cancer treatment</article-title><source>Genes &amp; Development</source><volume>34</volume><fpage>360</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1101/gad.334516.119</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suryawanshi</surname><given-names>RK</given-names></name><name><surname>Chen</surname><given-names>IP</given-names></name><name><surname>Ma</surname><given-names>T</given-names></name><name><surname>Syed</surname><given-names>AM</given-names></name><name><surname>Brazer</surname><given-names>N</given-names></name><name><surname>Saldhi</surname><given-names>P</given-names></name><name><surname>Simoneau</surname><given-names>CR</given-names></name><name><surname>Ciling</surname><given-names>A</given-names></name><name><surname>Khalid</surname><given-names>MM</given-names></name><name><surname>Sreekumar</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>P-Y</given-names></name><name><surname>Kumar</surname><given-names>GR</given-names></name><name><surname>Montano</surname><given-names>M</given-names></name><name><surname>Gascon</surname><given-names>R</given-names></name><name><surname>Tsou</surname><given-names>C-L</given-names></name><name><surname>Garcia-Knight</surname><given-names>MA</given-names></name><name><surname>Sotomayor-Gonzalez</surname><given-names>A</given-names></name><name><surname>Servellita</surname><given-names>V</given-names></name><name><surname>Gliwa</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>J</given-names></name><name><surname>Silva</surname><given-names>I</given-names></name><name><surname>Milbes</surname><given-names>B</given-names></name><name><surname>Kojima</surname><given-names>N</given-names></name><name><surname>Hess</surname><given-names>V</given-names></name><name><surname>Shacreaw</surname><given-names>M</given-names></name><name><surname>Lopez</surname><given-names>L</given-names></name><name><surname>Brobeck</surname><given-names>M</given-names></name><name><surname>Turner</surname><given-names>F</given-names></name><name><surname>Soveg</surname><given-names>FW</given-names></name><name><surname>George</surname><given-names>AF</given-names></name><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Maishan</surname><given-names>M</given-names></name><name><surname>Matthay</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>MK</given-names></name><name><surname>Wadford</surname><given-names>D</given-names></name><name><surname>Hanson</surname><given-names>C</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name><name><surname>Andino</surname><given-names>R</given-names></name><name><surname>Spraggon</surname><given-names>L</given-names></name><name><surname>Roan</surname><given-names>NR</given-names></name><name><surname>Chiu</surname><given-names>CY</given-names></name><name><surname>Doudna</surname><given-names>JA</given-names></name><name><surname>Ott</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination</article-title><source>Nature</source><volume>607</volume><fpage>351</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04865-0</pub-id><pub-id pub-id-type="pmid">35584773</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taha</surname><given-names>TY</given-names></name><name><surname>Chen</surname><given-names>IP</given-names></name><name><surname>Hayashi</surname><given-names>JM</given-names></name><name><surname>Tabata</surname><given-names>T</given-names></name><name><surname>Walcott</surname><given-names>K</given-names></name><name><surname>Kimmerly</surname><given-names>GR</given-names></name><name><surname>Syed</surname><given-names>AM</given-names></name><name><surname>Ciling</surname><given-names>A</given-names></name><name><surname>Suryawanshi</surname><given-names>RK</given-names></name><name><surname>Martin</surname><given-names>HS</given-names></name><name><surname>Bach</surname><given-names>BH</given-names></name><name><surname>Tsou</surname><given-names>CL</given-names></name><name><surname>Montano</surname><given-names>M</given-names></name><name><surname>Khalid</surname><given-names>MM</given-names></name><name><surname>Sreekumar</surname><given-names>BK</given-names></name><name><surname>Renuka Kumar</surname><given-names>G</given-names></name><name><surname>Wyman</surname><given-names>S</given-names></name><name><surname>Doudna</surname><given-names>JA</given-names></name><name><surname>Ott</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>2308</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-37787-0</pub-id><pub-id pub-id-type="pmid">37085489</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taha</surname><given-names>TY</given-names></name><name><surname>Suryawanshi</surname><given-names>RK</given-names></name><name><surname>Chen</surname><given-names>IP</given-names></name><name><surname>Correy</surname><given-names>GJ</given-names></name><name><surname>McCavitt-Malvido</surname><given-names>M</given-names></name><name><surname>O’Leary</surname><given-names>PC</given-names></name><name><surname>Jogalekar</surname><given-names>MP</given-names></name><name><surname>Diolaiti</surname><given-names>ME</given-names></name><name><surname>Kimmerly</surname><given-names>GR</given-names></name><name><surname>Tsou</surname><given-names>C-L</given-names></name><name><surname>Gascon</surname><given-names>R</given-names></name><name><surname>Montano</surname><given-names>M</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L</given-names></name><name><surname>Krogan</surname><given-names>NJ</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name><name><surname>Ott</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in vivo</article-title><source>PLOS Pathogens</source><volume>19</volume><elocation-id>e1011614</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1011614</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Ansari</surname><given-names>A</given-names></name><name><surname>Jadhav</surname><given-names>P</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Chopra</surname><given-names>A</given-names></name><name><surname>Ford</surname><given-names>A</given-names></name><name><surname>Chi</surname><given-names>X</given-names></name><name><surname>Ruiz</surname><given-names>FX</given-names></name><name><surname>Arnold</surname><given-names>E</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model</article-title><source>Science</source><volume>383</volume><fpage>1434</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1126/science.adm9724</pub-id><pub-id pub-id-type="pmid">38547259</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Delft</surname><given-names>A</given-names></name><name><surname>Hall</surname><given-names>MD</given-names></name><name><surname>Kwong</surname><given-names>AD</given-names></name><name><surname>Purcell</surname><given-names>LA</given-names></name><name><surname>Saikatendu</surname><given-names>KS</given-names></name><name><surname>Schmitz</surname><given-names>U</given-names></name><name><surname>Tallarico</surname><given-names>JA</given-names></name><name><surname>Lee</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Accelerating antiviral drug discovery: lessons from COVID-19</article-title><source>Nature Reviews. Drug Discovery</source><volume>22</volume><fpage>585</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1038/s41573-023-00692-8</pub-id><pub-id pub-id-type="pmid">37173515</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voorneveld</surname><given-names>J</given-names></name><name><surname>Rack</surname><given-names>JGM</given-names></name><name><surname>Ahel</surname><given-names>I</given-names></name><name><surname>Overkleeft</surname><given-names>HS</given-names></name><name><surname>van der Marel</surname><given-names>GA</given-names></name><name><surname>Filippov</surname><given-names>DV</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Synthetic α- and β-Ser-ADP-ribosylated Peptides Reveal α-Ser-ADPr as the Native Epimer</article-title><source>Organic Letters</source><volume>20</volume><fpage>4140</fpage><lpage>4143</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.8b01742</pub-id><pub-id pub-id-type="pmid">29947522</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voth</surname><given-names>LS</given-names></name><name><surname>O’Connor</surname><given-names>JJ</given-names></name><name><surname>Kerr</surname><given-names>CM</given-names></name><name><surname>Doerger</surname><given-names>E</given-names></name><name><surname>Schwarting</surname><given-names>N</given-names></name><name><surname>Sperstad</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>DK</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Unique mutations in the murine hepatitis virus macrodomain differentially attenuate virus replication, indicating multiple roles for the macrodomain in coronavirus replication</article-title><source>Journal of Virology</source><volume>95</volume><elocation-id>e0076621</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.00766-21</pub-id><pub-id pub-id-type="pmid">34011547</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wazir</surname><given-names>S</given-names></name><name><surname>Parviainen</surname><given-names>TAO</given-names></name><name><surname>Pfannenstiel</surname><given-names>JJ</given-names></name><name><surname>Duong</surname><given-names>MTH</given-names></name><name><surname>Cluff</surname><given-names>D</given-names></name><name><surname>Sowa</surname><given-names>ST</given-names></name><name><surname>Galera-Prat</surname><given-names>A</given-names></name><name><surname>Ferraris</surname><given-names>D</given-names></name><name><surname>Maksimainen</surname><given-names>MM</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name><name><surname>Heiskanen</surname><given-names>JP</given-names></name><name><surname>Lehtiö</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Discovery of 2-Amide-3-methylester Thiophenes that Target SARS-CoV-2 Mac1 and repress coronavirus replication, validating Mac1 as an Antiviral Target</article-title><source>Journal of Medicinal Chemistry</source><volume>67</volume><fpage>6519</fpage><lpage>6536</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c02451</pub-id><pub-id pub-id-type="pmid">38592023</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Muruato</surname><given-names>A</given-names></name><name><surname>Lokugamage</surname><given-names>KG</given-names></name><name><surname>Narayanan</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Schindewolf</surname><given-names>C</given-names></name><name><surname>Bopp</surname><given-names>NE</given-names></name><name><surname>Aguilar</surname><given-names>PV</given-names></name><name><surname>Plante</surname><given-names>KS</given-names></name><name><surname>Weaver</surname><given-names>SC</given-names></name><name><surname>Makino</surname><given-names>S</given-names></name><name><surname>LeDuc</surname><given-names>JW</given-names></name><name><surname>Menachery</surname><given-names>VD</given-names></name><name><surname>Shi</surname><given-names>PY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An infectious cDNA clone of SARS-CoV-2</article-title><source>Cell Host &amp; Microbe</source><volume>27</volume><fpage>841</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.04.004</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>LYR</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Verma</surname><given-names>AK</given-names></name><name><surname>Ortiz</surname><given-names>ME</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C</given-names></name><name><surname>Leidinger</surname><given-names>MR</given-names></name><name><surname>Knudson</surname><given-names>CM</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><name><surname>McCray</surname><given-names>PB</given-names><suffix>Jr</suffix></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice</article-title><source>Nature</source><volume>589</volume><fpage>603</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2943-z</pub-id><pub-id pub-id-type="pmid">33166988</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103484.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schoggins</surname><given-names>John W</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>The University of Texas Southwestern Medical Center</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study presents the development of a novel inhibitor for SARS-CoV-2 Mac1 that has potential utility both as an antiviral therapeutic and as a tool for probing the molecular mechanisms by which infection-induced ADP-ribosylation triggers robust host antiviral responses. Though minor gaps in understanding the compound's precise molecular mechanism of action and its ability to target Mac1 from other coronaviruses remain, the evidence for its effects on SARS-CoV-2 in relevant biological models is <bold>compelling</bold>.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103484.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>SARS-CoV-2 encodes a macrodomain (Mac1) within the nsp3 protein that removes ADP-ribose groups from proteins. However, its role during infection is not well understood. Evidence suggests that Mac1 antagonizes the host interferon response by counteracting the wave of ADP ribosylation that occurs during infection. Indeed, several PARPs are interferon-stimulated genes. While multiple targets have been proposed, the mechanistic links between ADP ribosylation and a robust antiviral response remain unclear.</p><p>Genetic inactivation of Mac1 abrogates viral replication in vivo, suggesting that small-molecule inhibitors of Mac1 could be developed into antivirals to treat COVID-19 and other emerging coronaviruses. The authors report a potent and selective small molecule inhibitor targeting Mac1 (AVI-4206) that demonstrates efficacy in human airway organoids and animal models of SARS-CoV-2 infection. While these results are compelling and provide proof of concept for the therapeutic targeting of Mac1, I am particularly intrigued by the potential of this compound as a probe to elucidate the mechanistic connections between infection-induced ADP ribosylation and the host antiviral response.</p><p>The precise function of Mac1 remains unclear. Given its presence in multiple viruses, it likely acts on a fundamental host immune pathway(s). AVI-4206, while promising as a lead compound for the development of antivirals targeting coronaviruses, could also be a valuable tool for uncovering the function of the Mac1 domain. This may lead to fundamental insights into the host immune response to viral infection.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103484.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors describe the development of a novel inhibitor (AVI-4206) for the first macrodomains of the nsp3 protein of SARS-CoV-2 (Mac1). This involves both medical chemical synthesis, structural work as well as biochemical characterisation. Subsequently the authors present their finding of the efficacy of the inhibitor both on cell culture as well as animal models of SARS-CoV-2 infection. They find that despite high affinity for Mac1 and the known replicatory defects of catalytically inactive Mac1 only moderate beneficial effects can be observed in their chosen models.</p><p>Strengths:</p><p>The authors employ a variety of different assay to study the affinity, selectivity and potency of the novel inhibitor and thus the in vitro data are very compelling.</p><p>Similarly, the authors use several cell culture and in vivo models to strengthen their findings. In addition, the authors address several aspects of the health impact of coronaviral infections from animal survival, over viral load to histological assessment of lung damage.</p><p>Weaknesses:</p><p>The selection of Targ1 and MacroD2 as off-target human macrodomains is sub-optimal as several studies have shown that the first macrodomains of PARP9 and PARP14 are much closer related to coronaviral macrodomains and both macrodomains are implicated in antiviral defence and immunity. However, the authors address this issue by providing modeling data that show clashes with AVI-4206 similarly to their models with MacroD2 and TARG1.</p><p>Comments on revisions:</p><p>While the authors have not addressed all my suggestions experimentally, I would like to nevertheless congratulate them on a significantly strengthened manuscript that will provide a valuable contribution to the field.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103484.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors were trying to validate SARS-CoV-2 Mac1 as a drug discovery target and by extension other viral macrodomains.</p><p>Strengths:</p><p>The medicinal chemistry and structure based optimization is exemplary. Macrodomains and ADPribosyl hydrolases have the reputation for being undruggable, yet the authors managed to optimize hits from a fragment screen using structure based approaches and fragment linking to make a 20nM inhibitor as a tool compound to validate the target.</p><p>In addition, the in vivo work is also a strength. The ability to reduce the viral count at a rate comparable to nirmatrelvir is impressive. Tracking the cytokine expression levels also supports much of the genetic data and mechanism of action for macrodomains.</p><p>Weaknesses:</p><p>The main compound AVI-4206, while being very potent and selective is not appreciably orally bioavailable. The fact that they have to use high doses of the compound IP to see in vivo effects may lead to questions regarding off target effects. The authors acknowledge this and point it out as a potential avenue for further optimization.</p><p>The cellular models are not as predictive of antiviral activity as one would expect. However, the authors had enough chutzpah to test the compound in vivo knowing that cellular models might not be an accurate representation of a living system with a fully functional immune system all of which is most likely needed in an antiviral response to test the importance of Mac1 as a target.</p><p>Comments on revisions:</p><p>All previous suggestions were addressed. I am satisfied with the author's modifications.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103484.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Suryawanshi</surname><given-names>Rahul K</given-names></name><role specific-use="author">Author</role><aff><institution>Gladstone Institute of Virology, UCSF</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Jaishankar</surname><given-names>Priyadarshini</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Correy</surname><given-names>Galen J</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Bioengineering and Therapeutic Sciences, University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Rachman</surname><given-names>Moira M</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Pharmaceutical Chemistry, University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>O'Leary</surname><given-names>Patrick C</given-names></name><role specific-use="author">Author</role><aff><institution>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Taha</surname><given-names>Taha Y</given-names></name><role specific-use="author">Author</role><aff><institution>Gladstone Institute of Virology</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Matsui</surname><given-names>Yusuke</given-names></name><role specific-use="author">Author</role><aff><institution>Gladstone Institute of Virology</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Zapatero-Belinchón</surname><given-names>Francisco J</given-names></name><role specific-use="author">Author</role><aff><institution>Gladstone Institute of Virology, Gladstone Institutes</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>McCavitt-Malvido</surname><given-names>Maria</given-names></name><role specific-use="author">Author</role><aff><institution>Gladstone Institute of Virology, Gladstone Institutes</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Doruk</surname><given-names>Yagmur U</given-names></name><role specific-use="author">Author</role><aff><institution>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Stevens</surname><given-names>Maisie GV</given-names></name><role specific-use="author">Author</role><aff><institution>University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Diolaiti</surname><given-names>Morgan E</given-names></name><role specific-use="author">Author</role><aff><institution>University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Jogalekar</surname><given-names>Manasi P</given-names></name><role specific-use="author">Author</role><aff><institution>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Huadong</given-names></name><role specific-use="author">Author</role><aff><institution>University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Richards</surname><given-names>Alicia</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kongpracha</surname><given-names>Pornparn</given-names></name><role specific-use="author">Author</role><aff><institution>University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Bali</surname><given-names>Sofia</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Montano</surname><given-names>Mauricio</given-names></name><role specific-use="author">Author</role><aff><institution>The J. David Gladstone Institutes</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Rosecrans</surname><given-names>Julia</given-names></name><role specific-use="author">Author</role><aff><institution>Gladstone Institute of Virology, Gladstone Institutes</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Matthay</surname><given-names>Micheal</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Medicine, University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Togo</surname><given-names>Takaya</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Pharmaceutical Chemistry, University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Gonciarz</surname><given-names>Ryan L</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Pharmaceutical Chemistry, University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Gopalkrishnan</surname><given-names>Saumya</given-names></name><role specific-use="author">Author</role><aff><institution>Quantitative Biosciences Institute (QBI), University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Neitz</surname><given-names>R Jeffrey</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Pharmaceutical Chemistry, University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Krogan</surname><given-names>Nevan J</given-names></name><role specific-use="author">Author</role><aff><institution>University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Swaney</surname><given-names>Danielle</given-names></name><role specific-use="author">Author</role><aff><institution>University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Shoichet</surname><given-names>Brian K</given-names></name><role specific-use="author">Author</role><aff><institution>University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Ott</surname><given-names>Melanie</given-names></name><role specific-use="author">Author</role><aff><institution>Gladstone Institute of Virology</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Renslo</surname><given-names>Adam R</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Ashworth</surname><given-names>Alan</given-names></name><role specific-use="author">Author</role><aff><institution>University of California San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Fraser</surname><given-names>James S</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the previous reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>Although this study is rigorous and the paper is well-written, I have a few concerns that the authors should address before publication.</p><p>(1) Cellular levels of protein ADP-ribosylation should be analyzed using anti-ADPR antibodies following infection, both with and without Mac1 and AVI-4206 treatment. While the authors have provided impressive in vivo data, these experiments could ideally be conducted in mice. However, I would be amenable to these analyses being performed in human airway organoids, as they demonstrate clear phenotypes following AVI-4206 treatment post-infection. For a more in-depth exploration, the authors could consider affinity purifying ADP-ribosylated proteins and identifying them via mass spectrometry. I would find it particularly compelling if this approach revealed components of the NF-kB signaling pathway, given the intriguing results presented in Fig. 5. I am also curious if there are differences in ADP ribosylated proteins when comparing Mac1 KO SARS-C0V-2 to AVI-4206 treatment.</p></disp-quote><p>We note that despite the recent flurry of activity around Mac1, there is a surprising lack of public data on overall ADPr levels or targets. While we will address the literature precedence for PARP14 signals specifically below (<bold>Reviewer 2 point (h)</bold>) by immunofluorescence, we note that overall levels have not been characterized biochemically previously. Recent PARP14 papers and the ASAP AViDD preprint show changes by immunofluorescence only: and the evidence in that preprint is quite modest - see Figure 7B - <ext-link ext-link-type="uri" xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11370477/">https://pmc.ncbi.nlm.nih.gov/articles/PMC11370477/</ext-link>.</p><p>We suspect the difficulty in tracking changes biochemically is due to multiple factors that influence the overall detectability and reproducibility. First, with regard to detectability - it is quite possible that only a small change in the ADPr status of a small number of targets is responsible for the phenotypes in vivo. Virus levels are very low in the organoid system and the variability in ADPr levels from tissue samples from in vivo experiments is high. Given the difficulty in translating back to cellular models, this problem is therefore magnified further. Second, with regard to reproducibility - we observe a great deal of reagent dependence on ADPr signals by Western blot+/- Mac1 expression in both cellular and tissue lysates (including when stimulated with H2O2, interferon, or during viral infection). Similarly, we do not observe reproducible proteins that pulldown with Mac1 when assayed by mass spectrometry. It is quite likely that these issues are a result of tissue/sample preparation that results in a loss of the ADPr modification during preparation (especially for acidic residue modifications). This also explains the reliance on IF assays in the PARP14 literature. A very good discussion of these issues is also contained in this paper: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1042/BSR20240986">https://doi.org/10.1042/BSR20240986</ext-link>.</p><p>Nonetheless we have attempted one final experiment. Here, we have measured ADPr modification of cellular lysates upon uninfected conditions as well as upon infection with either WT or N40D mutant virus. For all conditions, this was done with or without treatment of cells with 100 μM of AVI-4206. Measurement of ADPr modifications by western blot using a pan-ADPr antibody revealed a single prominent band with a molecular weight of ~130kDa, that showed a uniform increase in signal upon treatment of cells with AVI-4206 regardless of infection status. While this general trend was also observed with the mono-ADPr antibody, it was not statistically significant in its regulation upon AVI-4206 treatment. We suspect that the major band observed in these western blots is PARP1, as upon enrichment of ADPr proteins from these lysates by Af1521 immunoprecipitation, we find PARP1 to be among the most abundant proteins detected within this molecular weight range. We note that there is a baseline increase in polyADPr detection upon infection of virus with WT Mac1 (relative to uninfected and virus with N40D) and further increase when treated with AVI-4206. This compound-dependent increase is paralleled in the uninfected and N40D conditions. The counterintuitive increase upon WT Mac1 virus infection, which should erase ADPr marks, and the compound-dependent increase in the uninfected condition suggest that there are many indirect effects on ADPr signalling dynamics in this experiment. These results are difficult to reconcile with the specificity profiling of AVI-4206 (Supplementary Figure5: Thermal proteome profiling in A549 cellular lysates). As mentioned above, the lack of consistent signal across reagents for ADPr detection and the timing of monitoring ADPr levels are additional complicating factors.</p><p>We added to the results:</p><p>“However, we observed no strong consistent signals of global pan-ADP-ribose (panADPr) or mono-ADP-ribose (monoADPr) accumulation in infected cells treated with AVI-4206 in immunoblot analyses (Supplementary Figure 8).”</p><p>Methods for experiment:</p><p>Calu3 cells were obtained from ATCC and cultured in Advanced DMEM (Gibco) supplemented with 2.5% FBS, 1x GlutaMax, and 1x Penicillin-Streptomycin at 37°C and 5% CO<sub>2</sub>. 5x10<sup>6</sup> cells were plated in 15-cm dishes and media was changed every 2-3 days until the cells were 80% confluent. The cells were treated with INFy 50 ng/mL (R&amp;D Systems) w/without AVI-4206 100 μM. After 6 hours, the cells were infected with WA1 or WA1 NSP3 Mac1 N40D at a multiplicity of infection (MOI) of 1 for 36 hours. The cells were washed with PBS x 3 and scraped in Pierce IP Lysis Buffer (ThermoFisher) containing 1x HALT protease and phosphatase inhibitor mix (ThermoFisher) on ice. The lysate was stored at -80C until further processing.</p><p>The cell lysate was incubated for 5 minutes at room temperature with recombinant benzonase. Following incubation, the lysate was centrifuged at 13,000 rpm at 4°C for 20 minutes, and the supernatant was collected. The samples were then boiled for 5 minutes at 95°C in 1x NuPAGE LDS sample buffer (Invitrogen) with a final concentration of 1X NuPAGE sample reducing agent (Invitrogen). For the detection of ADPr levels in whole-cell lysates, the samples were subjected to SDS-PAGE and Immunoblotting. All primary and secondary antibodies (pan-ADP-ribose antibody (MABE1016, Millipore)), Mono-ADP-ribose antibody (AbD33204, Bio-Rad), HRP-conjugated (Cell signaling), used at a 1:1000 dilution were diluted in 5% non-fat dry milk in TBST. Signals were detected by chemiluminescence (Thermo) and visualized using the ChemiDoc XRS+ System (Bio-Rad). Densitometric analysis was performed using Image Lab (Bio-Rad). Quantification was normalized to Actin. The data are expressed as mean ± SD. Statistical differences were determined using an unpaired t-test in GraphPad Prism 10.3.1.</p><disp-quote content-type="editor-comment"><p>(2) SARS-CoV-2 escape mutants for AVI-4206 should be generated, sequenced, and evaluated for both ADP-ribosyl hydrolase activity and their susceptibility to inhibition by AVI-4206.</p></disp-quote><p>We thank the reviewer for this suggestion. These are indeed key experiments which are currently hampered by the lack of a cell line that is fully responsive to drug treatment. Although infected organoids and macrophages show an effect in response to AVI-4206, viral levels are ~3 logs lower than in cell lines and difficult to sequence. In the absence of a system that would allow meaningful screening for outgrowth of resistant viruses, we have conducted mass spectrometry studies that showed that Mac1 is the only significant hit for AVI-4206 (SupplementaryFigure 5). The suggested outgrowth experiments will be conducted once a responsive cell line model has been established.</p><disp-quote content-type="editor-comment"><p>(3) Given that Mac1 is found in several coronaviruses, it would be insightful for the authors to test a selection of Mac1 homologs from divergent coronaviruses to assess whether AVI-4206 can inhibit their activity in vitro.</p></disp-quote><p>As mentioned above, inconsistencies in ADPr staining limit our ability to directly measure cellular activity. As an alternative approach to measure AVI-4206 selectivity in cells, we have adapted our CETSA assay for SARS-1 and MERs macrodomain proteins and find evidence that AVI-4206 can shift the melting temperature of both proteins, albeit to a lesser degree than that seen for Mac1. In line with MERS being more structurally divergent than SARS-1 from SARS CoV2, the ΔTagg for SARS-1 and MERS are 4℃ and 1℃, respectively, compared to 9℃ for Mac1. These data have been added as Supplementary Fig S3C. Development of broader spectrum pan-inhibitors is on our radar for future work which will more thoroughly assess homologs from divergent coronaviruses.</p><p>We added the following sentence to the main results:</p><p>“Encouragingly, we were also able to adapt our CETSA assay for SARS-1 and MERs macrodomain proteins and find that AVI-4206 can shift the melting temperature of both proteins, albeit to a lesser degree than that seen for Mac1 (Supplementary Figure 3C).”</p><p>We also added this supplementary figure 3:</p><disp-quote content-type="editor-comment"><p>Minor</p><p>(1) Line 88, &quot;respectively.heir potency&quot;</p></disp-quote><p>Fixed, thank you!</p><disp-quote content-type="editor-comment"><p>(2) Line 149 add a period after proteome</p></disp-quote><p>Fixed, thank you!</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>(a) The authors assess inhibition of MacroD2 and Targ1 as of-targets for AVI-4206. However, Mac1 belongs to the MacroD-type class of macrodomains of which MacroD1, MacroD2 and MOD1s of PARP9 and PARP14 are the human members. In contrast Targ1 belongs to the ALC1-like class, which is only very distantly related to Mac1. Furthermore, recent studies have shown that the first macrodomains of PARP9 and PARP4 (MOD1 of PARP9/14) are much closer related to Mac1 and PARP9/14 were implicated in antiviral immunity. As such the authors should include assays showing the activity of their compounds against MacroD1 and MOD1s of PARP9/14.</p></disp-quote><p>We emphasize that we detect no significant shift for any protein other than Mac1 in A549 cells by CETSA-MS (Supplementary Figure 6). For Mac1 CESTA, we see an average of 6 PARP14 spectral counts across conditions and did not detect PARP9. In addition, for separate work in MPro, we ran similar CETSA experiments where we observed an average of 2 PARP9 and 15 PARP14 spectral counts across conditions. Although PARP9 and PARP14 massively increase expression upon IFN treatment in A549 cells, both proteins have been detected by Western Blot in A549 cells previously at baseline.</p><p>Nonetheless, we have included modeling of more diverse macrodomains as a supplemental figure and added to the text:</p><p>Modeling of other diverse macrodomains, including those within human PARP9 and PARP14 further suggests that AVI-4206 is selective for Mac1 (Supplementary Figure 4).</p><disp-quote content-type="editor-comment"><p>(b) In the context of SARS-CoV-2 superinfection are a known major complication of infections. These superinfections are associated with lung damage and therefore it would be good if the authors could assess lung damage, e.g. by histology, to see if their treatment has a positive impact on lung damage and thus may help to suppress complications.</p></disp-quote><p>We performed histology and the results are inconclusive, but suggest that AVI-4206 treatment could lower apoptosis.There is no difference in pathology between the N40D cohort and vehicle with these markers. This could suggest that AVI-4206 provides an additional mechanism that results in protection. We added to the results:</p><p>Caspase 3 staining shows that AVI-4206 treatment reduces apoptosis in the lungs compared to vehicle controls. Additionally, Masson's Trichrome staining reveals a significant reduction in collagen deposition, a surrogate for lung pathology, in the lungs of AVI-4206 treated animals (Supplementary Figure 9).</p><p>Histology:</p><p>Mouse lung tissues were fixed in 4% PFA (Sigma Aldrich, Cat #47608) for 24 hours, washed three times with PBS and stored in 70% ethanol. All the stainings were performed at Histo-Tec Laboratory (Hayward, CA). Samples were processed, embedded in paraffin, and sectioned at 4μm. The slides were dewaxed using xylene and alcohol-based dewaxing solutions. Epitope retrieval was performed by heat-induced epitope retrieval (HIER) of the formalin-fixed, paraffin-embedded tissue using citrate-based pH 6 solution (Leica Microsystems, AR9961) for 20 mins at 95°C. The tissues were stained for H&amp;E, caspase-3 (Biocare #CP229c 1:100), and trichrome, dried, coverslipped (TissueTek-Prisma Coverslipper), and visualized using Axioscan 7 slide scanner (ZEISS) at 40X. Image quantification was performed with Image J software and GraphPad Prism.</p><disp-quote content-type="editor-comment"><p>(c) Fig. 1D labelling is wrong</p></disp-quote><p>Thank you - fortunately the data were plotted correctly and it was just the inset table of values that was incorrect. This is now fixed!</p><disp-quote content-type="editor-comment"><p>(d) Line 88: &quot;T&quot; missing at start of sentence</p></disp-quote><p>Fixed, thank you!</p><disp-quote content-type="editor-comment"><p>(e) Line 118: NudT5/AMP-Glo assay was developed in <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/acs.orglett.8b01742">https://doi.org/10.1021/acs.orglett.8b01742</ext-link></p></disp-quote><p>We have added this foundational reference, thank you!</p><disp-quote content-type="editor-comment"><p>(f) Line 147ff: It would be good if the authors could highlight that the TPP methodology has known limitations (e.g. detection of low abundance proteins and low thermal shift of some binders) and thus is not an absolute proof that AVI-4206 &quot;engage with high specificity for Mac1&quot;</p></disp-quote><p>We added this important context to the concluding sentence of this paragraph:</p><p>“While this assay may not be sensitive to detection of proteins with low abundance proteins or low thermal shift upon ligand binding, collectively, these results indicate that AVI-4206 can cross cellular membranes and engage with high specificity for Mac1.”</p><disp-quote content-type="editor-comment"><p>(g) The authors use their well established in vitro Mac1 model as well as the SARS-CoV-2 WA strain. Given the ongoing diversification of SARS-CoV-2 and the current prevalence of the Omicron VOC it would be good if the authors could investigate whether alteration in Mac1 occurred or are detected which could influence the efficacy of their inhibitor. Similarly, it would be interesting to know how effective their drug is on other clinically relevant beta-CoV Mac1, e.g. from MERS or SARS1.</p></disp-quote><p>We thank the reviewer for the suggestion. Mac1 is one of the more conserved areas of the SARS-CoV-2 genome as there has only been one nonsynonymous mutation V34L (Orf1a:V1056L) that recently emerged in the BA.2.86 lineage and is now in all of the JN.1 derivatives. Currently, the mutation is only ~80% penetrant in circulating SARS-CoV-2 sequences suggesting that it might revert to wild-type and is not associated with a fitness benefit. Based on our structural analysis (shown in Supplementary Figure4D above), we do not believe this mutation affects AVI-4206 binding, but we are including this variant in our future in vitro and in vivo studies as well as other beta-CoV. For SARS and MERS, see response to Reviewer 1 using CETSA to show that these targets are engaged by AVI-4206.</p><disp-quote content-type="editor-comment"><p>(h) As methods to detect PARP14-derived ADP-ribosylation are available and it was shown that Mac1 can reverse this modification in cells. It would be good if the authors could investigate the impact of AVI-4206 on ADP-ribosylation in vivo.</p></disp-quote><p>To test this idea we adapted the IF assay used by others in the field and show an effect of AVI-4206. We have added to the text:</p><p>Although the IFN response was not sufficient to control viral replication, it is possible that the changes in ADP-ribosylation, in particular marks catalyzed by PARP14, downstream of IFN treatment could serve as a marker for Mac1 efficacy (Ribeiro et al. 2025). To investigate whether downstream signals from PARP14 were specifically erased by Mac1, we used an immunofluorescence assay that showed that Mac1 could remove IFN-γ-induced ADP-ribosylation that is mediated by PARP14 (Kar et al. 2024). We stably expressed wild-type Mac1 and the N40D mutant Mac1 in A549 cells. The data showed that Mac1 expression decreased IFN-γ-induced ADP-ribosylation, whereas the Mac1-N40D mutant did not (Figure 3E, F), indicating that Mac1 mediates the hydrolysis of IFN-γ-induced ADP-ribosylation. The PARP14 inhibitor RBN012759 completely blocked IFN-γ-induced ADP-ribosylation (Figure 3E, F), further confirming that IFN-γ-induced ADP-ribosylation is mediated by PARP14. AVI-4206 reversed the Mac1-induced hydrolysis of ADP-ribosylation and enhanced the ADP-ribosylation signal in Mac1-overexpressing cells (Figure 3E, F), further demonstrating its ability to inhibit the hydrolase activity of Mac1. We further validated this result using different ADP-ribosylation antibodies for immunofluorescence (Supplementary Figure 7). However, we observed no strong consistent signals of global pan-ADP-ribose (panADPr) or mono-ADP-ribose (monoADPr) accumulation in infected cells treated with AVI-4206 in immunoblot analyses (Supplementary Figure 8). Collectively, these results provide further evidence that simple cellular models are insufficient to explore the effects of Mac1 inhibition and that monitoring specific PARP14-mediated ADP-ribosylation patterns can provide an accessible biomarker for the efficacy of Mac1 inhibition.</p><p>A549 Mac1 expression cell construction</p><p>Mac1 wild-type (Mac1) and N1062D mutant (Mac1 N1062D) gene fragments were loaded into pLVX-EF1α-IRES-Puro (empty vector, EV) using Gibson cloning kit (NEB E5510). Lentivirus was prepared as previously described (PMID: 30449619; DOI: 10.1016/j.cell.2018.10.024). Briefly, 15 million HEK293T cells were grown overnight on 15 cm poly-L-Lysine coated dishes and then transfected with 6 ug pMD2.G (Addgene plasmid # 12259 ; <ext-link ext-link-type="uri" xlink:href="http://n2t.net/addgene:12259">http://n2t.net/addgene:12259</ext-link> ; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_12259">Addgene_12259</ext-link>), 18 ug dR8.91 (since replaced by second generation compatible pCMV-dR8.2, Addgene plasmid #8455) and 24 ug pLVX-EF1α-IRES-Puro (EV, Mac1, Mac1-N1062D) plasmids using the lipofectamine 3000 transfection reagent per the manufacturer’s protocol (Thermo Fisher Scientific, Cat #L3000001). pMD2.G and dR8.91 were a gift from Didier Trono. The following day, media was refreshed with the addition of viral boost reagent at 500x as per the manufacturer’s protocol (Alstem, Cat #VB100). Viral supernatant was collected 48 hours post transfection and spun down at 300 g for 10 minutes, to remove cell debris. To concentrate the lentiviral particles, Alstem precipitation solution (Alstem, Cat #VC100) was added, mixed, and refrigerated at 4°C overnight. The virus was then concentrated by centrifugation at 1500 g for 30 minutes, at 4°C. Finally, each lentiviral pellet was resuspended at 100x of original volume in cold DMEM+10%FBS+1% penicillin-streptomycin and stored until use at -80°C. To generate Mac1 overexpressing cells, 2 million A549 cells were seeded in 10 cm dishes and transduced with lentivirus in the presence of 8 μg/mL polybrene (Sigma, TR-1003-G). The media was changed after 24h and, after 48 hours, media containing 2μg/ml puromycin was added. Cells were selected for 72 hours and then expanded without selection. The expression of Mac1 was confirmed by Western Blot.</p><p>Immunofluorescence assay:</p><p>To assess the effect of Mac1 on IFN-induced ADP-ribosylation. A549-pLVX-EV, A549-pLVX-Mac1 and A549-pLVX-Mac1-N1062D cells were seeded in 96-well plate (10,000 cells/well). Cells were pre-treated with medium or 100 unit/mL IFN-γ (Sigma, SRP3058) for 24 hours to induce the expression of ADP-ribosylation. These 3 cell lines were then treated the next day with the indicated concentrations of AVI-4206 or RBN012759 (Medchemexpress, HY-136979). After 24 hours of exposure to drugs, treated cells were fixed in pre-cooled methanol at -20°C for 20 min, blocked in 3% bovine serum albumin for 15 min, incubated with Poly/Mono-ADP Ribose (E6F6A) Rabbit mAb (CST, 83732S) or Poly/Mono-ADP Ribose (D9P7Z) Rabbit mAb (CST, 89190S) antibodies for 1 h, and then incubated with Goat anti-Rabbit IgG Secondary Antibody, Alexa Fluor 488 (ThermoFisher, A-11008) secondary antibodies for 30 min and stained with DAPI for 10 minutes. Fluorescent cells were imaged with an IN Cell Analyzer 6500 System (Cytiva) and analyzed using IN Carta software (Cytiva).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>Just a couple of observations/details that might help strengthen the article:</p><p>(1) The caco-1 data for AVI4206 would suggest that there is some sort of efflux going on, yet there is no mention of it in the paper. This might be useful in the optimization paradigm moving forward.</p></disp-quote><p>We thank the reviewer for this observation and suggestion. Indeed, we believe that efflux is behind the low oral bioavailability of AVI-4206. We are working specifically to remove this liability in next-generation analogs, using the caco2 assay to guide this ongoing effort. Keep an eye out for a preprint on this soon! We have added to the discussion:</p><p>“In addition to dissecting such molecular mechanisms of macrodomain function and inhibition, future efforts will focus on improving pharmacokinetic properties, including a cellular efflux liability that results in low oral bioavailability of AVI-4206. ”</p><disp-quote content-type="editor-comment"><p>(2) There are some spectroscopic anomalies/mistakes in the NMR data. The carbon NMR for 1-((8-amino-9H-pyrimido[4,5-b]indol-4-yl)amino)pyrrolidin-2-one should only have 14 unique carbons, but the authors report 15. The HNMR for AVI1500 should only have 19 H's, but the authors list 20. The HNMR data for AVI3762/3763 should have 16 H's, but the authors only report 13. The CNMR for AVI4206 should only have 19 unique carbons, but the authors report 20.</p></disp-quote><p>Thank you for noting these inconsistencies regarding the reported NMR spectra. We have rectified them by more closely examining the spectra and in some cases acquiring new data. We identified one peak (47.9) in the 13C NMR of 1-((8-amino-9H-pyrimido[4,5-b]indol-4-yl)amino)pyrrolidin-2-one that is apparently an artifact of the automated peak picking in the data analysis software. In the 1H NMR of AVI-1500, the triplet peak at 7.20 integrates to 1H, but was erroneously reported as 2H in the original manuscript. This error has been corrected. Spectra were re-acquired for AVI-3762, AVI-3763, and AVI-4206 with longer acquisition times, and/or on a 600 MHz spectrometer to afford the complete line lists now reported in the revised manuscript. Please note AVI-4206 has 18 distinct 13C resonances due to the equivalence of the gem-dimethyl methyl groups.</p></body></sub-article></article>